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Abstract 
Over the past few decades stem cells have been extensively investigated due to 
their potentially invaluable therapeutic use.  Embryonic stem cells (ESCs) have 
wide-ranging therapeutic applications in tissue repair and regeneration due to their 
pluripotent properties and their ability to self-renew indefinitely.  However, ethical 
concerns surround their use and hence alternatives are sought.  Adult stem cells 
(ASCs) have been isolated from various adult tissues including the oral mucosa 
lamina propria (OMLP).  This study aims to isolate ASCs from the OMLP, reprogram 
these cells to induced pluripotent stem cells (iPSCs) and determine the potential for 
both to differentiate into functional neurons due to the limited regeneration of 
neurons in the central nervous system.  Such investigations into strategies for the 
treatment of neural damage are invaluable and timely due to current limitations in 
the availability of human-derived cells for potential autologous or allogeneic tissue 
repair.  OMLP-PCs represent an ideal cell source for use in regenerative medicine 
given their ease of isolation, proliferative potential, multipotent properties and 
immunosuppressive activities. Work in this Thesis has now demonstrated that these 
oral progenitors expressed numerous pluripotency markers and for the first time, 
that they could be reprogrammed to iPSCs utilising safer, non-integrating plasmids, 
thus increasing their potential for use in clinical applications.  OMLP-iPSCs were 
positive for a number of pluripotent stem cell markers including SSEA-4, SSEA-5, 
TRA-1-60, TRA-1-81, Oct-4 and Sox-2.  Moreover, their expression of early stage 
germ layer markers indicated their potential to differentiate into cell types of the 
mesoderm, endoderm and ectoderm.  OMLP-PCs were also demonstrated within 
this Thesis to differentiate down an early neural lineage as evidenced by the 
presence of typical neural markers (Nestin, βIII tubulin, MAP-2 and NF-M).  The 
presence of both ligand-gated and voltage-sensitive calcium channels indicated 
some limited potential functional phenotype.  Unfortunately, utilising the same neural 
differentiation methodology, OMLP-iPSCs were not able to be similarly driven down 
a neural pathway.  None-the-less this data suggests that OMLP-PCs and OMLP-
iPSCs may hold great promise for a wide range of regenerative medicine 
applications. 
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1.1  Introduction 
Stem cells have extensively been studied due to their invaluable potential 
use for therapeutic purposes.  Although there is much yet to be learnt, it is an 
area that is fast moving and new discoveries are continually reported.  It is 
also an area surrounded by much ethical debate which is mainly focused 
around the use of embryonic stem cells (ESCs) due to the way in which they 
are obtained. 
ESCs are pluripotent cells, capable of forming cells from all 3 germ layers; 
the endoderm, ectoderm and the mesoderm (Figure: 1.1).  They are derived 
from the inner cell mass of the blastocyst and have the capability to self-
renew indefinitely (Thomson et al, 1998).  As a result of these characteristics, 
it is clear to see why they are an attractive target for therapeutic purposes. 
Adult stem cells (ASCs) have fewer ethical issues associated with them as 
they are isolated from adult tissues and, therefore, do not require the 
destruction of foetal tissue.  These cells have the potential to be used as an 
autologous source of cells and as such, an immune response is also 
reduced.  ASCs are however, sometimes partially committed to become cells 
of their germ layer of origin and so are not pluripotent but are considered to 
be multipotent, with some very limited evidence of pluripotency. (Reviewed 
by Young and Black, 2004) 
Recently it has been demonstrated that somatic cells can be reverted back to 
an embryonic stem cell-like state, restoring pluripotent properties, by forcing 
the expression of factors known to keep cells in an undifferentiated state.  
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Figure 1.1: Properties of ESC, ASC and iPSC.  Different fates of stem cells from 
different origins.  Cells derived from the blastocyst are considered to be pluripotent 
as they can form cells from all three germ layers; ectoderm, endoderm and the 
mesoderm.  Multipotent stem cells exist within different adult tissues with the 
ability to form cells from their germ layer of origin and there is some evidence for 
the potential to form cells from other cell lineages. iPSCs are cells that have been 
genetically reprogrammed back towards an embryonic stem cell state, restoring 
pluripotency. 
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These cells are known as induced pluripotent stem cells (iPSCs).  This 
technique was first developed using mouse fibroblasts (Takahashi and 
Yamanaka, 2006) and then later successfully applied to human dermal 
fibroblasts (Takahashi et al, 2007) using four viral vectors containing Oct4, 
Sox2, c-Myc and Klf4.  The efficiency of converting cells to iPSCs still 
remains relatively poor and studies are ongoing to improve this. 
The purpose of this project is to isolate, expand and characterise a 
population of multipotent progenitor cells (PCs) that we know already resides 
within the oral mucosa lamina propria (OMLP) (Stephens and Genever, 
2007; Davies et al, 2010; Marynka-Kalmani et al, 2010) and reprogram these 
to iPSCs, giving the cells pluripotent properties.  The differentiation of these 
two cell populations (OMLP-PCs and iPSCs) to form functional neurons in 
vitro will be investigated to identify their potential for use as cell based 
treatments for neuronal damage. 
1.2 The Nervous System 
The adult nervous system is composed of two main components: (i) The 
Central Nervous System (CNS); consisting of the brain, spinal cord, optic, 
olfactory and auditory systems and (ii) The Peripheral Nervous System 
(PNS); consisting of cranial nerves, spinal nerves and sensory nerves.  The 
purpose of the CNS is to receive and interoperate signals, providing the PNS 
with excitatory signals.  The PNS responds to these signals and stimulates 
muscle tissue, whilst also relaying signals to and from the CNS. 
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Cells of the nervous system can be divided into two main cell types; neurons 
and glial cells.  The neurons are the main functional cells of the CNS and 
consist of a cell body, axons and dendrites.  Dendrites function to receive 
intercellular signals and relay these to the cell body. Axons are utilised to 
transmit electrical signals away from the neuron to downstream cells.  In the 
PNS, neurons consist of a cell body, motor and sensory axons.  Glial cells 
provide a support network: in the PNS these cells are known as Schwann 
cells and in the CNS the glial cells consist of oligodendrocytes, microglia, 
astrocytes.  Together these cells support neuronal survival and help maintain 
the myelin sheath which acts as an insulating layer and functions to facilitate 
and increase conductivity in the axons. 
1.2.1 Neural Damage 
Studies into strategies for the treatment of neural damage to the adult CNS 
are invaluable due to the limited regeneration of neurons in the CNS.  Unlike 
neurons of the adult PNS, axons in the CNS do not regenerate back into 
functional neurons once they have become damaged (Figure 1.2).  This is 
largely known to be as a result of inhibition from the environment surrounding 
the damaged cells, rather than the properties of the cells themselves 
(Richardson et al, 1980).  Molecules released by myelin sheath breakdown 
and the glial scar actively inhibit the re-growth of axons in the CNS 
(Mukhopadhyay et al, 1994; Chen et al, 2000), whereas, Schwann cells, 
macrophages and monocytes actively scavenge myelin at the site of injury in 
the PNS, allowing axonal re-growth (Stoll et al, 1989). 
 Chapter 1 General Introduction 
6 
Figure 1.2: Differences between neural repair in the PNS and CNS.  (A) Axon 
regeneration following injury of a neuron in the PNS. Myelin debris is removed by 
the collective work of the proliferating schwaan cells, macrophages and monocytes.  
(B) Inhibition of axon regeneration in the CNS.  Glial scar formation following injury 
which consists of astrocytes, oligodendrocytes and cell debris.  The glial scar blocks 
axon regeneration.  (From Schmidt and Leach, 2003) 
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Damage to the nervous system can occur as a result of trauma to the body or 
disease.  Whilst extensive damage to the PNS can be treated surgically by 
suturing severed nerves or using autologous nerve grafts (Sinis et al, 2009), 
damage to the CNS still remains a surgical challenge (Ruff et al, 2012).  
Neurodegenerative disorders, such as Alzheimer’s and Parkinson’s, present 
a stern challenge for regenerative medicine due to the continuous 
degeneration of axons and the resultant damage that is cumulative in nature.  
Spinal cord injury (SCI), as a result of trauma, lacks this progressive 
degradation.  
Injury to the spinal cord can be devastating with patients encountering loss of 
movement of limbs and/or bodily functions depending on the site of injury.  
There are two stages following SCI; primary injury and secondary injury.  
Primary injury occurs as a direct result of trauma, damaging blood vessels, 
axons and neural cell membranes.  This is followed by a secondary injury 
phase leading to loss of cells, swelling of the spinal cord to fill the spinal 
canal space, infiltration of inflammatory cells, activation of astrocytes and 
microglia, and the release of excitotoxic chemicals that damage the 
surrounding tissue (Balentine, 1978; Kwo et al, 1989; Macdonald and 
Sadowsky, 2002; Fleming et al, 2006).   
Inflammation occurs during the acute stages of SCI and some of the 
inflammatory cells can persist for weeks and even months after the injury 
(Fleming et al, 2006).  Secondary damage at the site of injury and to the 
surrounding tissue is caused by reactive oxygen species, proteolytic 
enzymes, pro-inflammatory cytokines and nitric oxide. 
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These are released by infiltrating neutrophils, macrophages, activated 
microglia and T-lymphocytes into the site of injury which is well documented 
in the acute stages of SCI in animal models (Banati et al, 1993; Taoka et al, 
1997; Popovich et al, 1997; Carlson et al, 1998; Popovich et al, 2002).   
Studying inflammation in the acute stages of human SCI does present a 
challenge due to limited availability of tissue. Nonetheless, there are some 
limited reports that demonstrate the production of pro-inflammatory cytokines 
from neurons and microglia following the primary injury (Yang et al, 2004) 
and infiltration of neutrophils, macrophages and T-lymphocytes to the site of 
injury in addition to microglia activation (Yang et al, 2004; Fleming et al, 
2006). Neutrophils, activated microglia and macrophages demonstrate 
expression of Myeloperoxidase (MPO), and gp91Phox (a catalytic subunit of 
nicotinamide adenine dinucleotide phosphate (NADPH).  MPO and NADPH 
are both oxidative enzymes and are involved in secondary damage to the 
surrounding healthy tissue (Flemming et al, 2006).  As such, therapies to 
reduce the inflammatory response have been considered. Blocking the influx 
of neutrophils and macrophages to the site of injury has demonstrated 
reduced functional deficits following SCI in animal models (Taoka et al, 1997; 
Popovich et al, 1999) and as such these present an interesting target for 
human SCI. 
During the acute stages of SCI excitotoxicity and oxidative damage 
contribute to secondary injury.  Glutamate plays a crucial role in the 
destruction of healthy neurons during secondary injury as large quantities of 
it are released from damaged axons and astrocytes.  This overexcites the 
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surrounding neurons, allowing masses of calcium ions to flow into the cell via 
activated N-methyl-D-aspartate (NMDA) receptors (Choi, 1992) resulting in 
the release of damaging free radicals, increasing oxidative stress which 
damages neurons and can induce apoptosis (Patel et al, 1996).  Glutamate is 
also known to destroy oligodendrocytes (Macdonald et al, 1998) and has 
been suggested to be the reason behind the chronic de-myelination of 
healthy neurons following SCI (Macdonald and Sadowsky, 2002).  A strategy 
to help regenerate and repair damaged nerves using cell based treatments is 
indeed an important area of research for SCI patients. 
1.2.2 Strategies for Neural Repair and Regeneration in Spinal 
Cord Injuries 
In the UK and Ireland, approximately 1000 people per year suffer a SCI and it 
is estimated that there are approximately 50,000 people living with such 
injury (Spinal Research, UK).  There is much research being carried out in 
the area that has added to our knowledge of the extent of the injury.  
However there is currently no cure and, at present, treatments focus on 
symptom management as research has yet to find a strategy that 
permanently improves neuronal function for SCI patients (Kwon et al, 2010).  
Therapies that are currently involved in clinical trials include; pharmaceutical 
intervention, functional electrical stimulation (FES) and cell based therapies.  
At present there has been no lasting functional benefit reported.  
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1.2.2.1 Pharmaceutical Intervention 
Methylprednisolone is a corticosteroid that initially demonstrated encouraging 
neurological benefits (Bracken et al, 1990).  However, recent developments 
have since demonstrated no difference between the recovery of neurological 
function in treated and untreated patients (Pointillart et al, 2000). 
Furthermore, the rate of infection is high following the administration of 
methylprednisolone and as such its use is now in decline (Pointillart et al, 
2000; Hurlbert and Hamilton, 2008). 
Anti-Nogo-A is an antibody against one of the inhibitory molecules produced 
as a result of myelin breakdown in the CNS.  Its use has promoted axon 
sprouting and some functional recovery in rat and primate SCI models 
(Freund et al, 2009; Leibsher et al, 2005).  This antibody is currently 
undergoing clinical trials with the hope that blocking this inhibition will allow 
axonal re-growth following injury in humans. 
Ion channel inhibitors have been developed with the hope that these will 
attenuate the damage cause by excitotoxic chemicals in the secondary injury 
stages of SCI.  Magnesium was investigated as a potential antagonist of 
NMDA receptors to reduce calcium influx into neurons as a result of the 
increase in glutamate levels. Initial studies of magnesium administered with 
polyethylene glycol (PEG) have demonstrated positive results in rat SCI 
models, where a neurological recovery was observed (Kwon et al, 2009).  
Phase I clinical trials have since been completed demonstrating the safety of 
the therapy and phase II clinical trials are currently underway (Kwon et al, 
2010). 
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1.2.2.2 Functional Electrical Stimulation 
FES is a process that has previously been used to suppress plasticity and 
pain but has more recently been used to stimulate the spinal cord to restore 
some locomotive function to SCI patients (Gerasimenko et al, 2008).  Studies 
have demonstrated that SCI patients treated with FES are able to bare their 
own weight and reactivation of remaining neural networks can restore some 
function. However this is largely lost following removal of the stimulus 
(Harkema et al, 2011).  Nevertheless, these are promising results and as 
such there are several FES clinical trials currently in progress.  
1.2.2.3 Cell-Based Therapies 
Cellular loss and death as a result of injury to the spinal cord remains a 
challenge for the regeneration and repair of a functional spinal cord.  This is 
largely due to the secondary injury cascade that occurs following the initial 
trauma.  As such, cell-based therapies could play a number of important 
roles in restoring function to SCI patients.  Not only could they directly 
replace lost cells but could also modify the environment, encourage 
endogenous repair and promote the re-myelination of axons that remain 
around the injury site to restore their ability to function.  
Cells, such as Bone Marrow Stromal Cells (BMSCs), Schwann cells (SCs), 
Olfactory ensheathing cells (OECs), ESCs, iPSCs and neural progenitor cells 
(NPCs) have received much attention for their potential use in SCI (Reviewed 
by Ruff et al, 2012).  Each of these cells have demonstrated promise and 
naturally, each have their own advantages and disadvantages. 
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1.2.2.3.1 Schwann Cells and Olfactory Ensheathing Cells 
SCs are present in the PNS and aid recovery of damaged axons following 
injury. SC grafts have been used in CNS damage to promote and guide axon 
re-growth and re-myelination following SCI (Weidner et al, 1998; Pearse et 
al, 2004). However, axonal re-growth was only demonstrated when SC 
transplantation was performed immediately following SCI in rodent models 
(Martin et al, 1996) which limits their clinical application. OECs are similar to 
SCs of the PNS and astroglia of the CNS. They act in a similar fashion to 
SCs in neural repair of the CNS, promoting myelinated axonal regeneration 
across lesion sites in SCI (Sasaki et al, 2004).  The ability of OECs to 
promote neural repair is variable and this has been linked to the different 
origins of these cells and also attributed to the in vitro handling of these cells 
(Richter et al, 2005). 
1.2.2.3.2 Stem Cells for Neural Transplantation Therapies  
BMSCs have received the most attention for their potential to be used as an 
autologous or allogeneic tissue source for tissue engineering applications.  
As such several groups have demonstrated that human mesenchymal stem 
cells (hMSCs) isolated from BMSC can be used to promote functional 
recovery in SCI rodent models (Kim et al, 2006, Cizkova et al, 2006; Sasaki 
et al, 2009).  However, some reports only demonstrate functional recovery 
with the addition of basic fibroblast growth factor (FGF-2: Kim et al, 2006) or 
brain derived neurotrophic factor (BDNF: Sasaki et al, 2009). 
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Additionally improved locomotive function in rodent SCI models varies with 
different hMSC donors (Neuhuber et al, 2005) indicating that there are some 
inconsistencies with the use of hMSCs and further research is required. 
NPCs are naturally found in adult neural tissues and present an attractive 
source of cells for use in neural repair. They have demonstrated the ability to 
activate re-myelination in myelin deficient mice (Eftekharpour et al, 2007) and 
promote functional recovery in SCI rat models (Moreno-Mansano et al, 
2009). Despite these promises, NPCs exist in very small numbers in adult 
tissues and harvest of these cells represents a risk to patients which limits 
their clinical application, therefore safer and more clinically relevant options 
are being explored.  These options include the use of ESCs and iPSCs. 
ESCs have self-renewal properties and are pluripotent in nature giving these 
cells the ability to differentiate into many different cells types including neural 
and glial cells (Reviewed by Erceg et al, 2009).  These properties make ESC 
a great source of cells for use in SCI repair and have demonstrated the ability 
to promote re-myelination and functional repair in vivo (Kierstead et al, 2005). 
However these positives are not without downsides. ESCs represent a 
population of cells that have the ability to differentiate into many different cell 
types, failure to differentiate all cells down a specific lineage before 
transplantation has clinical risks, including the formation of tumours (Matsuda 
et al, 2009). In addition to this, there are also potential problems with host 
rejection upon transplantation of the cells and the ethical issues that surround 
the derivation of ESCs.  More recently iPSCs have been developed 
(Takahashi et al, 2007). These cells are pluripotent and, therefore, have a 
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similar differentiation potential to ESCs.  However, unlike ESCs, these cells 
have the potential for use in autologous tissue engineering applications, 
representing an appealing target for SCI repair.  
Several of these therapies have reached human clinical trial stage, but as 
yet, none have demonstrated convincing efficacy data (Kwon et al, 2010; 
Ruff et al, 2012). 
It is clear that no single therapy alone will result in the complete functional 
recovery of SCI patients.  Rather, potential treatment is likely to consist of a 
combination of these therapies given together at appropriate times to control 
the environment, encourage native cell re-growth and repair, as well as 
incorporating new cells, potentially derived from stem cells, to replace those 
lost in the initial injury. 
1.3 Stem Cells 
Stem cells can be defined as a cell with the ability to self-renew as well as 
the potential to differentiate into many other cell types (Figure 1.1).  Stem 
cells can either divide to produce two identical daughter cells with the same 
self-renewal capacity or asymmetrically to produce one daughter cell 
identical to itself with self-renewal capacity and one with more limited 
capabilities.  Stem cells can be considered totipotent, pluripotent or 
multipotent.  Totipotent cells have the ability to form all cells of a given 
organism.  Pluripotent cells have the ability to form cells from the 3 germ 
layers; mesoderm, endoderm and ectoderm, whilst multipotent stem cells 
have a more limited differentiation potential often forming cells of only a 
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single lineage.  Stem cells can be divided into three broad categories: ESCs, 
iPSCs and ASCs. 
1.3.1 Embryonic stem cells 
The early development of a fertilised oocyte gives rise to many cell types 
making up all tissues of the entire organism.  Cells in the fertilised oocyte 
remain totipotent for five cell divisions.  After this, primary differentiation 
occurs forming the outer cells of the blastocyst, the trophoblast.  The inner 
cell mass of the blastocyst remains undifferentiated and these cells maintain 
the ability to form cells from all three germ layers (Thomson et al, 1998).  
Much of the initial ESC work was carried out on mouse ESCs (mESC), which 
were first isolated and expanded in culture in the early 1980s.  They were 
derived from the early embryonic blastocyst and characterised by their ability 
to proliferate whilst remaining undifferentiated (Evans and Kaufman, 1981).  
In the 1990s human ESCs (hESC) were successfully isolated and cultured 
from in vitro fertilisation of zygotes donated for research purposes (Thomson 
et al, 1998). mESCs were historically characterised by the expression of 
surface markers such as SSEA-1 (Solter and Knowles, 1978).  More recently 
these undifferentiated mESCs have been characterised by the expression of 
certain transcription factors known to be involved in pluripotency of cells, 
such as Oct4 (Scholer et al, 1990) and Nanog (Chambers et al, 2003) and 
also by telomerase activity maintaining the proliferative potential of ESCs 
(Armstrong et al, 2000).  Whilst expression of Oct4 and Nanog are also used 
to characterise hESCs, SSEA-1 is absent.  Instead the presence of alkaline 
phosphatase, SSEA-4, TRA-1-60 and TRA-1-81 are commonly used to 
 Chapter 1 General Introduction 
16 
characterise hESC (Andrews et al, 1984; Wenk et al, 1994; Thomson et al, 
1995; Thomson et al, 1998) in addition to teratoma formation upon 
transplantation into immuno-deficient mice (Thomson et al, 1998).  These 
tumours demonstrate the presence of tissues from all three germ layers, 
confirming pluripotency (Thomson et al, 1998). 
1.3.1.1 ESC Culture 
ESCs have successfully been cultured in vitro for a number of years 
however, studies concerning the optimum culture conditions are ongoing.  It 
is common when growing hESCs to culture these using a feeder layer 
consisting of inactivated mouse embryonic fibroblasts (iMEFs). Initially it was 
thought that the iMEFs were required to supply hESCs with leukaemia 
inhibitory factor (LIF), a key component that maintains mESCs on gelatin-
coated plates in an undifferentiated state.  Whilst mESCs differentiate 
following removal of LIF (Williams et al, 1988), it has been found that in the 
absence of a feeder layer, hESCs differentiate regardless of whether LIF is 
present (Thomson et al, 1998). This therefore suggests that the iMEF feeder 
layer is providing other factors that are important for maintaining hESCs in an 
undifferentiated state. 
mESCs and iMEFS are frequently cultured using foetal bovine serum (FBS) 
which has certain implications, specifically with culture of hESC, if they were 
ever to be used for clinical application.  Alternative methods have recently 
been investigated for hESC culture, with potential use in human medicine in 
mind, as the use of animal products would need to be avoided.  These 
methods include: (i) use of human derived feeder layers (Amit et al, 2003) 
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and (ii) use of extracellular matrix proteins (Xu et al, 2001). Both methods 
have been found to support the growth of hESC and maintain their 
undifferentiated properties. 
1.3.1.2 Embryoid Body Formation 
The potential for ESCs to be used in regenerative medicine is vast and many 
differentiation routes have been followed with mESCs and hESCs.  In vitro 
differentiation often begins with the formation of a three-dimensional 
embryoid body and these are said to imitate post-implantation embryos 
(Desbaillets et al, 2000). 
Embryoid bodies form spontaneously in the absence of anti-differentiation 
factors and importantly consist of mesoderm, ectoderm and endoderm 
tissues, allowing the subsequent differentiation into any cells from these 
germ layers.  This has been demonstrated using hESC by expression of ζ-
globin for presence of mesoderm tissue, neurofilament 68Kd for presence of 
ectoderm, and α-fetoprotein for endoderm (Itskovitz-Eldor et al, 2000).  
Formation of these bodies can be carried out in suspension culture on 
bacterial grade dishes.  This technique was first carried out with mESCs 
whereby a non-treated hydrophobic polystyrene bacterial grade dish was 
used to culture ESCs (Doetschman et al, 1985).  The basis of the technique 
is that ESCs do not adhere to the bacterial grade plate and instead adhere to 
each other forming aggregates.  The formation of these aggregates occurs 
spontaneously but a disadvantage of this is that there is great variability in 
size and shape resulting in a population of heterogeneous aggregates, 
affecting differentiation. 
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As a result, this technique has been improved to generate a more uniform 
aggregate by rotating/stirring the cell suspension, resulting in a more uniform 
aggregate which is preferential for differentiation (Zweigerdt et al, 2003; 
Cameron et al, 2006).  Methylcellulose cultures and hanging drop cultures 
have also been developed; however, these methods are more commonly 
used with mESC as they require the formation of a single cell suspension 
(Wiles and Keller, 1991; Kurosawa, 2007). 
1.3.1.3 Differentiation of ESCs 
mESC and hESC remain an area of extensive research and to date both 
have demonstrated the ability to successfully produce cells of a number of 
different lineages.  Table 1.1 demonstrates some examples of these lineages 
that have been followed. Differentiation of ESC from embryoid bodies to cells 
of specific lineages requires the addition of defined factors to culture 
conditions.  During embryoid body formation, cells randomly form cells of 
various lineages, with no further changes to the composition of the medium, 
myocardial cells will make up approximately one third of the cell types 
(Doetschman et al, 1985; He et al, 2003). In contrast, addition of certain 
factors, including growth factors and cytokines, is needed to direct cells 
preferentially down other lineages.  For example, addition of bone 
morphogenetic protein-4 (BMP-4) to culture medium during embryoid body 
formation causes preferential differentiation of cells into haematopoietic cells 
(Chadwick et al, 2003).  A further regulation of haematopoietic cells has been 
demonstrated with the addition of vascular endothelial growth factor (VEGF-
A165) which aids differentiation of erythrocytes (Cerdan et al, 2004).. 
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1.3.1.3.1 Neural Differentiation of ESCs 
Neural differentiation of hESCs is an area that has received much attention 
over the last decade due to the potential wide-ranging therapeutic 
applications of these differentiated cells in a number of clinical applications. 
As with all differentiation of hESCs, neural lineage differentiation requires the 
addition of factors at specified time points determined by the specific cell type 
required.  Several approaches have been utilised to differentiate hESCs 
towards neural cell types present in the CNS including; astrocytes and motor 
neurons.  A key element to note is the level of variation between different 
protocols. Each protocol differs in the different factors used and the duration 
of exposure to these factors as well as the different cell starting points; 
confluent ESC colonies, single hESCs, EBs and neurally induced spheres 
(Table 1.2 and Table 1.3).  However, there are several key factors that are 
required in neural differentiation protocols.  The most commonly adopted 
method historically was to treat the cells with retinoic acid (RA).  Although 
this method does result in a large proportion of the cells differentiating 
towards neural lineages, the population of cells remains very heterogeneous 
and requires further separation (Carpenter et al, 2001).  More recently, 
methods utilising stromal feeder layers to form neural rosettes (Lee et al, 
2007) and subsequent treatment of cells with RA and sonic hedgehog (SHH) 
demonstrated formation of neurons with morphological and physiological 
characteristics consistent with spinal motor neurons (Lee et al, 2007; 
Takazawa et al, 2012). 
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Brain derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic 
factor (GDNF) and insulin-like growth factor-1 (IGF-1) have also 
demonstrated improved differentiation towards motor neurons in vitro (Zurn 
et al, 1996; Zhang et al, 2001).  Despite the successful formation of 
differentiated neural cells from hESCs, these still exist within heterogeneous 
cell populations of undifferentiated cells, posing a risk for clinical application 
and further research is required to purify these cell populations for safe 
therapeutic use.  Increased knowledge in this area has resulted in the 
development of different protocols that do not require the need for embryoid 
body formation or the co-culture with stromal cells.  Instead, direct 
differentiation of hESCs in high density monolayer cultures have been 
developed, taking advantage of two inhibitors of SMAD signalling; Noggin 
and small molecule inhibitor SB431542 (Chambers et al, 2009).  Treatment 
of high density hESC culture with these two inhibitors have resulted in 
complete conversion of cells to a neural phenotype which adds promise to 
this area for therapeutic potential for these cells. 
1.3.2 Adult Stem Cells (ASCs) 
ASCs have promised new hope for tissue repair and regeneration in recent 
years. Unlike hESCs, ASCs have fewer ethical issues surrounding their use 
due to the fact that they are isolated from adult tissues.  Their ability to 
differentiate into a number of different tissues is beginning to demonstrate 
their usefulness for clinical application. 
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It was initially thought that these cells only existed in tissues that retain 
proliferative potential and maturation into specialised cells throughout adult 
life, such as bone marrow and skin (de Hann, 2002; Watt, 2001).  However, 
in recent years it has become apparent that stem cells reside in many other 
adult tissues and have been isolated from a number of different sources to 
date.  These stem cells are often referred to as progenitor cells or precursor 
cells, given their ability to differentiate into several different cell types that 
comprise their tissue of origin.  ASCs have been found to exist in tissues that 
lack a continuous renewal mechanism, for example in liver, central nervous 
system tissue and skeletal muscle (Theise et al, 1999; Reynalds and Weiss, 
1992; Beauchamp et al, 1999). It has been suggested that similar 
stem/progenitor cells potentially exist in many other adult tissues and will only 
proliferate and differentiate in response to signals produced from the organ 
they reside within (Jiang et al, 2002). 
1.3.2.1 ASC Culture 
ASCs are initially isolated from tissue samples either obtained by aspiration 
techniques (in the case of blood and bone marrow), biopsies, discarded 
tissue or from donated tissue postmortem.  Unlike ESC culture, the 
expansion of some ASCs once isolated, has been found to be quite 
challenging.  Haematopoietic stem cells, isolated from the bone marrow, are 
from a tissue where regeneration of new cells occurs quite readily.  However, 
they have been difficult to culture in vitro, with little success until recent years 
following discovery of Wnt proteins acting as growth factors to successfully 
expand haematopoietic stem cells (Willert et al, 2003).  A second population 
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of stem cells originating in the bone marrow have also been isolated, that 
unlike haematopoietic stem cells, proliferate readily in culture and these are 
termed bone marrow mesenchymal stem cells or bone marrow stromal cells 
(BMSCs) (Caplan, 1991).  These cells are characterised by their ability to 
form colonies that can be isolated (Friedenstein et al, 1974) and undergo 
approximately 20 population doublings (PDs) before the onset of cellular 
senescence.  Mixed clonal populations on the other hand can undergo more 
PDs but are limited to 30-40 PDs before growth arrest (Bruder et al, 1997). 
Although BMSCs are a potential preferential source of cell to utilise in clinical 
applications, there are some disadvantages to their use including the low cell 
numbers obtained on isolation and the invasiveness of obtaining human 
samples (Rickard et al, 1996; Bruder et al, 1997; Pittenger et al, 1999).  Due 
to these shortcomings, MSC-like populations are continually being isolated 
and investigated from alternative tissue sources, with their potential 
usefulness in clinical application at the forefront of these investigations.  The 
various conditions that cells require for expansion and differentiation in vitro 
is of great importance if these cells are to be used for clinical application. 
1.3.2.2 Differentiation of ASCs 
Much of the early work with ASCs was carried out using BMSCs.  These cells 
demonstrate differentiation down adipogenic, chondrogenic and osteogenic 
lineages from clonally isolated cell populations (Pittenger et al, 1999).  Non-
bone marrow derived MSCs have received more attention over the last 
decade following reports that these cells were able to differentiate into 
epithelial cells, haematopoietic cells, and have also demonstrated the ability 
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to form cells with mesoderm, endoderm and neuroectoderm characteristics 
(Jiang et al, 2002).  This suggests a potential for MSCs to be used in tissue 
regeneration and repair throughout the body.  Progenitor cells have been 
isolated from several other human tissues and demonstrated differentiation 
down multiple lineages.  Some of these are summarised in Table 1.4. 
1.3.2.3 Stem cells in Dental Tissues 
Dental tissues have demonstrated great promise as a potential source of 
MSC-like cells in recent years.  These progenitor cells have been isolated 
from several different dental tissues to date including; dental pulp (Gronthos 
et al, 2000), exfoliated deciduous teeth, (Miura et al, 2003), apical papilla 
(Sonoyana et al, 2008), dental follicle (Morsczeck et al, 2005), periodontal 
ligament (Seo et al, 2004), oral mucosa (Davies et al, 2010; Marynka-
Kalmani et al, 2010) and gingiva (Zhang et al, 2009). 
These isolated cell populations share some distinct similarities in their MSC-
like properties as well as characteristics that separate them.  The relationship 
between the different stem cell populations that reside within the dental 
tissue is still unclear, however, investigations are ongoing. 
Dental pulp progenitor cells (DPPCs) were the first progenitor cells to be 
isolated from dental tissues in 2000 (Gronthos et al, 2000).  Like BMSCs, 
these cells can be clonally isolated but more interestingly, demonstrate a 
higher proliferative capacity compared to BMSCs (Gronthos et al, 2000).   
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Table 1.4:  Adult stem cell differentiation. Examples of stem cells isolated from 
different adult tissues and their differentiation capacity. 
Tissue 
Progenitor 
Cells 
Differentiated Cell 
Types 
References 
CNS Neural Stem 
Cells 
Neurons, Astrocytes 
(limited 
oligodendrocytes) 
Uchida et al, 2000; 
Palmer et al, 2001 
Blood 
Circulating 
Skeletal Stem 
Cells 
Osteocytes, 
Adipocytes 
Kuznetsov et al, 
2001 
Umbilical cord 
blood stem cells 
Osteocytes, 
Adipocytes and 
chondrocytes 
Lee et al, 2003; 
Kern et al, 2006; 
Schuh et al, 2009 
Adipose 
Processed 
lipoaspirate 
cells (PLAs); 
Adipose 
Derived 
Multilineage 
Cells 
Adipocytes, 
Chondrocytes, 
Myogenic Cells and 
Osteocytes 
Zuk et al, 2001; De 
Ugarte et al, 2003; 
Kern et al, 2006 
Pancreas 
Nestin-Positive 
Islet-Derived 
Multipotential 
Stem Cells 
(NIP) 
Islets of Langerhans, 
Hepatic cells, 
Pancreatic, 
Acinar Cells,  
Ramiya et al, 
2000; Zulewski et 
al, 2001  
Craniofacial 
Dental Pulp 
Progenitor 
Cells, 
 
Dentine-Like Cells, 
Osteoblasts 
 
Gronthos et al, 
2000; Gronthos et 
al, 2002 
  
 
Oral Mucosa 
Lamina Propria 
Progenitor Cells 
Osteogenic, 
Adipogenic, 
Chondrogenic & 
Neuroectoderm 
Davies et al, 2010; 
Marynka-Kalmani 
et al, 2010 
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DPPCs also demonstrate multilineage differentiation potential, expressing 
typical markers and morphology of adipogenic and neurogenic cells 
(Gronthos et al, 2002) as well as the ability to differentiate down osteogenic, 
chondrogenic and myogenic lineages (Zhang et al, 2006).  Shortly after the 
isolation of DPPCs, stem cells from human exfoliated deciduous teeth 
(SHEDs) were isolated.  SHEDs represent a population of cells from a tissue 
source that would otherwise be discarded if not used and therefore represent 
a cell population with great potential.  In addition to this, these cells 
demonstrate greater proliferative capacity compared to DPPC (Miura et al, 
2003) and express numerous development markers including; Oct4, Sox2, 
SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 (Kerkis et al, 2006). 
The apical papilla, which develops to form the pulp structure of permanent 
teeth, has also demonstrated a resident stem cell population termed stem 
cells from the apical papilla (SCAP).  These cells, like DPPCs, demonstrate 
multilineage differentiation down osteogenic, adipogenic and neural lineages 
(Abe et al, 2007; Sonoyama et al, 2008) and are thought to be of neural crest 
origin (Sonoyama et al, 2008).  Similarly, stem cells have been isolated from 
the dental follicle of developing permanent teeth (Morsczeck et al, 2005).  
Although these cells demonstrate colony formation and osteogenic 
differentiation, the initial cell numbers obtained from a single isolation are low 
(Morsczeck et al, 2005) and therefore potentially have little use for clinical 
applications.  Periodontal ligament stem cells (PDLSCs) have been isolated 
from extracted molars and give rise to a population of stem cells that are 
positive for typical MSC markers, including STRO-1 and, consistent with 
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characteristics of other MSC populations, demonstrate differentiation down 
osteogenic, adipogenic and chondrogenic lineages (Seo et al, 2004). 
More recently investigations have been carried out on the tissue surrounding 
the teeth, including gingiva and the oral mucosa.  These are easily 
accessible tissue sources applicable to all patients, regardless of age as it 
does not require presence of deciduous teeth, tooth extraction, pulp 
extraction, or the presence of impacted teeth. 
The gingiva is a keratinized structure that, like the oral mucosa, bears a 
resemblance to the structure of the skin (Stephens and Genever, 2007).  
Gingiva-derived mesenchymal stem cells (GMSCs) have been isolated from 
the lamina propria of the gingiva (Zhang et al, 2009).  These cells maintain a 
higher proliferative rate than BMSCs, express stem cell markers; Oct4, 
SSEA-4 and STRO-1, and possess multipotent properties, demonstrating 
positive expression of typical markers of adipocytes, osteoblasts, endothelial 
cells and neural cells (Zhang et al, 2009).  In addition to this, these cells 
demonstrate immunosuppressive properties making them an attractive cell 
source for tissue engineering applications (Zhang et al, 2009; Zhang et al, 
2012). 
This thesis is based on a population of progenitor cells isolated from the 
lamina propria of the oral mucosa, which like gingiva, is a tissue that is easily 
isolated from patients undergoing routine dental treatment. 
. 
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1.3.2.3.1 Oral Mucosa 
The oral mucosa is the term used to describe the soft tissue lining of the oral 
cavity.  It has many different functions and consists of a distinct layered 
structure that is very similar to the structure and function of skin (Figure 1.3).  
The several discrete layers help to protect from bacterial infection and work 
to regulate temperature and water balance, much like the skin (Sloan et al, 
1991).  Three distinct layers make up the oral mucosa: the oral epithelium, 
lamina propria and sub mucosa. 
The epithelium makes up the surface of the oral mucosa and consists largely 
of multiple layers of keratinocytes ranging in their degree of maturation; 
immature cells at the base and mature cells at the surface. The epithelial 
layer is supported by a connective tissue layer, the lamina propria, which 
gives integrity to the oral mucosa.  This consists of an interwoven mesh of 
collagen (Type I and III), glycosaminoglycans, proteoglycans, glycoproteins, 
capillaries and elastic fibres which have been produced by the residing 
fibroblasts.  Various other cells types exist in this layer including; endothelial 
cells, pericytes, smooth muscle cells, Schwann cells, lymphocytes and 
macrophages.  
The sub-mucosa is the deepest layer of the oral mucosa and consists mainly 
of adipocytes.  The sub mucosa acts to provide a network of blood vessels to 
the lamina propria in order to supply nutrients to the tissue and remove 
waste. 
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Figure 1.3: Similarities between the oral mucosa and the skin.  The skin is 
a discrete layered structure consisting of the epidermis, dermis and the 
hypodermis which is similar in structure and function to the oral epithelium, 
lamina propria and the sub mucosa of the oral mucosa.  (Image from Stephens 
and Genever, 2007). 
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The composition of the sub mucosa determines the flexibility of the tissue 
that lies above it and is only present in non-keratinised tissues such as the 
buccal mucosa and found to be absent in keratinised tissues, such as gingiva 
and hard palate, where the oral mucosa is attached directly to the periosteum 
of bone beneath (Squier and Kremer, 2001; Stephens and Genever 2007). 
1.3.2.3.2 Wound Healing Properties of the Oral Mucosa 
Wound healing responses consist of tightly regulated and overlapping 
phases of haemostasis, inflammation, proliferation and remodelling, a 
process that frequently leads to scarring of skin.  Visualised healing of the 
oral mucosa differs from that of the skin due to the lack of scar formation 
(Stephens and Genever, 2007) and there are various reasons underlying this 
that can be used to support this difference.  It has been demonstrated that 
oral mucosal wounds have a diminished inflammatory phase with significantly 
fewer T-cells, macrophages and neutrophils in comparison to dermal wound 
(Szpaderska et al, 2003).  Another such potential reason is that oral mucosal 
fibroblasts have an increased ability over dermal fibroblasts to re-organise 
their ECM (Stephens et al, 1996).  Recently a potential progenitor cell 
population residing within the lamina propria was suggested to be in part 
responsible for this wound healing response (Stephens and Genever, 2007). 
This population of progenitor cells has since been isolated (Davies et al, 
2010; Marynka-Kalmani et al, 2010). 
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1.3.2.3.3 Oral Mucosa Lamina Propria Progenitor Cells (OMLP-PCs) 
This progenitor cell population from the lamina propria has been isolated by 
two separate research groups and, as such, can be found in the literature 
under two different names; OMLP-PCs (Davies et al, 2010) or human oral 
mucosa stem cells (hOMSC; Marynka-Kalmani et al, 2010).  Progenitor cells 
have been isolated from a heterogeneous cell population of the lamina 
propria by differential adhesion to fibronectin (Davies et al, 2010).  This 
separation is based increased active functional α5β1 integrins on the surface 
of progenitor cells compared to differentiated cells (Dowthwaite et al, 2003) 
and therefore progenitor cells adhere to a fibronectin coated surface in a 
shorter timeframe than more differentiated cell types.  The cells of the OMLP 
demonstrate expression of numerous developmental markers including 
markers of the notch signalling pathway; Notch 1, 2 & 3, Delta 1 and Jagged 
2 as well as neural crest markers; sox-10, snail, slug and twist.  This confirms 
the neural crest origin of these isolated cells (Davies et al, 2010). 
Similar to stem cells isolated from other dental tissues, these cells 
demonstrate a higher proliferative capacity compared to BMSCs and, in the 
case of GMSCs and OMLP-PCs, this is potentially due to the expression of 
hTERT (Zhang et al, 2009; Davies et al, 2010; Zhang et al, 2012).  Like other 
MSC populations, OMLP-PCs also demonstrate multipotent properties, 
differentiating down adipogenic, osteogenic, chondrogenic and early neural 
lineages (Davies et al, 2010; Marynka-Kalmani et al, 2010).  More recently, 
OMLP-PCs have demonstrated potent immunosuppressive properties, 
similar to GMSCs (Davies et al, 2012), making these cells interesting targets 
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for use in allogeneic tissue engineering applications as well as immune 
related disorders. 
Additionally the tissue of the lamina propria has demonstrated expression of 
factors recently used for reprogramming of cells to iPSCs including Sox2, 
Oct4 and Klf4 (Davies et al, 2010; Marynka-Kalmani et al, 2010), making 
these cells an attractive and interesting target for reprogramming purposes. 
1.3.2.3.4 Neural Differentiation of Stem/Progenitor Cells from Dental Tissues 
Given the early association of the dental tissues with the neural crest, it is not 
surprising that many of the stem/progenitor cell populations isolated from 
dental tissues demonstrate neural crest marker expression in addition to 
some early stage neural markers including Notch-1 and Nestin (Reviewed by 
Huang et al, 2009). This is an encouraging early indication that these cells 
have the potential to differentiate towards neural lineages and, as such, have 
potential for use in neural repair.  Early differentiation potential and 
expression of typical neural markers has been demonstrated for DPPCs 
(Arthur et al, 2008), SHEDs (Miura et al, 2003), SCAP (Sonoyama et al, 
2008) Dental follicle stem cells (Morsczeck et al, 2009), PDLSCs (Kawanabe 
et al, 2010), GMSCs (Zhang et al, 2009) and OMLP-PC (Davies et al, 2010; 
Marynka-Kalmani et al, 2010). 
Neural differentiation protocols differ for each dental tissue stem/progenitor 
cells. It is common to form a neurosphere-like structure prior to neural 
differentiation, similar to culturing of NPCs, which are grown as 3D bodies to 
help maintain their multipotency and their ability to differentiate into neuronal 
 Chapter 1 General Introduction 
35 
cell types when plated in monolayer culture (Arsenijevic et al, 2001; Wachs et 
al, 2003).  Neurosphere-like structures of dental tissue stem/progenitor is 
commonly achieved by culturing cells with FGF-2 and/or EGF (Widera et al, 
2007; Morsczeck et al 2010, Davies et al, 2010). This is often followed by the 
addition of neural growth factors; BDNF, neurotrophin-3 (NT-3) and Nerve 
Growth Factor (NGF) once cells are disaggregated and plated in monolayer 
culture, to encourage terminal differentiation.(Marynka-Kalmani et al, 2010; 
Davies et al, 2010).  Several groups have adopted an alternative method 
using direct differentiation of the cells in monolayer culture (Miura et al, 2003; 
Arthur et al, 2008; Sonoyama et al, 2008).  
At present, characterisation of differentiated neural cells has demonstrated 
the presence of typical early and some more terminally differentiated neural 
markers (Huang et al, 2009).  However, the ability of these cells to generate 
action potentials, and therefore function as a neuron, is yet to be reported. 
1.3.3 Induced Pluripotent Stem cells (iPSC) 
The reduced ethical issues that surround the use of ASCs over ESCs has led 
to further research into their use.  The major difference between ESCs and 
ASCs lies with the capacity to form cells of different lineages.  As already 
discussed, ESCs are considered to be pluripotent, with the ability to make 
cells types from all three germ layers, whereas ASCs are often only 
mulitpotent (Table 1.4) and therefore form a more limited number of cell 
types.  This has led to research into the genetic reprogramming of adult 
somatic cells back to an ESC-like state using factors already known to 
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maintain cells in an undifferentiated state. Thus, the production of iPSCs 
creates a source of cells that are pluripotent in nature (Figure 1.4), but have 
fewer associated ethical issues with regard to their tissue of origin and have 
great potential for use in cell-base therapies as well as high throughput drug 
screening.  
1.3.3.1 Important Factors in Pluripotency 
Although the mechanisms that maintain cells in an undifferentiated state are 
still not yet fully understood, parts of the pathway involved with the process of 
self-renewal of mESC and hESC have been investigated. There are several 
genes known to be important in the maintenance of stem cell state, allowing 
self-renewal without terminally differentiating.   
Oct4, Sox2 and Nanog are three transcription factors that have been found to 
be important in the regulation and maintenance of pluripotency in both 
mESCs (Nichols et al, 1998; Niwa et al, 2000; Avilion et al, 2003; Mitsui et al, 
2003; Chambers et al, 2003) and hESC (Hyslop et al, 2005; Fong et al, 2008; 
Adachi et al, 2010; Wang et al, 2012).  These three factors have played an 
important role in the reprogramming of both mouse and human somatic cells 
(Takahashi et al, 2007; Takahashi and Yamanaka, 2006) despite differences 
in the way the factors maintain pluripotency in the two species. Pluripotency 
in mESC is maintained by co-operative Oct4, Sox2 and Nanog regulation 
(Rodda et al, 2005), whereas in hESC, these transcription factors act 
independently to regulate different lineage specifications (Wang et al, 2012). 
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Figure 1.4: Reprogramming of adult somatic cell to iPSC and potential 
therapeutic applications.  A number of methods have been utilised to reprogram 
cells back to an embryonic stem cell state.by introducing different combinations of 
factors; Oct4, Sox2, Nanog, Klf4, Lin28 and c-Myc, resulting in pluripotency.  The 
resulting iPSCs are characterised as pluripotent cells by methods originally utilised by 
Thomson et al to characterise hESC (Thomson et al, 1998). These cells could 
potentially be utilised for development of patient specific drug therapies or could be 
used as cell based treatments following directed differentiation and re-implantation. 
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Following the successful genetic reprogramming of mouse dermal fibroblasts 
in 2006 and human dermal fibroblasts in 2007 (Takahashi and Yamanaka, 
2006; Takahashi et al, 2007), much research has been carried out around 
the molecular basis of pluripotency and the factors involved.  Myc has 
recently demonstrated a role in suppressing differentiation (Varlakhanova et 
al, 2011).  Reports suggest that Klf4 acts directly to control Nanog expression 
(Chan et al, 2009, Zhang et al, 2010) and has more recently been linked with 
hTERT expression, implicating the importance of Klf4 as a factor in the 
maintenance of pluripotency (Wong et al, 2010).  In addition to this, 
expression of Klf4 has been found to act directly with Oct4 and Sox2 to direct 
reprogramming of cells back to their ESC-like state (Wei et al, 2009).  
Similarly, Lin28 is implicated in the expression of Oct4 (Qui et al, 2009) 
highlighting its importance in the maintenance of pluripotency of hESCs.  
Research in this area is ongoing as there is still much to be discovered 
however, further research into the reprogramming of cells back to their ESC-
like state is likely to lead to a greater insight into the molecular basis of 
pluripotency. 
Signalling pathways play an important role in regulating these transcription 
factors to maintain the self-renewal properties of embryonic stem cells.  
Similar to the transcription factors, differences exist between the signalling 
pathways that maintain pluripotency of mESC and hESC, these pathways are 
summarised in Figure 1.5.  
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Figure 1.5: Signalling pathways involved in the maintenance of pluripotency. 
Summary of the different key signalling pathways; LIF, BMP’s, FGF-2 and TGF-β 
involved in maintenance of pluripotency and self-renewal properties in mESC and 
hESC (adapted from Omelyanchuk et al, 2009). 
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LIF has been found to be an important factor in the maintenance of mESCs 
in an undifferentiated state.  It activates the Janus kinase (JAK)/STAT3) 
signalling pathway  to suppress differentiation (Burdon et al, 1999) and the 
PI3K/Akt signalling pathway to protect degradation of c-Myc by inhibition of 
GSK3 (Bechard and Dalton, 2009).  LIF also activates the MEK/ERK1/2 
signalling pathway, which results in differentiation of mESC.  However, BMP 
acts against LIF to actively inhibit this pathway and stop differentiation, 
maintaining pluripotency (Lee et al, 2006; Ying et al, 2008).  Self-renewal of 
hESCs is maintained independently of STAT3 (Humphrey et al, 2004; Sato et 
al, 2004) despite containing the elements of the JAK/STAT3 pathway 
(Humphrey et al, 2004).  Instead, fibroblast growth factor- 2 (FGF-2) activates 
MEK/ERK1/2 pathway, which in contrast to mESC, maintains pluripotency of 
hESC (Dvorak et al, 2005; Li et al, 2007).  FGF-2 also activates the PI3K/Akt 
pathway, which similarly to mESC, acts to maintain pluripotency (Li et al, 
2007).  Proteins of the TGFβ family are known to be involved in activation of 
SMAD 2/3 signalling, upregulating Nanog and Oct4 to maintain pluripotency 
in hESC (James et al, 2005; Vallier et al, 2005), again opposite from its role 
in mESCs.  FGF-2 is known to inhibit SMAD 1/5/8 in the presence of TGFβ, 
suppressing differentiation of hESC (James et al, 2005). 
Research in this field is very much ongoing and reprogramming produces not 
only a great source of cells for use in regenerative medicine, but also adds to 
our increasing knowledge of the molecular basis of pluripotency.  This is an 
important factor when considering the use of these cells in transplant 
applications. 
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1.3.3.2 Reprogramming  
iPSCs were first reported in 2006, when mouse fibroblasts were found to be 
reprogrammed back to an ESC-like state by the introduction of four factors; 
Oct4, Sox2, Klf4 and c-Myc in viral vectors (Takahashi and Yamanaka, 
2006).  It was later found that the same four factors could induce an ESC-like 
state in human skin fibroblasts (Takahashi et al, 2007).  These key findings 
formed the basis of much research into the reprogramming of different cell 
populations back to their embryonic state.  It was later discovered that 
retroviral induction of c-Myc may be of little use for any potential clinical 
application as chimeras formed using the genetically reprogrammed cells 
developed a large number of carcinomas (Okita et al, 2007; Yamanaka, 
2007).  This has led to the use of different factors and methods to enable 
reprogramming of cells that would be safer for potential therapeutic 
applications.  These factors include the original factors used by Takahashi 
and Yamanaka, Oct4 and Sox2, with the addition of Nanog and Lin28 which 
is also known to be involved in the maintenance of pluripotency (Yu et al, 
2007).  These factors are sufficient for the reprogramming of human skin 
fibroblasts, with the resulting cells demonstrating ESC-like morphology, 
expression of classical pluripotency genes and cell surface markers such as 
SSEA-4.  However, without the use of c-Myc, low reprogramming efficiencies 
were observed (Yu et al, 2007; Okita et al, 2007; Nakagawa et al, 2008).  
The development of innovative techniques is continually opening up new 
avenues for potential clinical application of these cells.  Despite the 
development of such techniques, the use of viral vectors in the absence of c-
Myc, to reprogram these cells still poses a risk to patients even though 
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chimeras produced from iPSCs without retroviral c-Myc integration 
demonstrate no tumour formation (Nakagawa et al, 2008), as the vectors still 
integrate and are potentially harmful.  There are now a number of methods 
published for iPSC formation without the use of integrating viral vectors 
including: non-integrating adenoviral vectors (Stadtfeld et al, 2008), delivery 
of factors via PiggyBac (PB) transposition allowing the removal of the PB 
insertion (Woltjen et al, 2009), a minicircle DNA vector that does not contain 
any bacterial DNA (Jia et al, 2010) and vectors derived from the Epstein-barr 
virus (OriP/EBNA) with removal of the vector by culturing without drug 
selection (Yu et al, 2009).  These techniques have used different 
combinations of the factors and, as they are potentially non-integrating, have 
also involved the use of c-Myc.  In addition to this, it has been reported that 
iPSCs can be produced using significantly fewer reprogramming factors from 
human neural stem cells with the addition of Oct4 only (Kim et al, 2009).  
This is, of course, a step in the right direction for producing ESC-like cells 
suitable for clinical application.   
The main disadvantage of producing iPSCs currently is the general low 
efficiency of the process.  The removal of genes, such as the oncogene, c-
Myc, and the use of non-integrating methods for reprogramming has resulted 
in the process becoming less efficient (Yu et al, 2007; Yamanaka, 2007; Yu 
et al, 2009). Several studies have concentrated on the efficiency of 
reprogramming, resulting in new ideas regarding the process including the 
addition of SV40 T antigen to vectors previously used (Mali et al, 2008) and 
the role of p53 in regulating the reprogramming of cells with short telomeres 
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(Marion et al, 2009).  It has also been suggested that reducing the oxidative 
stress by addition of antioxidants such as vitamin C (Esteban et al, 2009) or 
culturing under low-oxygen conditions can increase the efficiency of 
reprogramming cells to iPSCs (Yoshida et al, 2009). 
Reprogramming of terminally differentiated cells has been found to be an 
inefficient process which can possibly be attributed to telomere length as 
cells with short telomeres are difficult to reprogram (Marion et al, 2009; Davy 
et al, 2009). p53 is now known to have a role in the regulation of 
reprogramming of damaged cells, such as those with short telomeres and 
other DNA defects, thereby controlling the formation of iPSCs from these 
cells (Marion et al, 2009).  It is interesting to note that there are differences 
emerging between the capabilities of different cells to be reprogrammed 
(Aasen et al, 2008), potentially not only due to their endogenous expression 
of genes of interest in reprogramming, but also as a result of different 
resident progenitor cell population numbers within the tissue used for 
reprogramming (Okita et al, 2007; Aasen et al, 2008).  
1.3.3.3 iPSC Culture 
Much of the initial work on cell reprogramming was performed by culturing 
cells with FGF-2 and on an iMEF feeder layers to provide the factors required 
to maintain emerging iPSCs in a pluripotent state (Takahashi et al, 2007; 
Okita et al, 2007; Yu et al, 2007; Stadtfeld et al, 2008; Nakagawa et al, 
2008), mimicking the environment known to sustain hESCs cultures.  In order 
for these cells to be considered for any medical applications in humans, they 
would first need to be confirmed as safe.  As such, much work is being 
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carried out, similar to the work carried out on hESC, to establish and maintain 
them in an environment free of animal products i.e. iMEF feeder layers.  
iPSCS have been derived using feeder-free culture conditions on matrigel® 
(Chung et al, 2012; Chang et al, 2013) and demonstrated decreased 
variability amongst iPSC lines when in these conditions compared to feeder-
dependent conditions (Chung et al, 2012).  In addition to this, human 
neonatal foreskin fibroblasts have been used to derive and expand iPSCs 
(Warren et al, 2012).  More recently, human MSCs have been suggested as 
potential feeder layers for iPSC maintenance and interestingly are able to 
support the growth and pluripotency of iPSCs (Havasi et al, 2013). Research 
in this area is ongoing and of great importance for these cells to have any 
clinical relevance. 
1.3.3.4 Differentiation of iPSCs 
Like ESCs and ASCs, differentiation of iPSCs is of great importance if these 
cells are to be used in tissue regeneration and repair. Reports have 
described varying degrees of success with differentiation of iPSCs (Hu et al, 
2010; Kim et al, 2011).  Research is ongoing despite the unanswered 
questions over the safety of these cells as differentiation of iPSCs will further 
our understanding of their potential. iPSCs demonstrate the ability to develop 
into cells of all three germ layers. This has typically been performed as part 
of the characterisation process for reprogrammed cells (Takahashi and 
Yamanaka, 2006; Takahashi et al, 2007; Yamanaka, 2007; Yu et al, 2007; 
Okita et al, 2007) and several studies have further investigated this promise.  
Similar to ESCs, differentiation of iPSCs often involves formation of an EB 
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(Sullivan et al, 2009; Zhang et al, 2009; Hu et al, 2010) followed by the 
directed differentiation which commonly includes;  cardiomyocytes (Zhang et 
al, 2009), neuronal cells (Hu et al, 2010) and hepatocytes (Sullivan et al, 
2010).  Examples of the differentiation potential and the source of iPSCs are 
summarised in Table 1.5.  Differentiation studies at present are largely 
focused on dermal fibroblasts as a cell source for iPSC formation as these 
were the first cell type to successfully be reprogrammed. 
Differences still remain between the differentiation of iPSC and ESCs. This 
has been demonstrated in studies which indicate that iPSC derived from 
mouse fibroblasts differentiate slower compared to mESCs (Morizane et al, 
2009).  Similarly, neural differentiation of iPSCs has been found to be an 
inefficient process with an even higher degree of variability than that seen in 
hESCs (Hu et al, 2010).  More recently, it was found that the donor cell type 
used for reprogramming was important as the resulting iPSCs demonstrated 
preferential differentiation towards cell types associated with the donor tissue 
(Kim et al, 2011; Bar-Nur et al, 2011). 
This has been explained due to an epigenetic memory maintained by the 
iPSCs following reprogramming (Kim et al, 2010; Kim et al, 2011; Bar-Nur et 
al, 2011).  These investigations outline the need for further research into the 
underlying differences that exist between ESCs and iPSCs before such cells 
can be used in clinical applications, to ensure that risk to the patient is 
limited. 
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Reprogrammed 
Cell Source 
Reprogramming 
Method 
Differentiated 
Cell Type 
References 
Dermal 
Fibroblasts 
 
Lentivirus, 
Episomal Vector, 
Retrovirus 
Neural 
Hu et al, (2010); 
Lohle et al, 
(2012) 
Lentivirus Cardiac 
Zhang et al, 
(2009) 
Lentivirus 
Endothelial & 
Haematopoietic 
Choi et al, (2009) 
Retrovirus 
Lentivirus 
Hepatic 
Sullivan et al, 
(2010), 
Ghodsizadeh et 
al, (2010) 
Neural stem cells Retroviral Neural 
Lohle et al, 
(2012) 
Keratinocytes 
Retroviral Neural 
Aasen et al, 
(2008) 
Retrovial and 
small molecule 
inhibitors 
Cardiomyocytes Zhu et al, (2010) 
Mesenchymal 
Stem Cells 
Lentivirus Bone 
Deyle et al, 
(2012) 
Table 1.5: iPSC reprogramming and differentiation potential. Examples of 
different cell sources, their reprogramming method and their differentiation potential 
towards different cell types. 
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1.3.3.5 Neural Differentiation of iPSCs 
iPSCs have characteristics that are similar to ESCs and, like ESCs, require 
the administration of different factors at defined time points in order to 
successfully differentiate these cells down the desired lineages.  The major 
challenge for iPSC differentiation is to gain comparable differentiation with 
hESC to confirm that these ethically obtained cells are a better potential 
candidate for tissue engineering applications.  When considering motor 
neuron differentiation in particular, the reported differentiation potential of 
iPSCs is variable (Hu et al, 2010).  As with hESC, each differentiation 
protocol varies but the important factors utilised for hESC differentiation have 
been utilised for iPSCs (Hu et al, 2010; Boulting et al, 2011). 
iPSC demonstrate differentiation towards motor neurons but with reduced 
efficiency compared to hESCs when culturing EBs with FGF-2, RA and SHH 
followed by mono-layer culture on laminin with BDNF, GDNF and IGF-1 (Hu 
et al, 2010).  In contrast, another group have differentiated iPSCs to motor 
neurons similar to those obtained from hESC (Boulting et al, 2011).  
However, different culture conditions were employed including culturing 
iPSCs as EBs with RA and a small molecule inhibitor of SHH, HAg, followed 
by culture with BDNF, GDNF and Ciliary Neurotrophic Factor (CNTF) prior to 
dissociation of EBs and plating as mono-layer cultures to induce motor 
neuron differentiation. 
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The differences observed between the two studies is potentially attributed to 
the different protocols used for differentiation but could also be due to the 
source of cells used in reprogramming to iPSCs as  well as the number of 
factors used as previously discussed (Kim et al, 2010; Kim et al, 2011, Bar-
Nur et al, 2011). 
1.3.4  Stem cells and oxidative stress 
Oxidative stress is a process that has long been known to affect different 
aspects of cell behaviour. In the presence of oxygen, reactive oxygen 
species such as superoxide radical (O2
.-), hydroxyl radical (.OH) and nitric 
oxide radical (NO.) can be generated and inflict cellular damage (Slater et al, 
1995).  The unpaired electrons in the outer orbitals of these free radicals 
make them highly reactive species. Non-radical derivatives of oxygen include 
hydrogen peroxide (H2O2) and hypochlorus acid (HOCl) (Halliwell, 1994).  
Cellular defences against free radicals exist and include superoxide 
dismutase (SOD) which is produced by the mitochonidria and in the cytosol.  
SOD acts to convert superoxide radicals to H2O2 (McCord and Fridovich, 
1969a).  This is produced by cells when the level of oxidative stress is 
relatively low, high levels of oxidative stress may result in irreversible 
damage to the cell and even cell death (McCord and Fridovich, 1969b; 
Halliwell,1994). 
The culturing of hESC is very difficult due to the spontaneous differentiation 
that can occur.  This is most likely as a result of the suboptimal culture 
conditions used to maintain them. It is common practice to culture these cells 
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at 21% O2 in vitro, however, the in vivo conditions are around 3-5% O2.  
When culturing hESC in vitro at low O2 tension spontaneous differentiation is 
reduced (Ezashi et al, 2005; Ludwig et al, 2006), pluripotency is maintained 
and proliferation is increased (Forristal et al, 2010). 
Alternative methods for reducing oxidative stress exist for hESC culture 
including the addition of antioxidants like β-Mercaptoethanol to the culture 
conditions.  Ascorbic acid is an additional antioxidant that is often added to 
culture media.  It has been well investigated and has long been known that 
addition of ascorbic acid to the culture medium of human dermal fibroblasts 
increases the transcription of genes encoding type I and III collagen (Tajima 
and Pinnell, 1996).  Its presence also alters the growth rates of various cell 
cultures as well as stimulating differentiation of mesenchymal derived cells in 
vitro potentially by changing their gene expression patterns (Alcain and 
Buron, 1994). 
The benefits of reducing oxidative stress for the purpose of increasing 
reprogramming efficiency have been investigated using hypoxic 
environmental conditions (Yoshida et al, 2009) and, more recently, by 
supplementing media with ascorbic acid (Esteban et al, 2010).  The 
mechanisms that underlie this improved efficiency are largely unknown at 
present however, it has been suggested that ascorbic acid acts on 
demethylases that potently regulate reprogramming by suppressing cellular 
senescence and stimulating cell cycle progression (Wang et al, 2011). 
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1.4 Current Clinical Applications of Stem Cells 
It is often forgotten that stem cells are already in use as clinical treatments 
and much can be learnt from the successes and failures of these treatments.  
Epithelial tissues have historically been cultured using autologous 
keratinocyte cells for use as skin grafts (Langdon et al, 1988), limbal stem 
cells have been transplanted to damaged corneal surfaces (Shortt et al, 
2007) and more recently the use of oral mucosa epithelial stem cells for 
corneal transplants has been reported (Inatomi et al, 2006; Nakamura et al, 
2013).  A treatment that has been widely used for many years is that of 
haematopoietic cell transplants (Perry and Linch, 1996) and, although it was 
not known at the time, stem cells underlie the success of this treatment.  
Bone marrow transplants from donor patients have been used in the 
treatment of cancers such as leukaemia for a number of years.  Advances in 
immunology have meant that donor patients can now be screened to find the 
best match to the patient that requires treatment, reducing immune rejection 
and, therefore, increasing the success of these transplants (Perry and Linch, 
1996).  Additionally, treatment of children with osteogenesis imperfect (OI) 
with BMSCs resulted in the formation of new dense bone (Horwitz et al, 
1999) which is now attributed to the presence of MSCs in the BMSCs.  
Treatment with purified populations of MSCs derived from BMSCs has been 
suggested to boost clinical benefit to OI sufferers (Horwitz et al, 2001).  
Although the mechanisms by which these therapies work are not yet fully 
understood, these are invaluable to our increasing knowledge of stem cells 
and their actions in vivo. 
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1.5 Aims 
The OMLP represents a tissue with a population of progenitor cells that 
already express numerous stem cell and developmental markers and can be 
acquired utilising a minimally invasive biopsy procedure.  The biopsy site will 
heal rapidly with minimal scarring to the patient.  These cells therefore 
represent an excellent and promising source of cells for use in clinical 
applications.  
There are three main aims to this project: 
1. Isolate, expand and characterise progenitor cell populations from the 
Oral (buccal) Mucosa Lamina Propria. 
2. Reprogram progenitor cells from the OMLP to iPSC and characterise such 
cells. 
3. Investigate the potential of oral progenitor cells and oral mucosal-
iPSCs to differentiate down a functional neuronal pathway.
  
2 - General Materials & Methods 
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2.1 Materials 
All materials were obtained from Invitrogen UK unless otherwise stated. 
2.1.1 Cell Strains and Cell Lines 
Primary oral mucosal fibroblasts were obtained from healthy oral (buccal) 
mucosa samples obtained from dental patients undergoing routine dental 
procedures at the School of Dentistry, Cardiff University, who had given 
informed consent and after full ethical approval (09/WSE03/18).  A 6mm 
biopsy from the buccal mucosa was obtained from each patient and placed 
into 1x Phosphate buffered saline (PBS).  Human Embryonic Stem Cells (H9) 
were obtained from Dr N Allen, School of Biosciences, Cardiff. 
2.2 Methods 
2.2.1 Cell Culture 
All cell culture was carried out using sterile conditions in a Microflow 
Advanced bio-safety Class II cabinet and cultures maintained in a Binder 
series CB CO2 incubator.  All tissue culture plastic was obtained from Greiner 
bio-one unless otherwise stated.   
2.2.1.1 Differential adhesion assay (Davies et al, 2010) 
Differential adhesion to fibronectin was undertaken for 6 patients; XLVII, 
XLVIII, XLIX, L, LII and LIV (Appendix I for patient details). 
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2.2.1.1.1 Enzymatic Digestion of the Oral Buccal Mucosa Biopsies 
Oral mucosa biopsies were washed in 70% (v/v) ethanol (40 seconds) then 
placed in a tissue culture dish containing Fibroblast-Serum Containing 
Medium (F-SCM): Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Foetal Calf Serum (FCS), 2mM L-Glutamine, 
antibiotics and antimycotics (100U/mL Penicillin G, 100µg/mL Streptomycin 
Sulphate and 0.25µg/mL Amphotericin B).  Any fat was then removed and 
the remaining biopsy was cut into 2mm squares and placed in a solution of 
2mg/mL pronase (Sigma, UK) made up in F-SCM.  Tissue samples were left 
at 4°C overnight. 
Epithelium was then removed from tissue pieces using tweezers and the 
remaining tissue was placed in a tissue culture dish (BD Falcon) containing a 
1mg/mL solution of collagenase A (Roche, UK) made up in F-SCM.  Tissue 
pieces were cut as finely as possible using a scalpel and placed in an 
incubator at 37°C overnight. 
2.2.1.1.2 Differential Adhesion to Fibronectin (Figure 2.1) 
Fibronectin coated plates were prepared using a 10µg/mL solution of bovine 
plasma fibronectin (Sigma, UK) diluted in 1x PBS+ (1x PBS supplemented 
with 0.1mM MgCl2 and 0.1mM CaCl2).  One mL of this solution was used to 
coat the bottom of each well of a 6-well plate.  Plates were covered with 
Parafilm and left overnight at 4°C. 
A 1mL pipette was then used to disaggregate the tissue by pipetting up and 
down, followed by successively smaller pipette sizes. 
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Finally a 10mL syringe with a 0.8/21 gauge needle attached was used to 
remove cells from the dish after the addition of serum free medium (SFM) 
(DMEM supplemented with 2mM L-Glutamine, antibiotics and antimycotics 
(100U/mL Penicillin G 100µg/mL Streptomycin Sulphate and 0.25µg/mL 
Amphotericin B) and placed into a 15mL centrifuge tube.  This was 
centrifuged at 400 x g for 5 minutes and the pellet re-suspended in 1mL 
SFM. The cells were counted by mixing 20µL of cell solution with 20µL trypan 
blue exclusion and counted using a Fastread 102 haemocytometer.  A cell 
solution was made up to 1 x 104 viable cells/mL in SFM. 
Cell populations were then selected on their bases to bind/not to bind to 
fibronectin (Figure 2.1).  Fibronectin solution was aspirated off each well of 
the 6 well plate and 1mL of the cell solution was placed in each well (leaving 
two wells free for further incubation) and the plate incubated at 37°C for 20 
minutes to isolate any potential oral progenitor cells (OP = Cell Population 1).  
Any remaining left over cell solution containing the total cell population (TP = 
Cell Population 2) was centrifuged at 400 x g, re-suspended in 1mL F-SCM 
and counted using trypan blue exclusion (1:1) and Fastread® 102 
haemocytometer. Cells were seeded in a separate 6 well plate at a density of 
2 x 104 cells/cm2 in F-SCM.  After the 20 minute incubation the medium in the 
primary 6-well plate (containing cells that had not adhered to fibronectin 
within the 20 min incubation period) was aspirated off the and 3mL of F-SCM 
placed into each of these wells to permit onward culture of the OPs.  The 
‘non-adherent’ cell medium was then centrifuged at 400 x g for 5 minutes, the 
medium aspirated off and the cells re-suspended in 3mL of serum free 
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medium.  This was then added to another fibronectin coated well and 
incubated at 37°C for 40 minutes.  This was then removed and transferred to 
another fibronectin coated well for a second 40 minute incubation at 37°C (F-
SCM was added to the second population of adherent cells to permit their 
culture).  Medium was aspirated off following the second 40 minute 
incubation and replaced with 3mL of F-SCM.  Finally, the remaining 
(aspirated) cell solution was centrifuged at 400 x g and counted using a 
haemocytometer.  These cells, the non-adherents (NA = Cell Population 3), 
were then re-seeded onto standard tissue culture plastic and left to adhere 
O/N.  OP cells developed as single cell derived colonies and were cultured in 
two ways; isolated as single cell derived clonal populations and expanded or 
the OP cells were allowed to merge together to form a merged progenitor 
(MP) cell population. 
2.2.1.2 Isolation of Colonies 
Colonies were picked from the fibronectin coated plates when colony cell 
number was greater than 32 cells.  Cell number for each colony was 
recorded.  Each colony was marked on the plate, medium removed and cells 
washed once in PBS.  A cloning ring was placed over the colony, using 
Vaseline® to make a seal.  One hundred µL of accutase was pipetted into 
the cloning ring and the plate was placed into the incubator at 37°C for 5 
minutes.  The contents of the cloning ring were pipetted up and down to 
release the cells from the surface of the plate.  Each colony was placed into 1 
well of a 96 well plated containing 150µL of F-SCM.  These were maintained 
in an incubator at 37°C and with 5% CO2/95% air and fed every 2-3 days 
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until 80-90% confluency was reached.  Medium was removed from the cells 
and cells were washed once with 200µL of PBS. This was removed and 
replaced with 100µL accutase and returned to the incubator for 5 minutes. 
Following incubation cells were mixed with 100µL F-SCM to inactivate the 
accutase and re-plated into a 24 well plate. Each passage following this, a 
cell count was performed as described below and cells were re-seeded as 
required. 
2.2.1.3 Oral Mucosa Lamina Propria Cell Culture 
Cell cultures were fed with F-SCM every 2-3 days.  Cells were left until they 
were 85-95% confluent before passaging.  Medium was aspirated off and the 
cell culture was washed once with PBS (2mL in 1 well of a 6 well plate, 5mL 
in a T25 and 10mL in a T75) which was then aspirated and replaced with 
accutase (500µL in 1 well of a 6 well plate, 1mL in a T25 and 3mL in a T75) 
to coat the plate/flask.  This was left at 37°C for 5-10 minutes until the cells 
detached from the plastic.  F-SCM (3mL in 1 well of a 6 well plate, 5mL in a 
T25 and 10mL in a T75) was added to the plate/flask to inactivate the 
accutase.  Medium was removed and placed into a centrifuge tube, 
centrifuged at 400 x g for 5 minutes, supernatant was removed and pellet 
resuspended in 1mL of medium.  Trypan blue (Sigma-Aldrich, UK) exclusion 
was used to calculate cell viability by mixing 20µL of Trypan blue with 20µL 
of cell suspension.  Viable cells were counted using a Fastread® 102 
haemocytometer Cell populations were re-seeded at the required density.   
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2.2.1.4 Cryopreservation and Re-establishment of Oral Mucosa Lamina 
Propria Cells 
Cells were re-seeded as required.  The remaining cells (between 3 x 105 and 
5 x 105) were re-suspended in a 1mL cryopreservation solution containing: 
10% (v/v) dimethyl sulfoxide (DMSO) and 90% (v/v) FCS and transferred to 
cryogenic vials and frozen in an iso-propanol freezing container at -80°C for 
24 hours.  Following this, cryovials were transferred to liquid nitrogen for long 
term storage.  When required, these frozen cells were thawed rapidly at 
37°C, added to 10mL of pre-warmed (37°C) F-SCM and centrifuged at 400 x 
g for 5 minutes to remove the DMSO and serum.  The supernatant was 
removed and the pellet re-suspended in 1mL of F-SCM.  Cells were counted 
using a haemocytometer and re-seeded as required. 
2.2.1.5 Dermal Fibroblast Cell Culture 
Human dermal fibroblast (DF) were previously isolated and expanded by 
members of the Wound Biology Group, (School of Dentistry, Cardiff 
University).  DF were treated in the same way as oral mucosa lamina propria 
cells and re-established from cryopreservation as previously described in 
section 2.2.1.4 and cultured as described in section 2.2.1.3. 
2.2.1.6 Mycoplasma Testing 
All cell populations were mycoplasma tested at confluency.  One hundred µL 
of conditioned medium was taken and tested using a Mycoplasma detection 
kit by PCR (Minerva Biolabs, Germany).  All mycoplasma testing was carried 
out by Dr M Stack, (School of Dentistry, Cardiff University).  Any 
contaminated cell populations were treated with F-SCM containing 10µg/mL 
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Ciprofloxacin for two weeks and then re-tested for mycoplasma.  Subsequent 
mycoplasma test were carried out every 5 passages.  Only mycoplasma 
negative cells were utilised in experiments. 
2.2.1.7 Formation of Feeder Layers 
Human embryonic stem cells require feeder layers in order to maintain their 
pluripotent state and mouse embryonic fibroblasts (MEFs) are often used to 
provide the required factors to maintain these stem cells (Thomson et al, 
1998). 
A pregnant mouse (CF1 strain) was sacrificed between days 13 and 14 post 
coitum by cervical dislocation.  The abdomen was washed with 70% (v/v) 
ethanol and cut using a pair of scissors to reveal the uterine horns.  These 
were dissected out and placed in a 50mL falcon containing 20mL PBS to 
wash them.  This was repeated twice more with a fresh 50mL falcon 
containing 20mL PBS.  The contents were placed in a 10cm tissue culture 
dish after the final wash and transferred to a sterile tissue culture hood.  The 
placenta and amniotic membranes were removed from each embryo, the 
head and organs were removed and discarded.  Each embryo was washed 
with PBS and transferred to a clean 10cm tissue culture dish.  Embryos were 
minced using a sterile scalpel and then further disaggregated using a 1ml 
pipette before adding 2mL of Trypsin/EDTA per embryo and incubating the 
plate at 37ºC for 15 minutes.  Following incubation the cell suspension was 
passed several times through a syringe fitted with an 18 G needle before 
adding an equal volume of fresh Trypsin/EDTA to the dish before returning to 
the incubator for a further 15 minutes.  An equal volume of Mouse Embryonic 
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Fibroblast (MEF) medium: DMEM supplemented with 10% FCS, 2mM L-
Glutamine, 100U/mL Penicillin, 100µg/mL Streptomycin Sulphate and Non- 
Essential Amino Acids (NEAA) (Glycine 7.5mg/L, L-alanine 8.9mg/L, L-
asparagine 1.32mg/L, L-aspartic acid 1.33mg/L, L-glutamic acid 1.47mg/L, L-
proline 1.15mg/L and L-serine 1.05mg/L) was added to the plate to neutralise 
the Trypsin/EDTA.  A 1mL aliquot of this was counted using a 
haemocytometer.  The cell suspension was spun at 400 x g for 5 minutes to 
pellet the cells and re-suspend in MEF medium to 1 x 106 cells/mL.  These 
cells were plated at 10mL/10cm tissue culture dish and returned to the 
incubator.  Medium was changed for 10mL of fresh MEF medium after 24 
hours to remove debris and non-viable cells.  Once cells reached high 
confluency after 2-3 days, medium from each 10cm dish was removed (1mL 
was kept for mycoplasma testing), washed once with 10mL PBS, replaced 
with 3mL of Trypsin/EDTA and returned to the incubator for 5 minutes.  When 
cells had detached, 5mL of MEF medium was added to each plate and cells 
were washed from the surface and collected in a 50mL falcon.  These cells 
were spun at 400 x g for 5 minutes, supernatant was removed, replaced with 
fresh MEF medium and cell suspension was re-plated into a 15cm tissue 
culture dish.  These were termed passage 2 cells.  Each 15cm tissue culture 
dish was split at a ratio of 1:5 when confluent to give passage 3 MEFs.  Cells 
after passage 4 were not used as embryonic stem cell feeders. 
2.2.1.8 Mitotic Inactivation of MEFS using γ-Irradiation 
MEF cells that were free of mycoplasma contamination were mitotically 
inactivated by γ-irradiating in order to be used as a feeder layer (iMEFs).  
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Cells to be irradiated were split by removing MEF medium from the 15cm 
tissue culture dish, washing once with 15mL PBS and replacing with 5mL of 
Trypsin/EDTA and returning to the incubator for 5 minutes.  Once the cells 
were detached an equal volume of fresh MEF medium was added to 
inactivate the Trypsin/EDTA and cell suspensions were collected in a 50mL 
falcon.  An aliquot of this was used to determine the cell number with a 
haemocytometer as in section 2.2.1.3.  The cell suspension was then spun at 
400 x g for 5 minutes to pellet the cells.  The supernatant was removed and 
the pellet resuspended to a cell concentration of 2 x 106 cells/mL before 
irradiating.  The cells were irradiated at 3000 rads using a γ-irradiator.  
Following irradiation, the cells were once again spun at 400 x g for 5 minutes 
to pellet the cells.  The supernatant was removed and the cells resuspended 
to 1 x 106 cells/mL with cryopreservation solution and transferred to cryogenic 
vials (1mL/vial).  These were placed in an iso-propanol freezing container at -
80°C for 24 hours.  Following this, cryogenic vials were placed in liquid 
nitrogen for long term storage. 
2.2.1.9 Human Embryonic Stem Cell Culture 
2.2.1.9.1 Preparing Feeder Layers 
MEFs were seeded at a density of 7.5 x 103 cells/cm2, equivalent to 7.2 x 104 
cells into each well of a 6 well plate.  Plates were pre-coated with 0.1% (w/v) 
gelatin (Milipore, UK) for 1 hour at room temperature.  Gelatin was removed 
and replaced with 2mL MEF medium containing the required number of 
MEFs.  Plates were returned to the incubator to allow the MEFs to settle.  
Feeder layers were best used after 24 hours and within 2 days of plating.  
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When feeder layers were required for ESCs, MEF medium was removed, 
cells were washed twice with 2mL PBS to remove all serum and replaced 
with 2mL Embryonic Stem Cell (ESC) Medium: Knockout® DMEM 
supplemented with 20% (v/v) Knockout® Serum Replacer, 2mM L-
Glutamine, 100U/mL Penicillin, 100µg/mL Streptomycin Sulphate, (NEAA) 
(Glycine 7.5mg/L, L-alanine 8.9mg/L, L-asparagine 1.32mg/L, L-aspartic acid 
1.33mg/L, L-glutamic acid 1.47mg/L, L-proline 1.15mg/L and L-serine 
1.05mg/L) and 10ng/mL basic Fibroblast Growth Factor (FGF-2, Peprotech, 
UK).  Plates were returned to the incubator to allow medium to equilibrate. 
2.2.1.9.2 Splitting and re-plating Human Embryonic Stem Cells 
When Human ESC colonies were at an optimal size, determined by a 
flattened colony with a tight boundary that was not touching adjacent colonies 
and could be viewed completely using the size of 10 x objective lens, they 
were prepared for splitting. 
Any differentiated colonies (distinguished by a change in morphology of the 
cells and colonies that lacked a tight colony boundary) were removed by 
scraping, using a flame pulled glass Pasteur pipette.  ESC Medium was 
removed and colonies were washed once with PBS to remove differentiated 
colonies and medium.  This was replaced with 2mL of 1mg/mL Collagenase 
IV in Knockout® DMEM and returned to the incubator for 40 minutes.  When 
colonies began to curl up at the edges, plates were removed from the 
incubator and colonies were gently washed from the surface using a 5mL 
pipette, keeping the colonies as large as possible.  The colonies were 
collected in a 15mL falcon and spun at 200 x g for 2 minutes to pellet them.  
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The supernatant was removed and the pellet was re-suspended with 1mL of 
pre-warmed ESC medium, pipetting up and down with a 1mL pipette tip (to 
break up the colonies) a maximum of 8 times depending on colony size.  The 
colonies were split in a 1:3 ratio onto the prepared MEF feeder layers, 
returned to the incubator and left undisturbed for 48 hours to allow colonies 
to attach.  After 48 hours, ESC medium was removed and replaced with 2mL 
of fresh pre-warmed ESC medium.  This was repeated daily until colonies 
required splitting. 
2.2.1.9.3 Cryopreservation and Re-establishment of Human Embryonic Stem 
Cells 
Colonies were re-seeded as required and when ready to be split, 
differentiated colonies were removed from the plates using a flame pulled 
Pasteur pipette, ESC medium was removed and colonies washed with 2mL 
of PBS to remove debris.   This was removed and replaced with 2mL 1mg/ml 
Collagenase IV solution and returned to the incubator for 40 minutes until 
colonies began to curl at the edges.  Colonies were washed from the plate 
with a 5mL pipette, keeping the colonies as large as possible.  The colonies 
were collected in a 15mL falcon tube and spun at 200 x g for 2 minutes to 
pellet the colonies, the supernatant was removed and colonies were gently 
re-suspended, avoiding breaking up the colonies, with 500µL of ESC medium 
and 500µL of 2 x Freeze mix: 20% (v/v) DMSO in 80% (v/v) FCS and 
transferred to cryogenic vials; colonies from one well of a 6 well plate were 
frozen into one vial.  Vials were frozen in an iso-propanol freezing container 
at -80°C for 24 hours.  Following this, cryovials were transferred to liquid 
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nitrogen for long term storage.  When required, these frozen colonies were 
thawed rapidly at 37ºC, transferred to 10mL of pre-warmed ESC medium and 
spun at 200 x g for 2 minutes to pellet colonies.  The supernatant was 
removed and colonies gently re-suspended (to avoid breaking the colonies) 
in 1mL of pre-warmed fresh ESC medium.  These colonies were then gently 
re-seeded onto prepared MEF plates, returned to the incubator and left 
undisturbed for 48 hours to settle. 
2.2.1.10 Imaging of Cells 
Digital images of cells were obtained using a Nikon Eclipse TS100 
microscope fitted with a Canon LA DC 58E digital camera (F stop 5.6) at 10x 
and 20x objective.  Confocal laser scanning microscope images were 
obtained using a Leica TCS SP5 confocal laser scanning microscope (Leica, 
Milton Keynes, UK).  Fluorescent images were obtained using an Olympus 
AX7 microscope fitted with a Nikon DXM-1000 camera (both Nikon, Japan) 
and images were acquired using ACT-1 imaging software. 
2.2.2 Gene Expression Studies 
2.2.2.1 Extraction of Total RNA 
When cell cultures were 90-95% confluent, medium was removed from cells 
and cells were washed once with PBS.  PBS was removed and replaced with 
1ml of Trizol®.  This was left to incubate at room temperature for 5 minutes.  
Cells were removed from the surface of the plastic with a cell scraper and 
placed into a 1.5mL eppendorf.  175µL of chloroform was added to each 
1.5mL eppendorf, inverted and left to incubate at room temperature for 3 
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minutes.  Heavy phase-lock tubes (5 Prime, UK) were centrifuged in an 
Eppendorf Centrifuge 5415R at 12000 x g for 1 minute to pellet the gel.  
Following the 3 minute incubation the whole RNA extraction mixture was 
transferred to the phase-lock tube and centrifuged at 13000 x g for 2 minutes 
to separate out the phenol layer.  The upper aqueous layer was removed 
from the phase-lock tube and transferred to a new 1.5mL eppendorf and an 
equal volume of isopropanol was added to each tube, mixed and left 
overnight at -20°C to precipitate the RNA.  The RNA pellet was isolated by 
centrifugation at 12000 x g for 10 minutes at 4ºC.  The supernatant was 
removed and replaced with 1mL of 75% ethanol to wash the pellet.  
Following washing, the pellet was centrifuged at 7500 x g for 5 minutes at 
4ºC, supernatant removed and the pellet allowed to air-dry for 10 minutes 
before resuspending in 43µL of RNase free water to give a final volume of 
50µL following DNase Treatment. 
2.2.2.2 DNase Treatment of Extracted RNA 
The resuspended pellet of extracted RNA was treated with 1µL of DNase 
(Promega, UK), 5µL of 10x DNase buffer (Promega, UK) and 1µL of RNasin 
(Promega, UK) giving a final volume of 50µL which was then heated to 37ºC 
for 15 minutes and rapidly cooled on ice. 
2.2.2.3 Purification of Treated RNA 
RNA was purified using the RNeasy® MinElute™ protocol for RNA cleanup 
(Qiagen, UK).  DNase treated RNA was made up to 100µL with RNase free 
water.  To this, 350µL of buffer RLT containing 1% (v/v) β-mercaptoethanol 
was added and mixed by vortex.  Following this, 250µL of 100% ice cold 
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ethanol was added and mixed by pipetting.  The 700µL was added to the top 
of an RNeasy® spin column and centrifuged for 1 minute at 8000 x g.  The 
elutant was disposed of and 500µL of buffer RPE was added to the column 
and centrifuged for a further minute at 8000 x g to wash the membrane.  The 
membrane was then dried by adding 500µL of buffer RPE and centrifuging at 
14000 x g for 2 minutes.  The RNA was eluted by the addition of 50µL of 
RNase free water to the column and centrifuging at 8000 x g for 1 minute.  
The concentration of RNA was determined using Nanovue® 
spectrophotometer, aliquoted and stored at -80ºC until required. 
2.2.2.4 Generation of cDNA by Reverse Transcription 
Following concentration determination of RNA samples, 0.5µg of RNA was 
mixed with 0.5µL of random hexamer primers (Promega, UK) and made up 
to 6.5µL with RNase free water.  This was mixed and heated to 70ºC for 5 
minutes, then cooled on ice for 5 minutes.  A master mix of 2.5µL mmLV 5x 
buffer, 0.5µL RNasin (20u), 2.5µL dNTPs (10mM) and 0.5µL mmLV RT 
(100u) (all Promega, UK) was added to each sample, mixed and incubated at 
25ºC for 10 minutes, 42ºC for 1 hour and finally 95ºC for 5 minutes.  Newly 
synthesised cDNA was stored at -20ºC until required. 
2.2.2.5 Amplification of cDNA by Polymerase Chain Reaction (PCR) 
A master mix of 12µL of Platinum Blue Super mix (containing 22U/ml 
complexed recombinant Taq DNA polymerase with Platinum® Taq antibody, 
22mM Tris-HCl (pH 8.4), 55mM KCl, 1.65mM MgCl2, 220µM dGTP, 220µM 
dATP, 220µM dTTP, 220µM dCTP, stabilizers, glycerol and blue tracking 
dye) was mixed with 0.5µL of 1µM forward primer specific to the gene of 
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interest and 0.5µL of 1µM reverse primer for the same gene (for details of 
primers see Chapter specific methods).  One µL of sample cDNA was added 
to each reaction to make the total volume 13 µL.  This was amplified in a 
thermal cycler (Software version 2.3.2, VWR, UK).  There was an initial 
denaturation step at 95°C for 10 minutes before amplification for 40 cycles, 
each cycle consisting of a 95°C denaturation step, followed by a 30 second 
annealing (Ta) step at the optimal temperature for each primer and finally an 
elongation step at 74°C for 1 minute.  Amplification was completed by a final 
elongation step at 74°C for 10 minutes.  Samples were stored at -20°C until 
required. 
2.2.2.6 Sequencing of PCR Products 
PCR products were purified to remove primers using the MinElute® PCR 
Purification kit (Qiagen, UK).  For each target gene, an extra 30µL reaction 
was run using the positive control (detailed in chapter specific methods) in 
order for each PCR product to be sequenced.  Ten µL of this reaction was 
run out on an agarose gel (see below) to check that the product was the 
correct size.  To the remaining 20µL reaction, 100µL of Buffer PB was added 
and mixed.  This was added to a MinElute® spin column in a 2mL collection 
tube and spun at 17900 x g in a bench top microcentrifuge for 1 minute to 
bind the DNA.  The flow-through was discarded from the collection tube and 
the MinElute® column placed back into the same collection tube.  Bound 
DNA was washed by adding 750µL Buffer PE to the spin column and 
spinning for 1 minute at 17900 x g.  Again, the flow-through was discarded 
and the MinElute® was placed back into the same tube and spun one final 
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time at 17900 x g for 1 minute to remove residual ethanol contained within 
Buffer PE.  Bound DNA was eluted from the MinElute® spin column by 
placing the column in a fresh 1.5mL microcentrifuge tube.  Ten µL of Buffer 
EB was added to the centre of the column membrane and this was left to 
stand for 1 minute followed by centrifugation at 17900 x g for 1 minute.  The 
purified products were sequenced by Andrew Francis from Central 
Biotechnology Service (CBS), Cardiff University. 
2.2.3 Agarose Gel Electrophoresis 
Agarose gels containing 0.5% (v/v) ethidium bromide were made up in 1 x 
TAE (50x stock: 242g Tris Base, 57.1mL glacial acetic acid and 100ml 0.5M 
EDTA) buffer.  The percentage gel was determined by product size; 1% gels 
were made up for PCR products above 500bp, 2% gels for products between 
500bp and 300bp and 3% gels for products smaller than 300bp.  The gel was 
buffered in 1 x TAE running buffer (as described previously), 5µL 100bp DNA 
ladder (Promega, UK) was loaded into the first well for estimating molecular 
weights followed by 10µL of each sample and run for 50 minutes at 80V.  
Products were visualised using a transilluminator and images were acquired 
using a Gel Doc-17 ™ (UVP doc, VWR, UK). 
2.2.4 Statistical Analysis 
All data is shown ± SD when applicable, where mean values from individual 
patient samples have been combined to give the mean.  Alternatively, when 
applicable, data has been shown ± SEM, where experimental repeats have 
been used to calculate the mean.  Data was analysed using GraphPad InStat 
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software and multiple groups were analysed using One-way Analysis of 
Variance (ANOVA) followed by post hoc Tukey-Kramer test and statistical 
significance was assumed when P<0.05. 
  
3 - Characterisation of cell 
populations from the oral 
mucosa 
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3.1 Introduction 
Embryonic stem cells are an invaluable source of cells for use in tissue 
engineering and repair due to their pluripotent properties however, there is 
much controversy surrounding their use (Wert and Mummery, 2003; 
McLaren, 2007; Bahadur et al, 2010).  This is due to the fact that these cells 
are isolated from a fertilised egg.  Their derivation involves destruction of the 
embryo and, thereby, initiates discussion regarding at what point an embryo 
becomes a life form and therefore gains human rights?  For this reason, 
alternative cell sources are currently being sought and, as a result, stem cell 
research is exploring the idea of isolating and modifying adult stem cell 
populations from patients before re-implanting them back into the patient as a 
cell-based treatment for tissue regeneration and repair.  Adult stem cell 
populations have been identified in various tissues within the human body 
including; skin (Jones & Watt, 1993), cornea (Barradon and Green, 1987) 
and bone marrow (Caplan, 1991; Colter et al, 2000) and much work has 
been carried out around their potential uses.  Adult stem cells are thought to 
be a more acceptable cell source for use in tissue regeneration. However, in 
contrast to embryonic stem cells, these cells are only multipotent, often only 
differentiating into cells from their germ layer of origin and, as such, much 
work has been carried out to isolate progenitor cells from many different 
sources.  Work within the Wound Biology Group (Cardiff University) has 
recently demonstrated that a progenitor cell population exists within the 
lamina propria of the oral mucosa (Davies et al, 2010).  These cells were 
isolated utilising differential adhesion to fibronectin (Jones & Watt, 1993; 
Dowthwaite et al, 2004) based on the presence of higher number of 
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functionally active α5β1 integrins on their surface compared to terminally 
differentiated cells.  The isolated cells are characterised by their ability to 
form colonies from single cells seeded at low density (a typical characteristic 
of progenitor cell populations; Jones and Watt, 1993), express numerous 
development markers and are of neural crest origin.  They have also recently 
been demonstrated to possess immunosuppressive properties (Davies et al, 
2012) making these cells an attractive target for use in tissue regeneration 
and repair. 
More recently it was reported that somatic cells (e.g. human dermal 
fibroblasts) could be reprogrammed back towards an embryonic stem cell-
like state, producing what has been termed induced Pluripotent Stem Cells 
(iPSCs; Takashia et al, 2007).  This procedure involves reprogramming adult 
cells to restore their pluripotent properties, making these cells an ideal 
alternative to embryonic stem cells.  Interestingly, cells isolated from the 
lamina propria have already been reported to express several pluripotency 
markers including Oct-4, Nanog and Sox-2 (Davies et al, 2010) and, as such, 
these cells would make an interesting target for applications in cellular 
reprogramming since these are three of the factors that have been used 
during iPSC reprogramming (Yu et al, 2007).  Much research has been 
carried out recently investigating the best cell type to derive iPSCs from with 
these factors and how to make the process more efficient (Yamanaka, 2012).  
Human dermal fibroblasts have been extensively used for reprogramming as 
these were the first cell type reported to be reprogrammed (Takashia et al, 
2007).  Although reprogramming efficiency remains relatively poor, work is 
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on-going to determine methods that safely (thinking of eventual translation of 
this technology into patients) improve this reprogramming efficiency.  One 
method found to improve the efficiency of these reprogramming methods is 
to reduce the levels of oxidative stress the cells in culture experience.   
The benefits of reducing oxidative stress for the purpose of increasing 
reprogramming efficiency have been investigated using hypoxic 
environmental conditions (Yoshida et al, 2009) and, more recently, by 
supplementing media with ascorbic acid (Esteban et al, 2010).  The 
mechanisms that underlie this improved efficiency are largely unknown at 
present however, it has been suggested that ascorbic acid acts on 
demethylases that potently regulate reprogramming by suppressing cellular 
senescence and stimulating cell cycle progression (Wang et al, 2011).   
The purpose of this chapter is to isolate a source of progenitor cells from the 
oral mucosa by differential adhesion to fibronectin and investigate the effects 
of ascorbic acid on these cells. This method has previously been optimised 
form cells from the oral mucosa lamina propria by members of the wound 
biology group, Cardiff University (Davies et al, 2010).  As a comparison, total 
cell population of the lamina propria, merged progenitor cells and cells that 
do not adhere to fibronectin after three different adhesion time points will also 
be investigated with the aim of identifying the most appropriate cell 
population to target for reprogramming purposes. Each of these cell 
populations will be treated and untreated with 50µg/mL ascorbic acid, the 
optimum concentration that demonstrated improved reprogramming 
efficiency (Esteban et al, 2010). 
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3.1.1 Hypothesis 
Reducing environmental oxidative stress will have a beneficial effect on oral 
mucosal lamina propria progenitor cells (and thereby provide a better 
candidate cell population for cellular reprogramming). 
3.1.2 Aims 
There are three main aims for the characterisation of the OMLP-PC cells 
during culture with/without the antioxidant ascorbic acid: 
1. To establish the colony forming efficiency of these cells when 
treated/untreated 
2. To determine the population doubling level of each of the isolated cell 
populations when treated/untreated 
3. To determine the baseline expression of pluripotency markers in each 
of the treated/untreated cell populations 
Together these data will be used to determine the best population of cells to 
target for reprogramming. 
3.2 Methods 
A number of general methods (Chapter 2) were used in the characterisation 
of cell populations of the oral mucosa: Differential adhesion assay, oral 
mucosa lamina propria (OMLP) cell culture, cryopreservation and re-
establishment of cells from the OMLP, dermal fibroblast cell culture, 
formation of feeder layers, mitotic inactivation of MEFS using γ-irradiation, 
human embryonic stem cell (hESC) culture, cryopreservation and re-
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establishment of hESCs, mycoplasma testing, imaging of cells, extraction of 
total RNA, generation of cDNA by reverse transcription, amplification of 
cDNA by PCR, agarose gel electrophoresis, sequencing of PCR products 
and statistical analysis. 
Two OP cell populations were developed; (i) individual colonies were left to 
merge together and (ii) colonies were individually isolated and maintained in 
monolayer culture to give a population of colonies from a single OP cell 
(colonies).  Colonies were indicated by a number before the patient number 
(e.g.  5 XLIX is colony 5 from patient XLIX).  From here on MP refers to a cell 
population of colonies that have merged together. 
 
 
3.2.1 Treatment of Oral Mucosa Lamina Propria Cell Cultures 
with Ascorbic Acid 
Cells were isolated from buccal mucosa biopsies as described in Chapter 2 
(Section 2.2.1.1).  At the point of isolation, duplicate cell cultures were set up 
for the three cell populations; OP, TP and NA.  One was maintained in F-
Cell Population of the 
oral mucosa lamina 
propria 
Abbreviation 
Merged oral progenitor 
cells 
MP 
Total cell population TP 
Non-adherent cell 
population 
NA 
Colonies e.g 5 XLIX 
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SCM, the other in F-SCM +50µg/mL Ascorbic Acid (Sigma, UK) so that cells 
were cultured and expanded directly from the digested lamina propria either 
with or without treatment with ascorbic acid.  Medium was replaced daily for 
each cell culture. Colonies were isolated and expanded from each of the 
treated and untreated OP cultures as previously described in Chapter 2 
(Section 2.2.1.2) and maintained ± ascorbic acid. Alternatively, treated and 
untreated populations of OP cultures were allowed to merge (MP) and again, 
maintained ± ascorbic acid. In summary, this experiment consisted of four 
cell populations, MP, TP, NA and isolated colonies, each of these cultures 
were treated or untreated with ascorbic acid and set up in triplicate. 
3.2.2 Colony Forming Efficiency   
Cells that attached during the 20 minute adhesion step and both 40 minute 
adhesion steps of the differential adhesion assay (Section 2.2.1.1.2) were 
counted after 24 hours to determine the number of cells that adhered in each 
well (n=3 wells for each patient sample).  This was carried out with cell 
cultures ± ascorbic acid.  For all subsequent counts after day 1, the number 
of colonies formed in each well was determined whereby only colonies > 32 
cells were counted to ensure exclusion of transit-amplifying cells that 
terminally differentiate after 5 population doublings (Jones & Watt, 1993).  
Colonies were counted in each well on days 3, 6, 9, 12 and 15 and the 
colony forming efficiency (CFE) was calculated using: 
CFE=  Number of colonies formed >32 cells 
Initial number of adherent cells 
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3.2.3 Calculation of Population Doubling Levels 
Population doubling levels (PDLs) were plotted against time to compare the 
proliferative potential of the different cell populations (MP, TP, NA and 
colonies) from the oral mucosa.  At each passage, cell numbers were 
determined using a haemocytometer, the number of cells reseeded was also 
recorded.  PDL was calculated using:  
PDL=   log10(total cell count obtained)- log10(total cell count re-seeded) 
     log10(2) 
 
3.2.4 End-point PCR Analysis of Pluripotency Markers 
PCR was carried out as described in Chapter 2 (Section 2.2.2.6) using 
primers specific to pluripotency markers and a house keeping gene (Table 
3.1).  These were the 6 factors that had been used in various combinations 
for the purpose of reprogramming cells to iPSCs (Takahashi et al, 2007; Yu 
et al, 2007, Yu et al, 2009). 
3.2.5 Quantitative analysis of Pluripotency Markers 
cDNA (prepared as in Chapter 2: Section 2.2.2.5) from the cell populations 
isolated from patients XLIX, L, LII and dermal fibroblasts samples were used 
to establish the level of pluripotency gene expression in relation to hESCs 
(H9).  Taqman® Gene Expression Assays for Oct-4, Sox-2, Nanog, Klf-4 and 
C-myc were utilised (Table 3.2).  GAPDH was used as a house keeping 
gene.  A standard curve method was employed to ensure linear reactions of 
the target genes of interest.  H9 cDNA was used as a standard and ten-fold 
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serial dilutions were carried out (namely 1/10, 1/100, 1/1000, 1/10000 and 
1/100000).  Gene expression assays and cDNA samples were thawed on 
ice.  TaqMan® Gene Expression Master Mix (containing: AmpliTaq Gold® 
DNA Polymerase (Ultra Pure), Uracil-DNA Glycosylase, dNTPs with dUTP, 
Passive Reference dye ROX and invitrogen optimized mix components) was 
swirled to mix the contents.  The number of required reactions was calculated 
with each sample being assessed in triplicate.  For each reaction the 
following was mixed in a sterile eppendorf: 10µL Expression Master mix, 8µL 
RNase free water and 1µL Taqman Gene Expression Assay.  This was 
mixed thoroughly and 19µl was added to the relevant wells of a white qPCR 
96 well plate (Primer Design, UK).  One µl of serially diluted standard or 
sample cDNA (at 1/10 dilution used to ensure levels were within the linear 
range of the standard curve) was added to the relevant wells of the 96 well 
plate.  The plate was sealed with an adhesive optical seal (PrimerDesign, 
UK) and spun at 800 x g for 5 minutes.  The 96 well plate was then loaded 
into the qPCR machine (Applied Biosystems 7000).  There was an initial 
denaturation step at 95°C for 10 minutes before amplification for 40 cycles, 
each cycle consisting of a 95°C denaturation step for 15 seconds then an 
annealing step at 60ºC for 30 seconds. When the reaction was complete, an 
appropriate threshold value was selected before analysis of cycle numbers 
(Ct) was made.  The 2-ΔΔCt method was adopted to analyse the relative 
quantities of gene expression (Livak and Schmittgen, 2001). 
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Table 3.1: Forward and reverse primers for target genes; Oct-4, Sox-2, Nanog, 
Lin-28, Klf-4, C-myc and the house keeping gene β-actin.  Annealing temperature 
and product length is demonstrated for each gene of interest. 
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β-actin 
NM_0
0110
1.3 
F 5’-CCACACTGTGCCCATCTACGAGGGGT-3’ 
 
R 5’-AGGGCAGTGATCTCCTTCTGCATCCT-3’ 
564 – 589 
1043 - 1018 
60 454 
 
Oct-4 
 
 
NM_0
0270
1.4 
F 5’-AGGAGTCGGGGTGGAGAG-3’ 
 
R 5’-CGTTTGGCTGAATACCTTCC-3’ 
351 – 368 
600 - 581 
54 249 
 
Sox-2 
 
NM_0
0310
6.2 
F 5’-AACCCCAAGATGCACAACTC-3’ 
 
R 5’CGGGGCCGGTATTTATAATC-3’ 
614 – 633 
765 - 746 
55 152 
Nanog 
NM_0
2486
5.2 
 
F 5’-ATAACCTTGGCTGCCGTCTCTGG-3' 
 
R 5'-AAGCCTCCCAATCCCAAACAATACG-3' 
 
 
1677-1699 
1826-1802 
44 150 
Lin-28 
NM_0
2467
4.4 
F 5’-GAAGCGCAGATCAAAAGGAG-3’ 
 
R 5’-GGGTAGGGCTGTGGATTTCT-3’ 
504 – 523 
721 - 702 
53 218 
Klf-4 
NM_0
0423
5.4 
F 5’-ACCCACACAGGTGAGAAACC-3’ 
 
R 5’ATGTGTAAGGCGAGGTGGTC-3’ 
1849 – 1868 
2018 - 1999 
55 149 
C-myc 
NM_0
0246
7.4 
F 5'-CCCTTGCCGCATCCACGAAACT-3' 
 
R 5'-AAGGGAGAAGGGTGTGACCGCA-3' 
 
341-362 
816-795 
50 476 
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 Table 3.2: Invitrogen Taqman® Gene Expression Assays for target genes; 
Oct-4, Sox-2, Nanog, Klf-4, C-myc and GAPDH detailing accession number, primer 
location and product size. 
 
Invitrogen ID Gene 
Accession 
Number 
Assay 
location 
(bp) 
Size 
(bp) 
Hs00999634_gH Oct-4 
 
NM_002701.4 
 
872 
 
64 
Hs01053049_s1 Sox-2 NM_003106.3 1541 91 
Hs02387400_g1 Nanog NM_024865.2 363 109 
Hs00358836_m1 Klf-4 NM_004235.4 723 110 
Hs00905030_m1 C-myc NM_002467.4 561 87 
Hs03929097_g1 GAPDH NM_002046.4 1226 58 
 Chapter 3 Characterisation of cell populations from the oral mucosa 
82 
3.3 Results 
3.3.1 Phenotypic Analysis of Cell Populations from the Oral 
Mucosa 
OP cells from digested 6mm biopsies of the lamina propria were isolated by 
differential adhesion to fibronectin after a 20 minute incubation step and 
maintained in monolayer culture.  A further two incubation steps (40 minutes 
each) followed this.  Cells that failed to adhere to the fibronectin in these 
steps were maintained in a separate monolayer culture, the NA cells.  A third 
monolayer (unselected) culture was maintained; the TP cells of the digested 
lamina propria.  Figure 3.1 demonstrates the formation of a single colony 
following adhesion to fibronectin-coated plates. 
3.3.1.1 The Effects of Vitamin C on Colony Forming Efficiency 
Two sets of cultures were set up for each of the 3 differential adhesion steps 
(20 minute step and two 40 minutes steps) for cells from three patients (XLIX, 
LII and LIV) so that cell cultures could be maintained in F-SCM ± 50µg/mL 
ascorbic acid.  Triplicate wells were prepared for each condition.  Colony 
forming efficiency (CFE) and the effects of ascorbic acid on OP cell 
populations was determined over a 15 day period.  Initial numbers of cells 
that adhered to the fibronectin coated plates for each time step (20 minute 
well, 40 minute well and second 40 minutes well) were determined on day 1 
and colonies > 32 cells were counted for each time step on days 3, 6, 9, 12 
and 15.   
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Figure 3.1: Example of colony formation in Patient LIV. (A) Day 1 
following adhesion to fibronectin-coated plates after the first 20 minute time 
point, (B) Day 7 post-differential adhesion, (C) Day 9 post-differential 
adhesion, (D) Day 13 post-differential adhesion.  Scale bar = 100µm  
 Chapter 3 Characterisation of cell populations from the oral mucosa 
84 
Days 6, 9 and 12 were used to make comparisons between treated and 
untreated cultures (Figure 3.2) as colonies had not formed in either culture by 
day 3 and on day 15, colonies of untreated cells had merged and could no 
longer be distinguished and counted as separate colonies.  Formation of 
colonies in cultures treated with ascorbic acid was much slower and 
significantly less (p<0.001) on days 9 and 12 compared to untreated cell 
cultures. 
When comparing the difference in colony formation of each of the different 
time steps of the differential adhesion assay (20 minute and both 40 minute 
time steps), for treated and untreated cells, day 12 was used.  After this time, 
colonies of untreated cells merged in the 20 minute wells.  Comparisons 
between treated and untreated cells in the 20 minute adhesion wells on day 
12 have already been described above and demonstrated a significant 
difference.  However, differences between treated and untreated cultures in 
both 40 minute wells of the differential adhesion assay did not demonstrate a 
significant difference (Figure 3.3).   
CFEs for both treated and untreated cultures were highest in the 20 minute 
well when compared to CFEs in both 40 minute wells of the differential 
adhesion assay (Figure 3.3).  The differences in CFEs were only found to be 
significant in the untreated cell populations, with differences between the 20 
minute time step and the first 40 minute step demonstrating a significant 
difference (p<0.05) and the difference between the 20 minute step and the 
second 40 minute step demonstrating a highly significant difference 
(p=<0.001).   
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3.3.1.2 The Effects of Vitamin C on Cell Proliferation  
Separate cultures were maintained for each cell population (MP, TP and NA), 
one culture fed with F-SCM and one with F-SCM + 50µg ascorbic acid.  Each 
culture was fed daily due to the degradation of ascorbic acid when dissolved 
in medium.  Cultures were established from which to pick colonies and were 
also maintained ± 50µg/mL ascorbic acid.  Following isolation of the 
individual colonies, 3 colonies were maintained for longer periods of time in 
culture ± ascorbic acid. 
Growth profiles were established for all cell populations (MP, TP, NA and 
colonies) isolated from the oral mucosa lamina propria for three patients; 
XLIX, L and LII.  Growth profile of MP cells for patient XLIX demonstrated the 
fastest initial rate in comparison to TPs and NAs (Figure 3.4A).  This was 
followed by TP cells which demonstrated a sharp increase in proliferative rate 
after about 20 days in culture and NA cells demonstrated the lowest 
proliferative rate.  A similar growth profile was demonstrated with the different 
cell populations (MP, TP and NA) of patients L (Figure 3.5A) and LII (Figure 
3.6A).  When comparing the different growth profiles ofthe cell populations of 
XLIX treated with ascorbic acid, the same pattern of growth existed between 
MP, TP and NA cell populations of untreated cells (i.e.  MP+ascorbic acid 
>TP+ascorbic acid >NA+ascorbic acid) and no difference between treated 
and untreated MP, TP and NA cell populations was demonstrated.  Again, a 
similar pattern existed with respect to the treated cell populations of patient L 
and no difference was observed between the treated and untreated MP, TP 
and NA cell populations. 
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Figure 3.4: Growth profiles for patient XLIX ± 50µg ascorbic acid treatment.  
(A) Growth profiles of OP, TP and NA ± ascorbic acid.  (B) Growth profiles of 
isolated colonies 19, 26 and 29 + ascorbic acid, 4, 5 and 10 – ascorbic acid. (n=1) 
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Figure 3.5: Growth profiles for patient L ± 50µg ascorbic acid treatment.  (A) 
Growth profiles of OP, TP and NA ± ascorbic acid.  (B) Growth profiles of isolated 
colonies; 13, 14 and 15 + ascorbic acid, 4, 5 and 9 – ascorbic acid. (n=1) 
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A 
B 
Figure 3.6: Growth profiles for patient LII ± 50µg ascorbic acid treatment.  (A) 
Growth profiles of OP, TP and NA ± ascorbic acid.  (B) Growth profiles of isolated 
colonies; 14, 17 and 20 + ascorbic acid, 1, 2 and 4 – ascorbic acid. (n=1) 
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Cell populations of patient LII treated with ascorbic acid demonstrated 
different growth profiles compared to the untreated cell populations.  Treated 
cell populations typically demonstrated slower rates of proliferation when 
compared to untreated cell populations, with NA+ascorbic acid failing to 
grow.  Treated TP cells demonstrated a sharp increase in growth after 30 
days in culture with, at this point, them demonstrating a similar PDL as 
untreated TP populations.  Over the time course studied, treated MP 
demonstrated a much slower initial growth rate compared to untreated MP.  
Overall, across the three patients there was no consistent alteration in the 
growth profiles of the treated cell populations compared to untreated cells 
populations. 
Growth profiles of the colonies isolated from cultures ± ascorbic acid and 
then maintained ± ascorbic acid from patient XLIX all demonstrated similar 
growth patterns (Figure 3.4B).  The isolated colonies from patient L, again ± 
ascorbic acid, and as with patient XLIX, all demonstrate similar growth 
patterns with no obvious differences between cells treated with ascorbic acid 
(Figure 3.5B).  Colonies isolated and maintained ±ascorbic acid from patient 
LII demonstrate some variation in growth profiles but with no obvious 
difference between treated and untreated cell populations (Figure 3.6B). 
3.3.1.3 Expression of Pluripotency Markers in Different Cell 
Populations Obtained from the Oral Mucosa 
RNA was extracted from MP, TP and NA cell populations of three patients 
XLIX, L and LII, all ±ascorbic acid, at early time points (between PDL 10-15) 
to determine which pluripotency markers were being expressed by each cell 
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population and whether the addition of ascorbic acid to the cultures was 
affecting this expression.  The pluripotency markers analysed were Oct-4, 
Sox-2, Nanog, Lin-28, Klf-4 and C-myc as these are the classical induced 
pluripotent stem cell (iPSC) factors used to reprogram cells back to their 
embryonic stem cell-like state (Takahashi et al, 2007; Yu et al 2007).  For 
each gene, RNA extracted from skin fibroblasts (DF) was utilised as a 
comparative control as these cells have been classically used to reprogram 
back to an embryonic stem cell state.  DFs demonstrated positive expression 
of all genes (Figures 3.7-3.9).  The positive control, human embryonic stem 
cell (H9), as expected, demonstrated positive expression of all pluripotency 
markers.  Two negatives were used, a reverse transcriptase negative and a 
DEPC water negative (DEPC). 
All treated and untreated cell populations for all three patients were found to 
express Oct-4, Klf-4, C-myc and Nanog (Figures 3.7-3.9).  However, 
expression of Lin-28 and Sox-2 demonstrated patient-specific differences.  
Untreated MP and TP cell populations express Sox-2 in all three patients.  
However, expression of Sox-2 was absent in the treated MP cell population 
of patient XLIX and NA of patient L  and absent in both treated and untreated 
NA cell populations of patient XLIX.  Expression of Lin-28 was absent in all 
treated and untreated cell populations of patient XLIX, patient L with the 
exception of treated MP and patient LII with exception of untreated NA.  
Authenticity of the PCR products was confirmed by DNA sequencing 
(Appendix II).   
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Figure 3.7: Pluripotency marker expression for different populations from 
the OMLP ± 50µg/mL ascorbic acid at early time points.  Expression of 
pluripotency markers; Oct-4, Sox-2, Klf-4, C-myc and Lin-28 for Patient XLIX MP, 
TP ± ascorbic acid and NA+ ascorbic acid between PDL 10-15. 
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Figure 3.8: Pluripotency marker expression for different populations from 
the OMLP ± 50µg/mL ascorbic acid at early time points.  Expression of 
pluripotency markers; Oct-4, Sox-2, Klf-4, C-myc and Lin-28 for Patient L MP, TP 
± ascorbic acid and NA ± ascorbic acid between PDL 10-15. 
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Figure 3.9: Pluripotency marker expression for different populations from 
the OMLP ± 50µg/mL ascorbic acid at early time points.  Expression of 
pluripotency markers; Oct-4, Sox-2, Klf-4, C-myc and Lin-28 for Patient LII MP, 
TP ± ascorbic acid and NA ± ascorbic acid between PDL 10-15. 
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3.3.1.4 Quantitative analysis of Pluripotency Markers 
Endpoint PCR analysis is useful as an indication of presence or absence of 
target genes however, it does not provide quantitative information.  
Quantitative PCR allows confirmation of expression levels of target genes 
compared to a calibrator known to express the genes of interest.  H9 were 
utilised as a calibrator as they are known to express all the pluripotency 
genes of interest (see Figures 3.7-3.9).  Untreated MP cell populations from 
patients XLIX, L and LII were selected for reprogramming and further 
analysis by qPCR as treatment of cell populations with ascorbic acid 
appeared to offer no benefit in terms of proliferative potential and expression 
of pluripotency markers.  Before relative quantities of the pluripotency genes 
could be determined, a standard curve was established using serial dilutions 
of the calibrator to determine whether the reaction was linear or not.  Each 
reaction was linear (Figure 3.10A) confirming the relative quantities could be 
determined between H9 and the patient samples.  Expression of Oct-4, Sox-
2 and Nanog was found to be significantly (P<0.001) lower in MP XLIX, MP 
L, MP LII and DF (Figures 3.10B, 3.11A and 3.12A).  Expression of C-myc 
was also found to be significantly lower in MP XLIX, MP L and MP LII 
(P<0.001) however, expression levels were higher in DF and, therefore, the 
difference between C-myc expression in H9 and DF was less significant than 
in OP samples (Figure 3.11B, P<0.01).  Expression of Klf-4 was the only 
gene that was found to be expressed at a higher level in MP samples and DF 
when compared to H9 (Figure 3.12B).   
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Figure 3.10:  Quantitative PCR comparing pluripotency marker expression 
levels of OMLP and DF with hESCs.  (A) Standard curve data for genes of 
interest; Oct-4, Sox-2, Nanog, Klf-4, C-myc and the house keeping gene GAPDH 
demonstrating linear reactions n=3 ± SEM.  (B) Relative expression levels of Oct-4 
in H9, MP XLIX, MP L, MP LII and DF n=3 ±SEM ***P<0.001. F value=47.512. 
Degrees of freedom 14 
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Figure 3.11:  Quantitative PCR comparing pluripotency marker expression 
levels of OMLP and DF with hESCs.  (A). Relative expression levels of Sox-2 in 
H9, MP XLIX, MP L, MP LII and DF n=3 ±SEM ***P<0.001. F value=128.33. 
Degrees of freedom 14.  (B) Relative expression levels of C-myc in H9, MP XLIX, 
MP L, MP LII and DF n=3 ±SEM ***P<0.001 **P<0.01. F value=34.069. Degrees of 
freedom 14 
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Figure 3.12:  Quantitative PCR comparing pluripotency marker expression 
levels of OMLP and DF with hESCs.  (A) Relative expression levels of Nanog in 
H9, MP XLIX, MP L, MP LII and DF n=3 ±SEM ***P<0.001. F value=17.347. 
Degrees of freedom 14.  (B) Relative expression levels of Klf-4 in H9, MP XLIX, 
MP L, MP LII and DF n=3 ±SEM ***P<0.001 **P<0.01 *P<0.05. F value=14.414. 
Degrees of freedom 14 
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For Klf-4 the most significant difference was demonstrated between LII and 
H9 (P<0.001), the difference between patient L and H9 and DF and H9 was 
less significant (P<0.01 and P<0.05 respectively); the difference between 
patient XLIX and H9 was not significant.  Quantitative PCR product sizes 
were confirmed utilising gel electrophoresis (Appendix III). 
3.4 Summary 
 Ascorbic acid reduces the CFE of OMLP-PCs 
 Ascorbic acid has no effect on proliferation of cell populations of the 
OMLP 
 Addition of ascorbic acid does not change expression of pluripotency 
markers at end point PCR level 
 With the exception of Klf-4, pluripotency markers are expressed at 
lower levels compared to H9 cells 
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3.5 Discussion 
Many different cell populations exist within each tissue of the body and 
progenitor cell populations have been successfully isolated from a variety of 
different tissues including the epidermal layer of the skin (Jones and Watt, 
1993) and articular surface cartilage (Dowthwaite et al, 2004).  Similarly, 
progenitor cells have been isolated from various dental tissues including; 
dental pulp, deciduous teeth, dental follicle, periodontal ligament, apical 
papilla and gingival (Gronthos et al, 2000; Miura et al, 2003; Seo et al, 2004; 
Morsczeck et al, 2005; Sonoyama et al, 2008; Zhang et al, 2009).  However, 
oral progenitor cells isolated from the oral mucosa present an attractive 
source of progenitor cells due to the fact that they are easily accessible via a 
relatively non-invasive procedure and such biopsying of tissue generates 
wounds that will heal with little to no scarring (Stephens and Genever, 2007). 
The investigations in this chapter have been carried out to establish the 
effects of ascorbic acid on cell populations isolated from the OMLP as one of 
the aims of this thesis is to generate oral iPSCs.  Recent reports suggest that 
iPSC reprogramming efficiency is improved in cultures supplemented with 
ascorbic acid (which acts as an antioxidant, reducing levels of oxidative 
stress; Esteban et al, 2010).  Reducing oxidative stress has been known for 
some time to support embryonic stem cell growth as culturing these cells in 
hypoxic conditions is thought to mimic the natural growth conditions that 
embryonic stem cells would be subjected to in vivo (Ezashi et al, 2005).  The 
addition of antioxidants, such as ascorbic acid, is thought to work in a similar 
 Chapter 3 Characterisation of cell populations from the oral mucosa 
 
102 
way by reducing the oxidative stress that has been found to affect different 
aspects of cell behaviour (Reviewed by Halliwell, 2003). 
3.5.1 The Effects of Vitamin C on Colony Forming Efficiency 
Colony forming efficiency of cells has long been used as a way of 
discriminating between terminally differentiated transit-amplifying cells and 
populations of potential progenitor cells.  This is due to the increased CFE of 
progenitor cells when compared to such transit-amplifying cells.  These 
transit amplifying cells can only typically undergo 5 population doublings 
before becoming terminally differentiated (Jones and Watt, 1993).  Cells with 
the highest level of CFEs have also been found to have the greatest number 
of functional β1-integrins (Jones and Watt, 1993) which underpins the 
rationale for the isolation of OP cells from the oral mucosa using differential 
adhesion to fibronectin (Davies et al, 2010).  This assay is based on the fact 
that progenitor cells have been found to have increased levels of functional 
β1 integrins on their cell surface in comparison to terminally differentiated 
cells allowing these progenitors to adhere preferentially to fibronectin in a 
shorter time-frame.  This supports the results demonstrated in this study due 
to the fact that the cells that adhere within the first 20 minute step of the 
differential adhesion assay have the highest CFE, similar to previous studies 
on the isolation of progenitor cells from skin and cartilage (Jones and Watt, 
1993; Dowthwaite et al, 2004).  The same result was also observed in OPs 
treated with ascorbic acid however, CFEs were overall greatly reduced and 
the differences found in CFEs between each time step for the treated cells 
was not found to be significantly different.  The findings for untreated OP 
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cells adds weight to the notion that the oral cells used throughout this project 
are progenitor cells which is in line with the findings of Davies et al (2010). 
Treatment of cells with ascorbic acid resulted in a lower CFE in comparison 
to untreated cells at the final time point where comparisons could be made.  
This could potentially be explained by an initial growth arrest in these 
progenitor cells causing an increased lag time before colony formation 
begins.  However, it is also possible that treatment with this concentration of 
ascorbic acid (the concentration suggested by the work of others; Esteban et 
al, 2010) could have potentially been cytotoxic at this very early time point 
resulting in the growth arrest observed.  Interestingly, proliferation of human 
dermal fibroblasts at low density is inhibited following treatment with ascorbic 
acid (Duarte et al, 2007), whilst higher density cultures are unaffected.  This 
is thought to be as a result of potential pro-oxidant effect of ascorbic acid in 
cell culture models, resulting in the production of ascorbate free radicals and 
H2O2.  Additional investigations into the effects of different concentrations of 
ascorbic acid, by establishing a dose responsive curve, on CFE and the 
analysis of media components following treatment would need to be 
conducted in order to determine this.  It is possible that addition of ascorbic 
acid has changed the CFE properties of these progenitor cells, modifying 
their stem cell characteristics however, this is purely speculative and further 
investigation of these cells would need to be carried out, including 
differentiation capacity, in order to confirm this. 
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3.5.2 Cell Proliferation in Different Cell Populations of the 
Oral Mucosa and the Effects of Vitamin C on these 
Populations 
Growth profiles from the first 40 days of culture of all three cell populations 
(MP, TP and NA) isolated from the oral mucosa have demonstrated potential 
differences between the populations.  MP cell populations for three patient 
samples demonstrated the fastest initial cell proliferation which was similar to 
previous findings whereby oral progenitor cells were found to have a rapid 
initial proliferation (Davies et al, 2010).  The complete proliferative potential of 
this cell population is yet to be determined but would be expected to have a 
finite lifespan as previously demonstrated for clonal populations isolated from 
the OMLP (Davies et al, 2010) as well as mixed cell populations of the oral 
mucosa (Enoch et al, 2009).  The proliferation of MP cell populations was 
closely followed by TPs for all patients.  TP populations for each patient 
demonstrated a slower initial proliferation in comparison to MP cells however, 
each patient also demonstrated an increase in proliferation after 
approximately 25 days in culture.  This may be explained by the fact that the 
cells have been derived from the total cell population of the oral mucosa and 
oral progenitors will be present within this mixed heterogeneous population, 
eventually becoming the predominant cell populations within the mixed 
culture and leading to this sudden increase in proliferation.  This is supported 
by the fact that mixed heterogeneous cell populations, without any further 
isolation, have been utilised by several groups to investigate potential 
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progenitor cell populations within the OMLP-PC and dental pulp (Gronthos et 
al, 2000: Marrynka-Kalmani et al, 2010). 
NA cell populations from both patients demonstrate the slowest initial 
proliferation which is as expected given that this cell population is a 
potentially ‘older’ (non-progenitor) cell population than that of the oral 
progenitor cells.  This is because potential progenitor cells are removed from 
the NA cell population by three separate fibronectin adhesion steps.  Each 
step demonstrates reduced CFEs indicating that very few progenitor cells 
would remain in final NA cell population consistent with previous findings 
(Jones and Watt 1993; Dowthwaite et al, 2003; Davies et al, 2010).  This cell 
population would therefore consist mainly of transit-amplifying cells which 
eventually terminally differentiate reducing their proliferative potential 
resulting in replicative senescence at an earlier time point in comparison to 
oral progenitor cells (Watt, 2001).  Colonies isolated from each of the three 
patients demonstrated similar rapid initial proliferation as the MP cell 
populations of all three patients, which is as expected and again these 
isolated colonies would be expected to have a finite lifespan with continued 
expansion in vitro consistent with the work by Davies et al, (2010).  In similar 
studies using differential adhesion to fibronectin, dental pulp stem cells have 
been isolated from rat pulp, these clonal progenitor cells had PDLs of 10 over 
50 days in culture (Waddington et al, 2009).  In contrast, colonies from the 
OMLP appear to have a faster initial proliferation, undergoing approximately 
double the amount of PDLs in the same period.  The PDLs for these cells is 
important when considering their potential for use in clinical applications. 
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As culturing cells with ascorbic acid has been reported to improve 
reprogramming efficiency towards iPSCs (Esteban et al, 2010), each of these 
cell populations (MP, TP, NA and colonies) were maintained ±ascorbic acid 
to determine the effects of this anti-oxidant on cell proliferation.  Treated and 
untreated MP, TP, NA and the colonies for patients XLIX and L did not 
demonstrate any notable changes in their proliferative profiles in vitro.  This is 
consistent with similar studies on human dermal fibroblast, where ascorbic 
acid did not affect the proliferation of these cells when the cells were at a 
high density (Duarte et al, 2007).  This study was primarily investigating 
whether or not ascorbic acid was acting as a pro-oxidant not an anti-oxidant 
and interestingly another study demonstrated no difference in proliferation of 
MSCs when treated with low levels of H2O2. (Brandl et al, 2011).  These 
studies suggest that low levels of treatment with ascorbic acid would not 
make a difference to the proliferative potential of cells from the OMLP. 
Additional investigations could be carried out for each of the individual 
colonies isolated from the OMLP, by culturing each colony with and without 
ascorbic acid which would require expanding the colony first without ascorbic 
acid treatment until there were sufficient cells to form two cultures.  Primarily 
this investigation was looking at the effects of ascorbic acid from the initial 
isolation. 
Patient LII demonstrated a longer lag in the treated growth profiles when 
compared to untreated populations, with treated NA cells actually failing to 
grow.  Colonies from patient LII demonstrated the most variation in growth 
potential between different colonies, with no obvious pattern between treated 
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and untreated colonies.  The general finding was that treatment with ascorbic 
acid had no beneficial or detrimental effect on cell growth.  Analysis of 
additional patient samples and extended growth profile analysis would further 
confirm these findings. 
3.5.3 The Expression of Pluripotency Markers in Different Cell 
Populations of the Oral Mucosa 
Induced pluripotent stem cell studies have highlighted specific factors that 
are required to reprogram cells back to their embryonic stem cell like state.  
These factors include Oct-4, Sox-2, Klf-4 and C-myc and were the first 
factors found to reprogram adult human skin fibroblasts back to their 
embryonic stem cell-like state (Takahashi et al, 2007).  Later it was 
demonstrated that the oncogene C-myc was not required and iPSC could be 
generated using a lentiviral system containing the factors Oct-4, Sox-2, 
Nanog and Lin-28 however, the reprogramming efficiency was lower (Yu et 
al, 2007).  Subsequently, various combinations of these factors have been 
used in cellular reprogramming, including all 6 factors (Yu et al, 2009).  It has 
since been reported that some cell types require much fewer factors in order 
to be reprogrammed; for example neural stem cells have been demonstrated 
to require only one factor, Oct-4, to reprogram these cells back to their ESC-
like state (Kim et al, 2009).   
It has previously been reported that cells within the lamina propria of the oral 
mucosa express some of these previously used reprogramming factors 
(namely Oct-4, Sox-2, Nanog and Klf-4) and that progenitor cells can be 
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isolated from these tissues (Davies et al. 2010; Marynka-Kalmani et al, 
2010).  This therefore, makes cells isolated from this tissue an interesting 
target for iPSC studies to form an ESC-like state with a potentially reduced 
requirement for genetic manipulation. 
Within this Chapter, studies into the endpoint expression of these six 
pluripotency markers demonstrated positive expression of 5 of these factors 
in MP cells and TP cells of three patient samples.  Expression of Oct-4, Sox-
2, Nanog and Klf-4 is consistent with previous findings for OMLP cells as well 
as progenitor cells from the gingiva (Zhang et al, 2009; Davies et al, 2010; 
Marynka-Kalmani et al, 2010).  Lin-28 was not expressed in all populations of 
the oral mucosa but, interestingly, it was expressed in patient LII NA cell 
populations and following treatment of patient L MP cells with ascorbic acid 
suggesting that ascorbic acid can potentially influence some gene 
expression.  Changes in gene expression have previously been 
demonstrated following treatment of human dermal fibroblasts with ascorbic 
acid (Tajima and Pinnell, 1996).  Treatment with ascorbic acid appeared to 
have no obvious effect on the expression of the other 5 pluripotency markers. 
As these cell populations already seemed to be expressing the majority of 
the factors required for reprogramming, it was an obvious step to compare 
these expression levels with the expression levels of hESCs.  Following 
analysis of the results, it was found that expression levels of three factors; 
Oct-4, Sox-2 and Nanog were all expressed at significantly lower levels than 
hESCs, consistent with previous findings for keratinocytes (Aasen et al, 
2008).  Expression of C-myc was found to be lower than hESC, but not quite 
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as low as Oct-4, Sox-2 and Nanog and, interestingly, expression of Klf-4 was 
found to be higher in all MP cell populations compared to hESCs.  The 
elevated levels of Klf-4 and C-myc are consistent with findings for 
keratinocytes (Aasen et al, 2008) and have also been demonstrated by 
several other groups using endpoint PCR analysis to be present in dermal 
fibroblasts (Takahashi et al, 2007; Nakawada et al, 2008).  Kfl-4 has recently 
been linked to the self-renewal properties of stem cells and has, moreover, 
been linked with the activation of hTERT, a catalytic subunit of human 
telomerase in dermal fibroblasts (Wong et al, 2010).  The elevated levels of 
Klf-4 demonstrated by MP cells is therefore consistent with the elevated 
levels of telomerase activity previously reported in cells isolated from the 
OMLP (Davies et al, 2010).  Furthermore, dermal fibroblasts demonstrate 
shorter telomeres and a reduced proliferative potential compared to cells 
from the oral mucosa (Enoch et al, 2009).  Expression of Klf-4 was lower in 
DF cells compared to two patient MP cell populations which could potentially 
account for the differences in telomere lengths.  To confirm this, additional 
samples of dermal fibroblast cells would need to be analysed since this 
investigation was carried out with only one dermal fibroblast patient sample.  
The elevated levels of Klf-4 and C-myc in dermal fibroblasts could potentially 
be the reason underlying the reprogramming of dermal fibroblasts without 
requiring the use of C-myc or Klf-4 (Yu et al, 2007).  Reprogramming without 
these factors could potentially apply to OP cells from the OMLP. 
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3.6 Conclusions 
In conclusion, the purpose of this chapter was to determine which cell 
population would be the most suitable population to select for 
reprogramming.  It was demonstrated that treatment with ascorbic acid 
significantly reduced CFE of cells isolated from the OMLP; high CFEs is a 
typical characteristic of progenitor cell populations.  Exposure to ascorbic 
acid did not increase cell proliferation of the different populations isolated 
from the OMLP as previously reported for Mesenchymal Stem Cells (MSCs) 
(Choi et al, 2008).  With the exception of a few anomalies, gene expression 
was found to be the same when cultures were treated with ascorbic acid.  For 
these reasons, it was decided to continue all further experiments without 
ascorbic acid as treatment appeared to offer no benefit. 
It is well known that long-term culture of cells in vitro can change gene 
expression and given that cells from the OMLP express numerous 
pluripotency markers at an early time point, it was decided that these cells 
would be utilised for future studies at this early time point.  Reprogramming 
cells to iPSCs requires a large numbers of cells due to the low efficiency of 
the process, therefore, the best populations to select for this would be the MP 
cell populations as they have the highest initial growth rate when compared 
to TP and NA populations.  Thus, they would achieve the required number of 
cells faster in vitro (with less time in culture).  Furthermore, when deciding 
between the use of either clonal (single cell) populations or MP (Merged 
clonal) populations, it again became apparent that cell number could be a 
limiting factor due to the fact that clonal populations developing from a single 
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cell would take significantly longer to reach the required cell number and 
would be much further though their proliferative lifespan. Hence, utilising the 
MP cells from numerous colonies that had merged together represent a cell 
population that would be much ‘younger’ in terms of proliferative potential.  
This is important, since cellular senescence is known to reduce 
reprogramming efficiency (Li et al, 2009; Marion et al, 2009).  Thus, in future 
chapters, merged clonal MP populations were utilised to generate oral iPS 
cells.
  
 
4 - Reprogramming of oral 
mucosa lamina propria 
progenitor cells 
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4.1 Introduction 
Although the idea of reversing the effects of development on early gene 
expression is not a new phenomenon (Briggs and King, 1952; King and 
Briggs, 1955), reprogramming of cells has received much attention over the 
last 6 years since the reprogramming of mouse somatic cells back towards 
an embryonic stem cell–like state was first reported (Takahashi and 
Yamanaka, 2006).  One year later the reprogramming of human somatic cells 
was further reported (Takahashi et al, 2007).  During this time, many 
methods for the formation of iPSCs have been described including retroviral 
(Takahashi and Yamanaka, 2006; Okita et al, 2007; Maherali et al, 2007) and 
lentiviral (Brambrink et al, 2008; Maherali et al, 2008) transduction of genes 
as well as transient expression of genes using non-integrating systems (Okita 
et al, 2008; Yu et al, 2009).  Retroviral systems reprogram somatic cells with 
considerably higher efficiency compared to non-integrating transient 
expression systems and as such are sometimes a good initial starting point 
for producing iPSCs utilising cells with unknown reprogramming ability.  
However, like many of the reprogramming systems, there are limitations to 
the retroviral system.  Many iPSCs from this system are often only partially 
reprogrammed and continue to rely on the frequently poorly silenced 
exogenous expression of the pluripotency factors in place of activating their 
own endogenous pluripotency gene expression to maintain their pluripotent 
state (Takahashi and Yamanaka, 2006).  This can lead to reactivation of 
oncogenic transgenes and potential formation of tumours in chimeras (Okita 
et al, 2007).  It has also been reported that transgene expression in lentiviral 
systems is often silenced even less efficiently than retroviral transgene 
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expression, which in turn affects the differentiation of the resulting iPSCs 
(Brambrink et al, 2008).  
Non-integrating systems for transient expression of pluripotency gene 
expression result in a better likelihood of fully reprogrammed iPSC 
populations however, this is at the cost of a much lower efficiency (Okita et 
al, 2008).  Weighing up these two factors, efficiency and safety, will be 
important when considering the use of these cells for translational medicine.  
Alongside these considerations, the choice of pluripotency factors used will 
also be an important factor to consider. Since the discovery of iPSCs, many 
different combinations of the pluripotency factors; Oct-4, Sox-2, Nanog, Lin-
28, Klf-4 and C-myc have been tested.  The first four that were confirmed to 
produce iPSC by retroviral transduction were Oct-4, Sox-2, Klf-4 and C-myc 
(Takahashi and Yamanaka, 2006).  These factors have already been used to 
successfully produce iPSCs from oral mucosal fibroblasts with a retroviral 
transduction system (Miyoshi et al, 2010).  There has been a reduction in the 
use of retroviral transduction of the oncogene C-myc since studies indicated 
that iPSCs reprogrammed using this factor later developed adult chimaeras 
with tumours due to reactivation of C-myc thereby limiting the use of this 
gene in retroviral systems for therapeutic purposes.(Okita et al, 2007; Sumi 
et al, 2007).  Lentiviral systems without C-myc have been described and 
have demonstrated that Oct-4, Sox-2, Nanog and Lin-28 are sufficient to 
reprogram fibroblasts to iPSCs however, in the absence of C-myc the 
efficiency is much lower (Yu et al, 2007).  Ideally a non-integrating system 
would be a safer option for translational applications and many systems have 
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been tested.  It was found that using all six factors: Oct-4, Sox-2, Nanog, Lin-
28, Klf-4 and C-myc across two plasmids in a non-integrating system was the 
most efficient way to produce iPSCs that were free of any exogenous gene 
expression (Yu et al, 2009).  
Given the aim of producing iPSCs from oral progenitor cells for their potential 
use in therapeutic applications, a lentiviral approach without the use of C-myc 
or a non-integrating system approach would appear to be the most 
appropriate systems to use.  In the first instance, given the low efficiency 
associated with plasmid transfection, an efficient lentiviral system would be 
most appropriate to establish whether these cells can first be reprogrammed, 
followed by a plasmid system utilising all six pluripotency factors.  With 
translational medicine in mind, the way in which these cells are cultured will 
also be important.  Historically, human ESCs have been cultured on mouse 
embryonic fibroblasts as a feeder layer to provide the appropriate factors in 
order to maintain the cells in their pluripotent state (Thomson et al, 1998).  
However, this raises the concern of the safety of these cells for therapeutic 
applications as cells would need to be grown in an animal-free culture 
system.  More recently, ESC have been cultured using feeder free systems 
by culturing the cells on Matrigel® coatings (Xu et al, 2001) however, some 
argue that matrigel is such a highly complex (and undefined) mixture of 
extracellular matrix components, growth factors and cytokines, with batch to 
batch variation that caution should be exercised with its use (Hughes et al, 
2010).  As an alternative to animal culture systems and in vitro growth 
matrices, growing ESCs on human foreskin fibroblast feeder layers has been 
 Chapter 4 Reprogramming of oral mucosa lamina propria progenitor cells 
116 
 
found to maintain the cells pluripotent properties and as such reduces the 
need for concern over therapeutic safety of using these cultures (Amit et al, 
2003).  For this reason, producing and maintaining iPSCs from oral 
progenitor cells on foreskin fibroblast feeders, as well as mouse embryonic 
feeder layers, is of great interest. 
Once reprogrammed, the resulting iPSCs undergo some classical 
characterisation similar to that originally published for hESC (Thomson et al, 
1998).  The main purpose of this characterisation is to confirm that the cells 
have been reprogrammed and poses pluripotent properties. There are key 
cell surface markers and transcription factors that are commonly utilised for 
this purpose including; SSEA-4, SSEA-5, TRA-1-60, TRA-1-81, Oct-4 and 
Sox-2 (Thomson et al, 1998; Mali et al, 2008; Li et al, 2009; Tang et al, 
2011). To confirm the pluripotent nature of these cells, demonstrating the 
ability to differentiate into cells/tissues from all three germs layers is 
necessary. This is often carried out by formation of teratomas following 
implantation into mice (Thomson et al, 1998; Takahashi et al, 2007). The 
resulting teratomas are then analysed for presence of tissues from all three 
germ layers by H& E staining. In addition to this, the cells can be 
differentiated towards cell types of the endoderm, mesoderm and ectoderm 
and stained with specific markers of the germ layers to confirm early 
differentiation potential (Maherali et al, 2008). 
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4.1.1 Hypothesis 
Oral mucosa lamina propria progenitor cells can be reprogrammed back 
towards an embryonic stem cell-like state utilising iPSC technology. 
 
4.1.2 Aims 
There are three main aims for the reprogramming of oral progenitor cells 
from the oral mucosa lamina propria: 
1. Reprogram the oral progenitor cells to iPSCs  
2. Establish the presence of typical ESC markers and pluripotent 
properties of iPSCs  
3. Carry out a comparison of on two different feeder layers; inactivated 
mouse embryonic fibroblasts (iMEFs) and inactivated foreskin 
fibroblasts (iFCFs) for formation and maintenance of iPSCs. 
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4.2 Materials and Methods 
A number of general methods have been utilised in this Chapter which have 
been previously described (Chapter 2) including OMLP cell culture, formation 
of feeder layers, human embryonic stem cell culture, mycoplasma testing and 
imaging of cells. 
4.2.1 Formation of Foreskin Fibroblast Feeder Layers  
Foreskin fibroblasts are sometimes used as an alternative to MEFs when 
culturing hESCs.  Foreskin fibroblast were previously isolated and cultured by 
members of the Wound Biology Group, Cardiff University. Early passage 
foreskin fibroblasts (FCF101) were thawed rapidly from cryopreservation and 
placed in 10mL of pre-warmed MEF media: DMEM supplemented with 10% 
FCS, 2mM L-Glutamine, 100U/mL Penicillin, 100µg/mL Streptomycin 
Sulphate and NEAA.  Cells were spun at 400 x g for 5 minutes to pellet the 
cells.  The supernatant was discarded and the pellet re-suspended in 1mL of 
MEF media. Cells were counted using a haemocytometer seeded at an initial 
high seeding density of 5 x 105 cells/ T75 flask to allow cells to settle 
following cryopreservation.  Cells were fed every 2-3 days with MEF media 
until 90-95% confluent. One mL of media was removed from the confluent 
cells to test for mycoplasma contaminations.  
Cells were passaged using Trypsin/EDTA (0.05%(v/v)/0.53mM).  Media was 
removed from the flask and cells washed with 10mL of PBS.  This was 
replaced with 1mL of Trypsin/EDTA, and flasks were returned to the 
incubator for 3-5 minutes until the cells detached.  Ten mL of MEF media 
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was added to neutralise the Trypsin/EDTA.  The resulting cell suspension 
was placed in a 15mL falcon and spun at 400x g for 5 minutes to pellet the 
cells.  These were counted using a haemocytometer and re-seeded at a 
density of 3.5 x105 cells/T175. Subsequent passages were split at a 1:5 ratio 
and resulting confluent cultures were irradiated as previously described in 
Chapter 2.  These irradiated cells were termed iFCF and treated as per 
iMEFs for use as feeder layers. 
 
4.2.2 Derivation of Induced Pluripotent Stem Cells 
4.2.2.1 Plasmid induction of Pluripotency Factors  
Several methods have been described for the formation of iPSCs.  Induction 
of pluripotency factors using plasmids have previously been described by Yu 
et al, 2009.  Plasmids were commercially available from addgene, UK (Figure 
4.1).  These plasmids were chosen to allow transient expression of the 6 
pluripotency factors; Oct-4, Sox-2, Nanog, Klf-4, Lin-28 and C-myc. 
 
4.2.2.2 Making LB Agar Plates 
Sixteen g of LB agar was mixed with 500mL of distilled water in a 1L 
autoclavable glass bottle.  This was autoclaved for one hour (121ºC steam 
temperature) then placed in a water bath at 56ºC until required. When ready 
to pour the plates, LB agar was allowed to cool until the bottle was warm to 
touch before ampicillin was added at a final concentration of 20µg/mL.
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Figure 4.1:  Plasmids utilised in the reprogramming of OMLP (A) AddGene 
Plasmid # 20924 containing all 6 pluripotency factors; Oct-4, Sox-2, Nanog, Klf-4, 
Lin-28 and C-myc.  (B) AddGene Plasmid # 20927 containing Oct-4, Sox-2, 
SV40\LT and Klf-4 (images of plasmids from Addgene). 
A 
B 
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This was mixed thoroughly before carefully pouring the LB agar into a 10cm 
petri dish in a Microflow Advanced bio-safety Class II cabinet. LB agar was 
divided between petri dishes to a depth of 1cm, avoiding the formation of air 
bubbles and dishes left at the back of the cabinet to set.  Once set, the plates 
were stored in a sealed container at 4ºC until required. 
4.2.2.3 Growing TOP10 Containing Plasmids on LB Agar Plates 
A vial of One Shot® TOP10 chemically competent E. coli was thawed on ice 
for each plasmid.  The concentration of both plasmids was determined using 
a nanovue® spectrophotometer and 1µg of each plasmid was added to a 
separate thawed vial of TOP10 cells.  These vials were very gently mixed 
before returning the vials to ice to incubate for 30 seconds.  Following the 
short incubation period, cells were heat shock treated for a further 30 
seconds in a water bath set to 42ºC.  Two hundred and fifty µL of room 
temperature S.O.C medium (containing: 2% tryptone, 0.5%yeast extract, 
10mM sodium chloride, 2.5mM potassium chloride, 10mM magnesium 
chloride, 10mM magnesium sulphate and 20 mM glucose per litre.) was 
added to each vial, capped tightly and placed horizontally in a shaking 
incubator for 1 hour at 37ºC at 200 r.p.m.  Two volumes, 100µl and 200µl, 
from each transformation were spread onto pre-warmed selective LB agar 
plates, to ensure well-spaced colonies. 
These plates were then inverted and incubated O/N at 37ºC.  Eight colonies 
were picked from each plasmid culture using a clean sterile 200µL pipette tip 
for each colony and plated onto a fresh selective LB agar plate and once 
again incubated O/N at 37ºC.  The 200µL pipette tip was placed in 5µL of 
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DEPC water to dilute the remainder of the colony from the tip.  PCR was 
carried out on this dilution for Oct-4 pluripotency gene (present on both 
plasmids) as previously described in Chapters 2 & 3 to check for plasmid 
expression.  
4.2.2.4 Maxi Prep of Plasmids 
As the plasmids have an extremely low copy number the Qiagen Endofree 
Maxi prep kit was used in order to obtain sufficient plasmid quantity for 
transfection.  A colony from the fresh LB agar plates was picked to inoculate 
a starter culture of 5mL LB medium containing 20µg/mL ampicillin.  This 
culture was incubated at 37ºC for 8 hours in a shaking incubator at 300 r.p.m.  
After 8 hours, 500µL of started culture was diluted in 250mL of LB medium 
containing 20µg/mL ampicillin in a 1L conical flask.  This culture was grown 
at 37ºC for 12-16 hours at 300 r.p.m. in the shaking incubator.  Following 
incubation, cells were pelleted by centrifugation at 6000 x g for 15 minutes at 
4ºC.  The supernatant was discarded and cells re-suspended with 10mL 
Buffer P1 until no clumps remained and were then transferred to a 50mL 
falcon.  Ten mL of Buffer 2 was added to this and mixed by inverting the tube 
4-6 times to lyse the cells.  This solution was left to incubate at room 
temperature for 5 minutes.  The QIAfilter Maxi Cartridge was fitted with a 
screw cap on the outlet nozzle and placed inside a 50mL falcon tube during 
the incubation step.  Following incubation, 10mL of pre-chilled Buffer 3 was 
added to the lysate, mixed by inversion 4-6 times and added to the top of the 
Maxi Cartridge.  This was left to incubate at room temperature for 10 
minutes.  The cap was removed after 10 minutes and a plunger inserted into 
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the top of the cartridge to filter the lysate.  Two and a half mL of Buffer ER 
was added to the filtered lysate and mixed by inverting the tube 10 times 
before incubating on ice for 30 minutes.  Following incubation, 10 mL of 
Buffer QBT was added to a QIAGEN-Tip 500 and allowed to flow through by 
gravity into a 50 mL Falcon tube.  This was discarded and replaced with a 
fresh 50mL Falcon tube before the filtered lysate was added to the top of the 
QIAGEN-Tip 500 and, again, allowed to enter the Falcon tube by gravity flow.  
The flow-through was discarded and the bound DNA washed twice with 
30mL Buffer QC before being eluted using 15mL of Buffer QN into a clean 
50mL Falcon tube.  DNA was precipitated by adding 10.5mL of isopropanol 
which was mixed and centrifuged at 15000 x g for 30 minutes at 4ºC.  The 
supernatant was carefully removed before washing the DNA pellet with 5mL 
of endotoxin-free 70% ethanol and centrifuging at 15000 x g for 10 minutes.  
The supernatant was removed and the pellet left to air-dry for 5-10 minutes 
before re-suspension in 100µL of endotoxin-free Buffer TE. DNA 
concentration was determined using the nanovue®. 
4.2.2.5 Nucleofection  
Two different cell types were nucleofected; (i) DF, as a positive control as 
these had already been reported to be able to be reprogrammed using the 
two plasmids (Yu et al, 2009) and (ii) MPs.  MP XLIX was selected for 
reprogramming due to available cell numbers at point of nucleofection.  As 
part of these methodology two different feeder layers were tested; iMEFs and 
iFCFs.  The nucleofection and subsequent culture of cells involved a number 
of different steps illustrated in Figure 4.2  
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 Each condition (i.e. DF on iMEF or iFCFs and MP on iMEFs or iFCFs) was 
set up in triplicate.  For each condition 3 x 10cm tissue culture dishes were 
coated for 1 hour with 6mL of 0.1% gelatin (Millipore, UK).  The gelatin was 
removed and feeder cells were seeded at 8 x 105 cells per 10cm dish in 
10mL of MEF media.  The cells were allowed to attach for 24 hours.  The 
following day, the MEF media was removed and replaced with 10mL of 
foreskin fibroblast media (HFF; Yu et al, 2009) containing: MEM (eagle) 
supplemented with 10% heat inactivated fetal bovine serum, 2.0mM 
Glutamax, 0.1mM β-mercaptoethanol, 100U/mL Penicillin, 100µg/mL 
Streptomycin Sulphate and 0.1mM NEAA..  This was returned to the 
incubator and allowed to equilibrate for at least 1 hour.  Cells were seeded in 
to T175 flasks at a density of 2 x 104 cells/cm2 as previously described.  
When cells reached 80-90% confluency, they were passaged. Culture media 
was removed and cells washed with 15mL HBSS.  This was removed and 
replaced with 3mL Trypsin/EDTA.  Cells were returned to the incubator for 1-
3 minutes to allow the cells to detach.  Once detached, Trypsin/EDTA was 
neutralised using 12mL DMEM supplemented with 2% FBS.  The total 
number of cells was calculated by counting a 1mL aliquot.  A volume of 
media containing 1 x106 cells was removed and placed in a 15mL falcon, this 
was spun at 200 x g for 10 minutes to pellet the cells.  The supernatant was 
removed and cells were re-suspended in 100µL of room temperature 
nucleofector solution (NHDF - VPD-1001, Lonza, UK) in the 15mL falcon.  To 
this, 7.3µg pEP4 E02S CK2M EN2L and 3.2µg pEP4 E02S ET2K plasmid 
DNA were added and mixed.  The cell/DNA suspension was transferred to a 
certified cuvette (NHDF - VPD-1001, Lonza, UK) and placed into the 
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nucleofector (Amaxa, Lonza, UK).  Program U-20 was selected. Following 
nucleofection, 500µL of pre-equilibrated HFF medium was added to the 
cuvette.  The sample was removed from the cuvette very gently using a 
plastic pipette, avoiding repeated aspiration, and pipetted onto the prepared 
feeder dish.  The plate was promptly returned to the incubator and allowed to 
settle for 24 hours.  A transfection control was set up using the eGFP plasmid 
provided to calculate transfection efficiency.  One µg of plasmid was added 
to 1 x 106 cells resuspended in 100µL of nucleofector solution.  This was 
placed in the nucleofector and run on program U-20.  The nucleofected cells 
were seeded into 10cm tissue culture dishes without feeder layers.  The 
following day medium was removed and replaced with 10mL of fresh foreskin 
fibroblast media.  The plates were returned to the incubator for a further 48 
hours.  The transfection control plates were removed and viewed using the 
Delta Vision in order for transfection efficiencies to be calculated (Detailed in 
section 4.2.1.4).  On day 4 post-transfection, medium was removed and cells 
were washed with 10mL PBS and replaced with 10mL of fresh Human ES 
media containing DMEM/F-12 1:1 supplemented with 20% knockout serum 
replacement, 0.1mM NEAA, 1mM L-Glutamine, 0.1mM β-mercaptoethanol 
and 100ng/mL of basic fibroblast growth factor (bFGF).  Cells were fed every 
48 hours with fresh Human ES media.  Conditioned medium was used from 
day 8 post-transfection due to deterioration of the feeder layers.  Feeder 
layers for conditioned medium were seeded at a density of 5 x 104 cells/cm2 
in a pre-gelatin coated 6 well plate and allowed to settle for 24 hours in 
2mL/well MEF medium.  After 24 hours the feeder layers were washed twice 
with 2mL/well PBS and this was replaced with 2mL/ well Human ES media 
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without bFGF.  Medium was removed and replaced with fresh human ES 
media daily.  The conditioned medium was combined in 15mL Falcon tubes 
and stored at -20ºC until required.  Cultures were fed with conditioned 
medium until colonies began to form on days 18-25. 
4.2.2.6 Calculating Transfection Efficiency 
Transfection control plates were viewed using an Olympus IX71 inverted 
microscope and camera (Applied Precision, USA).  Imaging equipment was 
within an environmental chamber, maintaining the temperature at 37ºC. 
Images were analysed using Delta Vision imaging software (Applied 
Precision, USA).  Images were acquired using a FITC filter (Excitation 461-
489nm and emission 523-536nm), these were overlaid phase contrast 
images acquired from the same field of view and used to calculate 
transfection efficiency using the following equation: 
 
Transfection Efficiency = GFP positive cells  X 100 
Total number of cells 
 
4.2.2.7 Alkaline Phosphatase Staining 
A typical characteristic of hESC is presence of high levels of alkaline 
phosphatase when in an undifferentiated state (Thomson et al, 1998) 
therefore, to determine the presence or absence of iPSC colonies, one of the 
10cm dishes was used to stain for alkaline phosphatase on day 20 post 
transfection.  Medium was removed from the dish and cells were washed 
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twice with 10mL pre-warmed DMEM/F-12 1:1.  Alkaline phosphatase stain 
was provided as 500x stock solution.  Twelve µL was mixed with 6mL of pre-
warmed DMEM/F-12 to make up a 1x working stock.  Following washes, this 
working stock solution was added to the 10cm dish and incubated for 20-30 
minutes.  After this time, the solution was removed and the plate washed with 
10mL DMEM/F-12 twice for 5 minutes each.  The final wash was removed 
and replaced with 10mL of fresh DMEM/F-12 prior to visualisation.  Cells 
were imaged using a FITC filter on an Olympus IX71 microscope as 
described in section 4.2.2.6 and alkaline phosphatase-positive colonies were 
marked. 
4.2.2.8 iPSC Culture 
4.2.2.8.1 First Passage Post-Nucleofection 
During the initial stages of reprogramming when colonies first began to 
emerge, the colonies were very delicate and as such they were treated using 
mechanical passaging techniques.  This was carried out using sterile flame 
pulled Pasteur pipettes.  Feeder layers were set up as previously described 
in 24 well plates at a seeding density of 1.5 x 102 cells/mL.  When required, 
MEF medium was removed and the cells washed twice with 500µL PBS.  
This was replaced with 500µL of Human ES medium supplemented with 
100µg/mL bFGF.  These cells were placed back in the incubator to allow the 
media to equilibrate at 37ºC and 5% CO2.  Each colony was cut into smaller 
pieces by scoring through the colony with the tip of a flame pulled Pasteur 
pipette and then around the borders of the colony to release the pieces.  The 
colony pieces were removed using a 20µL pipette and seeded into one well 
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of the prepared feeder plates and returned to the incubator to settle for 48 
hours.  After the colonies had settled, the cultures were fed daily with fresh 
Human ES medium supplemented with 100ng/mL bFGF. 
 
4.2.2.8.2 iPSC Colony Expansion 
Not every colony picked from the initial transfection plate went on to form 
colonies that were similar in morphology to Human ES cells.  The colonies 
that were similar to Human ES cells were selected for further expansion.  The 
colonies were split from one well of the 24 well plate into one well of a 12 well 
plate prepared with feeder cells by mechanical passage, as previously 
described.  These cultures were left to settle for 48 hours then fed daily with 
fresh Human ES medium supplemented with 100ng/mL bFGF.  When the 
colonies were large enough to fill the x10 objective on the microscope they 
were split once more.  The size of the plate used for expansion was 
determined by the number of colonies present.  When the number of colonies 
in one well of a 12 well plate had reached 10-15 colonies, the culture was 
mechanically passaged to one well of a 6 well plate prepared with feeder 
cells.  Once there were sufficient colonies to fill one well of a 6 well plate 
without the colonies merging, passaging was carried out enzymatically with 
collagenase IV. 
4.2.2.8.3 Enzymatic Passaging of iPSCs.  
When colonies were ready to be passaged, differentiated colonies were 
removed using the tip of a pipette, medium was removed and colonies were 
washed once with 2mL PBS to remove debris.  This was removed and 
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replaced with 2mL of 1mg/mL Collagenase IV in DMEM/F-12 and returned to 
the incubator for 20-30 minutes until the colonies began to curl up at the 
edges.  Once curled, the plates were removed from the incubator and 
colonies were gently washed from the surface using a 5mL pipette.  
Detached colonies were collected in a 15mL falcon and spun at 200 x g for 2 
minutes to pellet the colonies.  Supernatant was removed and colonies were 
resuspended 1mL pre-equilibrated medium from the prepared feeder plates.  
Colonies were broken by pipetting up and down using a 1mL pipette a 
maximum of 8 times.  Colonies from one well of a 6 well plate were split at a 
ratio of between 1:4 and 1:6 depending on the number of undifferentiated 
colonies present.  When plated, colonies were returned to the incubator and 
allowed to settle for 48 hours.  Following this, cultures were fed daily with 
fresh Human ES media supplemented with 100ng/mL bFGF.  Cultures were 
split typically every 4-5 days. 
4.2.2.9 iPSC Characterisation 
Oct-4, Sox-2, SSEA-4, SSEA-5, TRA-1-60 and TRA-1-81 are typical markers 
expressed by pluripotent stem cells (Thomson et al, 1998; Takahashi et al, 
2007; Tang et al, 2011).  Expression of these markers in MP iPSCs was 
determined by immunocytochemistry.  H9 cells were used as a positive 
control. 
4.2.2.9.1 Pluripotency Marker Expression  
Chamber slides were prepared with feeder cells as previously described.  
Colonies were mechanically passaged onto chamber slides at a density of 4-
6 colonies/well.  Each well was allowed to settle for 48 hours before feeding 
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daily with fresh Human ES medium supplemented with 100ng/mL bFGF.  
When colonies were a sufficient size for passaging, they were fixed in 4% 
paraformaldehyde (PFA) for 15 minutes at room temperature.  MP XLIX cells 
were seeded onto chamber slides at a density of 2 x 103 cells/cm2 and 
allowed to settle for 48 hours before fixing with 4% PFA.  These control cells 
were used to determine presence of these markers prior to reprogramming.  
Each chamber was washed 3 times in PBS for 5 minutes, cells were then 
permeabilised with 0.1% (v/v) Triton X 100 (TX) for 20 minutes at room 
temperature.  Non-specific binding of the secondary antibody was blocked 
using a solution of 2% (w/v) BSA (diluted in PBS) and left to incubate for 1 
hour at room temperature.  This was aspirated off and replaced with primary 
antibody (Rabbit polyclonal antibody against Oct-4, Mouse monoclonal 
antibodies against Sox-2, SSEA-4, TRA-1-60 and TRA-1-81 (All abcam, UK) 
and mouse monoclonal antibody against SSEA-5 (from Micha Drukker, 
Stanford University) were diluted to 1:200 (Sox-2 1.25µg/mL, SSEA-5 
2.5µg/mL), 1:250 (Oct-4 2.8µg/mL) or 1:500 (SSEA-4 2µg/mL, TRA-1-60 
4µg/mL and TRA-1-81 4µg/mL) in 2% BSA in PBS and incubated at 4°C 
overnight.  Chamber slides were washed 3 times for 5 minutes with PBS.  
Secondary antibodies (Swine anti-rabbit (0.81g/L) and Rabbit anti-mouse 
(2.3g/L), both Dako, UK) were diluted 1:50 in 2% BSA in PBS and added to 
the cells and incubated for 1 hour at room temperature.  Chamber slides 
were washed 3 times for 5 minutes with PBS before counterstaining the 
nuclei with DAPI (1.5µg/mL) in mounting media (Vector shield, UK).  
Appropriate IgG control and IgM control (Both Santa Cruz Biotechnology, 
UK) were used for each antibody to verify specificity by absence of staining. 
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4.2.2.9.2 Embryoid Body Formation 
A key stage in the differentiation of Human ES cells is the formation of a 3D 
body termed an embryoid body.  This 3D body is thought to mimic the 
environment of a stem cell in the embryo, aiding development into all three 
germ layers; Endoderm, Mesoderm and Ectoderm. 
MP iPSC colonies were passaged enzymatically from 2 wells of a 6 well plate 
as previously described for splitting.  Colonies were seeded into a 10cm non-
tissue culture coated petri dish in 10mL fresh Human ES medium without 
bFGF.  Cells were fed every second day.  Again, as a comparative control, 
MP XLIX cells from 2 wells of a 6 well plate were enzymatically passage for 
splitting, as previously described, and seeded in a 10cm non-tissue culture 
coated petri dish in 10mL Human ES medium.  Medium containing the cell 
bodies in suspension was removed and collected in a 15mL falcon.  This was 
spun at 200 x g for 2 minutes to pellet the bodies.  Supernatant was removed 
and replaced with 10mL fresh Human ES medium without bFGF.  These 
embryoid bodies were grown for 8 days before differentiation was initiated. 
4.2.2.9.3 Differentiation of Embryoid Bodies 
Chamber slides and 24 well plates were pre-coated with 100µL and 250µL 
Matrigel® respectively at a concentration of 0.1% (v/v) in Human ES medium 
without bFGF for 1 hour at 37ºC and 5% CO2.  Plates were removed from the 
incubator and left at room temperature O/N.  Media and 8 day old embryoid 
bodies were removed from the 10cm petri dishes and collected in a 15mL 
falcon.  These were spun at 200 x g, supernatant was removed and embryoid 
bodies were re-suspended in 9mL Human ES medium.  Three conditions 
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were set up to differentiate the embryoid bodies down the three lineages; 
Mesoderm, Endoderm and the Ectoderm.  Medium alone was used to allow 
spontaneous differentiation, Human ES medium supplemented with 10µM 
retinoic acid (diluted in Dimethyl Sulfoxide (DMSO)) to promote ectoderm 
differentiation and Human ES medium supplemented with 1:1000 dilution of 
DMSO as a vehicle control for retinoic acid.  Three 15mL falcons were set up 
containing 4mL of each medium condition.  One mL of re-suspended EBs 
was taken from the main stock and added to each medium condition making 
a final volume of 5mL.  When required, medium was removed from the 
Matrigel®-coated wells and replaced with 500µL of medium for one well of a 
24 well plate and 250µL for one well of a chamber slide.  These were 
returned to the incubator and fed with fresh medium (human ES medium, 
medium supplemented with retinoic acid and medium supplemented with 
DMSO) every other day. 
4.2.2.9.4 Mesoderm, Endoderm and Ectoderm marker expression  
Following 14 days of differentiation, chamber slides were fixed in 4% PFA for 
15 minutes at room temperature.  Each chamber was washed 3 times in PBS 
for 5 minutes, cells were then permeabilised with 0.1% (v/v) TX for 20 
minutes at room temperature.  Non-specific binding of the secondary 
antibody was blocked using a solution of 2% (w/v) BSA (diluted in PBS) and 
left to incubate for 1 hour at room temperature.  This was aspirated off and 
replaced with primary antibody (Rabbit polyclonal antibody against Brachyury 
and Mouse monoclonal antibodies against α-1-fetoprotein and βIII tubulin (all 
abcam, UK) diluted 1:200 (Brachyury 5µg/mL, α-1-fetoprotein 5µg/mL) and 
 Chapter 4 Reprogramming of oral mucosa lamina propria progenitor cells 
135 
 
1:500 (βIII tubulin 2µg/mL) in 2% BSA in PBS and incubated at 4°C O/N.  
Chamber slides were washed 3 times for 5 minutes with PBS.  Secondary 
antibodies (Swine anti-rabbit (0.81g/L) and Rabbit anti-mouse (2.3g/L), both 
Dako, UK) were diluted 1:50 in 2% BSA in PBS and added to the cells and 
incubated for 1 hour at room temperature.  Chamber slides were washed 3 
times for 5 minutes with PBS before counterstaining the nuclei with DAPI 
(1.5µg/mL) in mounting media (Vector shield, UK).  Appropriate IgG controls 
(Santa Cruz Biotechnology, UK) were used for each antibody to verify 
specificity by absence of staining. 
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4.3 Results 
The initial plan to produce iPSCs from OMLP-PCs involved a lentiviral 
system to transfect four pluripotency factors; Oct-4, Sox-2, Nanog and Lin-28 
into the cells. This was performed as part of a collaboration with Dr James 
Uney, Bristol University.  Three attempts using this system failed to produce 
any iPSC-like colonies and the plasmid based technology was selected in 
place of the lentiviral approach. 
4.3.1 Reprogramming of Oral Mucosa Lamina Propria 
Progenitor Cells with Plasmid Vectors 
4.3.1.1 Comparison of Reprogramming Dermal Fibroblasts versus Oral 
Mucosa Lamina Propria Progenitor Cells 
DF were used as a positive control for reprogramming as they had already 
been successfully reprogrammed using these two plasmids (Yu et al, 2009).  
Each cell type; MP XLIX cells and DFs were cultured as previously described 
and prepared for nucleofection.  MP XLIX cells were used at passage 5 and 
DF cells were used at passage 17.  MP XLIX and DF were nucleofected with 
a GFP plasmid in order to calculate the transfection efficiencies of each cell 
type.  Ten bright field images and corresponding GFP images were captured 
and analysed using image J software.  The total number of cells and the 
number of GFP-positive cells were counted and used to calculate the 
transfection efficiency of DF (Figure 4.3 A) and MP XLIX (Figure 4.3 B).  
Transfection efficiency of DF was found to be 38.7% (± 2.290 SD) which was 
significantly lower (p<0.001) than MP XLIX which was 63.6% (±2.771 SD) 
(Figure 4.3 C). 
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Figure 4.3: Transfection efficiencies of MP XLIX and DF.  (A) Merged bright field and 
GFP images of transfected cells in Patient 4 DF.  (B) Merged bright field and GFP 
images of transfected cells in MP XLIX.  (C) Percentage transfection efficiency of both 
samples; Patient 4 DF and MP XLIX (n=3 ±SD) (***= P< 0.001). 
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4.3.1.2 Comparison of Feeder Layers for Formation and Maintenance of 
iPSCs  
Following nucleofection, each cell type, MP XLIX and DF, were seeded onto 
two different feeder layers; iMEFs and iFCFs, in order to carry out a 
comparison between colonies that developed on these plates.  These four 
different culture conditions were set up in triplicate and followed for 30 days.  
Potential colonies developed on all MP XLIX iMEF plates and all MP XLIX 
iFCF plates after 18 days. No colonies were visible on DF plates (either 
feeder layer) after 30 days in culture.  Live alkaline phosphatase stain was 
used to confirm the presence of potential iPSC colonies (Figure 4.4 B).  
Colonies were picked from MP XLIX iMEF and MP XLIX iFCF plates.  Each 
colony was transferred into an individual well of a 24 well plate prepared with 
either iMEFs or iFCFs and left to settle for 48 hours.  Colonies similar in 
morphology to human ES cells were present in the iMEF 24 well plate (Figure 
4.4 C) and the iFCF 24 well plate (Figure 4.4.E) 5 days after mechanical 
passage from the original plate.  These colonies consisted of small cells and 
demonstrated tight colony boundaries with a high nuclear to cytoplasmic ratio 
(Figure 4.4 D & F) that are normally observed in human ES cell culture.  In 
total, six colonies displaying morphology similar to human ES cells were 
isolated and successfully cultured from the iMEF plates and one colony with 
this morphology was isolated from the iFCF plates. 
4.3.2 Characterisation of MP iPSCs  
Characterisation of iPSCs typically involves confirmation of the presence of 
pluripotency markers typically expressed by human ES cells.  
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Figure 4.4: Alkaline phosphatase stain and first colony formation on iMEFs 
and iFCFs.  (A) Bright field image of initial colony formation post-nucleofection.  
(B) Live Alkaline phosphatase staining of colony A. (C) First colony to form 5 
days after first passage on iMEFs.  (D) Higher magnification image of colony C 
demonstrating tight colony boundaries and cells with high nuclear to cytoplasmic 
ratio.  (E) First colony to form 5 days after first passage on iFCF.  (F) Higher 
magnification image of colony E demonstrating tight colony boundaries and cells 
with high nucler to cytoplasmic ratio.  (Scale bar = 100µm) 
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Further characterisation can then be carried out to determine the potential of 
these cells to differentiate down the three germ layers of origin; mesoderm, 
ectoderm and endoderm, confirming pluripotent stem cell properties. 
4.3.2.1 Expression of Pluripotency Markers 
Each of the isolated colonies (iMEF (n=6) iFCF (n=1)) (n that were similar in 
morphology to human ES cells were expanded in culture, firstly by 
mechanical and then by enzymatic passaging.  When a sufficient number of 
colonies were achieved, they were passaged onto culture slides prepared 
with feeder layers in order to carry out immunocytochemistry for the 
pluripotency markers.  The colonies were stained for two transcription 
factors: Oct-4 and Sox-2 and four cell surface markers: SSEA-4, SSEA-5, 
TRA-1-60 and TRA-1-81.  Human ES cells (H9) were cultured as previously 
described and used as a positive control for the markers.  MP XLIX cells that 
had not been transfected with the plasmids were used as a comparative 
control.  The transcription factors Oct-4 and Sox-2 were found to be produce 
by all 6 potential iPSC cultures on iMEFs (Figure 4.5 A, Figure 4.6 A and 
Table 4.1) and the potential iPSC culture on iFCF (Figure 4.5 B and Figure 
4.6 B).  H9 cells demonstrated positive production of Oct-4 and Sox-2 (Figure 
4.5 C and Figure 4.6 C) and presence was also detected in MP XLIX cultures 
(Figure 4.5 D 4.6 D).  Primary omission control, Swine anti Rabbit secondary 
omission control and IgG (Rabbit) control for Oct-4 were found to be negative 
(Figure 4.5 E, F, G).   
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Figure 4.5: Immunocytochemistry for transcription factor Oct-4.  (A) Oct-4 stain 
for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) Oct-4 stain for iPSC 
on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control H9.  (C’) DAPI 
counterstain for H9.  (D) Oct-4 stain for MP XLIX.  (D’) DAPI counterstain for MP XLIX. 
(E) Primary emission control for iPSC on iMEF.  (E’) DAPI counterstain for primary 
emission control.  (F) Swine anti Rabbit secondary emission control for iPSC on iMEF.  
(F’) DAPI counterstain for secondary emission control.  (G) IgG (Rabbit) control for 
iPSC on iMEF.  (G’) DAPI counterstain fo IgG control(Controls for iPSC on iFCF, H9 
and MP XLIX in appendix IV, V & VI (Scale bar = 100µm)). 
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Figure 4.6: Immunocytochemistry for transcription factor Sox-2.  (A) Sox-2 stain 
for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) Sox-2 stain for iPSC 
on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control H9.  (C’) DAPI 
counterstain for H9.  (D) Sox-2 stain for MP XLIX.  (D’) DAPI counterstain for MP 
XLIX.  (E) Primary emission control for iPSC on iMEF.  (E’) DAPI counterstain for 
primary emission control.  (F) Rabbit anti mouse secondary emission control for iPSC 
on iMEF.  (F’) DAPI counterstain for secondary emission control.  (G) IgG (Mouse) 
control for iPSC on iMEF.  (G’) DAPI counterstain for IgG control ( Controls for iPSC 
on iFCF, H9 and MP XLIX in appendix IV, V & VI (Scale bar = 100µm)) 
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Primary omission control, Rabbit anti Mouse secondary omission control and 
IgG (Mouse) control for Sox-2 were found to be negative (Figure 4.6 E, F, G).  
The presence of cell surface markers SSEA-4 and SSEA-5 were also found 
to be positively produced by all 6 potential iPSC culture on iMEFs (Figure 4.7 
A, Figure 4.8 A and Table 4.1) and the potential iPSC culture on iFCF (Figure 
4.7 B and Figure 4.8 B).  H9 cells also demonstrated production of both 
SSEA-4 and SSEA-5 (Figure 4.7 C and Figure 4.8 C) however, MP XLIX 
cells were negative for these cell surface markers (Figure 4.7 D and Figure 
4.8 D).  Primary omission control, Rabbit anti Mouse secondary omission 
control and IgG (Mouse) control for SSEA-4 and SSEA-5 were found to be 
negative (Figure 4.7 &4.8 E, F, G).  Presence of the final two cell surface 
markers; TRA-1-60 and TRA-1-81 were also found to be positively produced 
by all 6 potential iPSC colonies on iMEFs (Figure 4.9 A and Figure 4.10 A, 
Table 4.1) and the potential iPSC colony of iFCF (Figure 4.9 B and Figure 
4.10 B).  Protein production was detected in H9 cells for both TRA-1-60 and 
TRA-1-81 (Figure 4.9 C and Figure 4.10C) however, presences was not 
detected in MP XLIX cells for these markers (Figure 4.9 D and Figure 4.10 
D).  Primary omission controls, Rabbit anti Mouse secondary omission 
controls and IgM control for TRA-1-60 and TRA-1-81 were found to be 
negative (Figure 4.9 & 4.10 E, F, G).  
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Figure 4.7: Immunocytochemistry for cell surface marker SSEA-4.  (A) SSEA-4 
stain for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) SSEA-4 stain 
for iPSC on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control H9.  
(C’) DAPI counterstain for H9.  (D) SSEA-4 stain for MP XLIX.  (D’) DAPI counterstain 
for MP XLIX.  (E) Primary emission control for iPSC on iMEF.  (E’) DAPI counterstain 
for primary emission control.  (F) Rabbit anti mouse secondary emission control for 
iPSC on iMEF.  (F’) DAPI counterstain for secondary emission control.  (G) IgG 
(Mouse) control for iPSC on iMEF.  (G’) DAPI counterstain for IgG control (Controls for 
iPSC on iFCF, H9 and MP XLIX in appendix IV, V & VI (Scale bar = 100µm)). 
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Figure 4.8: Immunocytochemistry for cell surface marker SSEA-5.  (A) SSEA-5 
stain for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) SSEA-5 stain 
for iPSC on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control H9.  
(C’) DAPI counterstain for H9.  (D) SSEA-5 stain for MP XLIX.  (D’) DAPI counterstain 
for MP XLIX.  (E) Primary emission control for iPSC on iMEF.  (E’) DAPI counterstain 
for primary emission control.  (F) Rabbit anti mouse secondary emission control for 
iPSC on iMEF.  (F’) DAPI counterstain for secondary emission control.  (G) IgG 
(Mouse) control for iPSC on iMEF. (G’) DAPI counterstain for IgG control (Controls for 
iPSC on iFCF, H9 and MP XLIX in appendix IV, V & VI) 
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Figure 4.9: Immunocytochemistry for cell surface marker TRA-1-60.  (A) TRA-1-
60 stain for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) TRA-1-60 
stain for iPSC on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control 
H9.  (C’) DAPI counterstain for H9.  (D) TRA-1-60 stain for MP XLIX.  (D’) DAPI 
counterstain for MP XLIX.  (E) Primary emission control for iPSC on iMEF.  (E’) DAPI 
counterstain for primary emission control.  (F) Rabbit anti mouse secondary emission 
control for iPSC on iMEF.  (F’) DAPI counterstain for secondary emission control. (G) 
IgM control for iPSC on iMEF.  (G’) DAPI counterstain for IgG control.(Controls for 
iPSC on iFCF, H9 and MP XLIX in appendix IV, V & VI (Scale bar = 100µm) 
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Figure 4.10: Immunocytochemistry for cell surface marker TRA-1-81.  (A) TRA-1-
81 stain for iPSC on iMEF.  (A’) DAPI counterstain for iPSC on iMEF.  (B) TRA-1-81 
stain for iPSC on iFCF.  (B’) DAPI counterstain for iPSC on iFCF.  (C) Positive control 
H9.  (C’) DAPI counterstain for H9.  (D) TRA-1-81 stain for MP XLIX.  (D’) DAPI 
counterstain for MP XLIX.  (E) Primary emission control for iPSC on iMEF.  (E’) DAPI 
counterstain for primary emission control.  (F) Rabbit anti mouse secondary emission 
control for iPSC on iMEF.  (F’) DAPI counterstain for secondary emission control.  (G) 
IgM control for iPSC on iMEF.  (G’) DAPI counterstain for IgG control.  (Controls for 
iPSC on iFCF, H9 and MP XLIX in appendix IV, V & VI (Scale bar = 100µm)). 
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  Pluripotency Marker Expression 
Feeder 
Layer 
Sample 
Name 
Oct-4 Sox-2 
SSEA-
4 
SSEA-5 
TRA-1-
60 
TRA-1-
81 
iMEF iP15 + + + + + + 
iMEF iP14 + + + + + + 
iMEF iP18 + + + + + + 
iMEF iP1 + + + + + + 
iMEF iP4 + + + + + + 
iMEF iP40 + + + + + + 
iFCF iP17 + + + + + + 
iMEF H9 + + + + + + 
N/A MP XLIX + + - - - - 
Table 4.1: Pluripotency marker production of Oct-4, Sox-2, SSEA-4, SSEA-5, 
TRA-1-60 and TRA-1-81 for all isolated iPSC on both iMEFs and iFCFs, H9 and 
MP XLIX. 
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4.3.2.2 Formation of Embryoid Bodies 
Further characterisation of the potential iPSCs was carried out by 
determining the differentiation capacity of each culture.  Numerous protocols 
exist for differentiation of human ES cells and iPSCs and many include an 
initial EB formation step before differentiation is commenced.  The first 
potential iPSC culture isolated on iMEFs (iP14) was selected as a 
comparison with the potential iPSC culture on iFCF (iP17) for EB formation.  
MP XLIX cells that had not been transfected were again used as a 
comparative control.  The simplest method for EB formation was selected to 
determine the potential for each culture to form EBs.  Colonies were 
passaged, disaggregated and plated onto non-tissue culture coated plastic 
and cultured in iPSC media without bFGF allowing random formation of EBs. 
Following 48 hours in culture, iP17 readily formed small EB structures (Figure 
4.11 A) and following 8 days in culture, EBs had increased slightly in size 
(Figure 4.11 B).  Similarly, following 48 hours in culture iP14 readily formed 
small EB structures (Figure 4.11 C).  However, following 8 days in culture EB 
size was considerably larger on average compared to EBs formed in iP17 
cultures (Figure 4.11 D).  When MP XLIX cells were cultured on non-tissue 
culture coated plastic, some cells were found to aggregate to form EB-like 
structures after 48 hours in culture however, despite the plate coating, some 
cells were found to have adhered to the bottom of the dish (Figure 4.11 E).  
Following 8 days in culture EB-like structures that were present were slightly 
larger in size compared to those after 48hours in culture and very regular in 
shape (Figure 4.11 F). 
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Figure 4.11: Embryoid body formation on non-tissue culture coated plastic 
cultured in Human ES medium without bFGF.  (A) EB formation from iP17 on 
iFCF 48 hours post passage.  (B) EB formation from iP17 on iFCF after 8 days in 
culture.  (C) EB formation from iP14 on iMEFs 48 hours post passage.  (D) EB 
formation from  iP14 on iMEFs after 8 days in culture.  (E) EB formation in MP 
XLIX 48 hours after passage.  (F) EB formation from MP XLIX after 8 days in 
culture.  (Scale bar = 100µm) 
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4.3.2.3 Differentiation down Mesoderm, Endoderm and Ectoderm 
lineages 
In order to determine whether these EBs cultured from iP17, iP14 and MP 
XLIX had the potential to form cells from all three germ layers, they were 
subjected to three different differentiation conditions.  Each of the EBs were 
plated down onto dishes pre-coated with matrigel and cultured in (i) iPSC 
medium without bFGF to allow spontaneous differentiation of EBs (Figure 
4.12 A, D & G), (ii) iPSC medium supplemented with retinoic acid to promote 
differentiation down a neuronal lineage to demonstrate ectoderm 
differentiation (Figure 4.12 B, E & H) and (iii) iPSC medium supplemented 
with DMSO as a vehicle control for retinoic acid (Figure 4.12 C, F & I).  In all 
cases, EBs derived from each cell type demonstrated flattening out and 
outgrowth of cells from the original EB structure by day 14.  Each of these 
cultures was stained for typical early stage markers of mesoderm, endoderm 
and ectoderm.  iP17 EBs were found to differentiate down early endoderm 
lineages by demonstrating positive production of α-1-fetoprotein (Figure 4.13 
A), early ectoderm lineages by presence of βIII tubulin (Figure 4.13 B) and 
early mesoderm lineage by some limited positive presence of Brachyury 
(Figure 4.13 C). All IgG controls and secondary omission controls were found 
to be negative (Figure 4.13 D, E, F & G).  Cells cultured in all three media 
conditions were found to express the three lineage markers (Table 4.2).  iP14 
EBs demonstrated similar results to iP17, with positive production of α-1-
fetoprotein (Figure 4.14 A), βIII tubulin (Figure 4.14 B) and Brachyury (Figure 
4.14 C) with the three different culture conditions resulting in differentiation  
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Figure 4.12: Differentiation of iP17, iP14 and MP XLIX EBs 14 days after they 
were plated down onto matrigel®-coated plastic in three different media 
conditions.  (A) Differentiation of iP17 in iPSC medium.  (B) Differentiation of iP17 
in iPSC medium supplemented with retinoic acid.  (C) Differentiation of iP17 in 
iPSC medium supplemented with DMSO. D Differentiation of iP14 in iPSC 
medium.  (E) Differentiation of iP14 in iPSC medium supplemented with retinoic 
acid.  (F) Differentiation of iP14 in iPSC medium supplemented with DMSO.  (G) 
Differentiation of MP XLIX in iPSC medium.  (H) Differentiation of MP XLIX in 
iPSC medium supplemented with retinoic acid.  (I) Differentiation of MP XLIX in 
iPSC medium supplemented with DMSO.  (Scale bar = 100µm) 
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Figure 4.13: Immunocytochemistry for typical early stage endoderm, 
ectoderm and mesoderm differentiation for iP17.  (A) Production  of α-1-
fetoprotein.  (A’) DAPI nuclear stain for A.  (B) Production of βIII-tubulin.  (B’) 
DAPI nuclear stain for B.  (C) Production of Brachyury.  (C’) DAPI nuclear stain for 
C.  (D) IgG (Rabbit) control.  (D’) DAPI nuclear stain for D.  (E) IgG (Mouse) 
control.  (E’) DAPI nuclear stain for E.  (F) Swine anti Rabbit secondary emission 
control.  (F’) DAPI nuclear stain for F.  (G) Rabbit anti Mouse secondary emission 
control.  (G’) DAPI nuclear stain for G.  (Scale bar = 100µm).(n=1) 
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Figure 4.14: Immunocytochemistry for typical early stage endoderm, 
ectoderm and mesoderm differentiation for iP14.  (A) Production of α-1-
fetoprotein.  (A’) DAPI nuclear stain for A.  (B) Production of βIII-tubulin.  (B’) 
DAPI nuclear stain for B.  (C) Production of Brachyury.  (C’) DAPI nuclear stain for 
C.  (D) IgG (Rabbit) control.  (D’) DAPI nuclear stain for D.  (E) IgG (Mouse) 
control.  (E’) DAPI nuclear stain for E.  (F) Swine anti Rabbit secondary emission 
control.  (F’) DAPI nuclear stain for F.  (G) Rabbit anti Mouse secondary emission 
control.  (G’) DAPI nuclear stain for G.  (Scale bar = 100µm).(n=1) 
 Chapter 4 Reprogramming of oral mucosa lamina propria progenitor cells 
155 
 
down all three lineages (Table 4.2).  Again, all controls were found to be 
negative (Figure 4.14 D, E, F & G).  When subjected to identical 
differentiation conditions, MP XLIX EBs failed to demonstrate expression of 
any of the early lineage markers; α-1-fetoprotein (Figure 4.15 A), βIII tubulin 
(Figure 4.15 B) and Brachyury (Figure 4.15 C).  Culturing in the different 
media conditions did not alter this (Table 4.2) and all controls were found to 
be negative (Figure 4.15 D, E, F & G). 
4.4 Summary 
 MPs can be reprogrammed to cells with morphology similar to hESCs 
 The iPSC colonies produce cell surface markers and transcription 
factors typical of pluripotent stem cells 
 iPSCs were able to differentiate into cells producing early stage 
markers of all three germ layers; mesoderm, endoderm and ectoderm, 
confirming their pluripotent properties 
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Figure 4.15: Immunocytochemistry for typical early stage endoderm, 
ectoderm and mesoderm differentiation for MP XLIX.  (A) Production of α-1-
fetoprotein.  (A’) DAPI nuclear stain for A.  (B) Production of βIII-tubulin.  (B’) 
DAPI nuclear stain for B.  (C) Production of Brachyury.  (C’) DAPI nuclear stain for 
C.  (D) IgG (Rabbit) control.  (D’) DAPI nuclear stain for D.  (E) IgG (Mouse) 
control.  (E’) DAPI nuclear stain for E.  (F) Swine anti Rabbit secondary emission 
control.  (F’) DAPI nuclear stain for F.  (G) Rabbit anti Mouse secondary emission 
control.  (G’) DAPI nuclear stain for G.  (Scale bar = 100µm).(n=1) 
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Sample iPSC medium 
iPSC medium + 
retinoic acid 
iPSC medium + DMSO 
 AFP 
βIII 
tubulin 
Brach-
yury 
AFP 
βIII 
tubulin 
Brach-
yury 
AFP 
βIII 
tubulin 
Brach-
yury 
iP17 + + + + + + + + + 
iP14 + + + + + + + + + 
MP XLIX - - - - - - - - - 
Table 4.2: Early stage endoderm (α-1-fetoprotein (AFP)), ectoderm (βIII tubulin) and 
mesoderm (Brachyury) marker production for iP17, iP14 and MP XLIX in iPSC medium, 
iPSC medium supplemented with 10µM retinoic acid and iPSC medium supplemented 
with DMSO. 
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4.5 Discussion 
4.5.1 Reprogramming with Plasmid Vectors 
Two different cell types were used for reprogramming; oral progenitor cells 
and dermal fibroblast cells.  Dermal fibroblasts were used as a positive 
control for the nucleofection of the plasmids since they have previously been 
used for this application. (Yu et al, 2009).  However, no colonies formed in 
these transfected cells, which may be explained by the low transfection 
efficiency observed.  Given that the efficiency of the non-integrating plasmid 
system is very low, high overall transfection efficiency would be required to 
result in colony formation.  A potential explanation for this could be the age of 
the dermal fibroblasts used.  These cells were isolated from adult tissue by a 
previous member of the Wound Biology Group (Cardiff University) and were 
used for this investigation at passage 17 as these were the lowest passage 
available in cryopreservation.  Whilst still long before the onset of cellular 
senescence for this cell type, the manufacturer optimised protocol 
recommends that cells above passage 9 can reduce the transfection of 
plasmids and result in increased cell death when nucleofected with the 
amaxa® nucleofector®.  In order to confirm this, additional experiments 
would need to be carried out by nucleofecting dermal fibroblasts at early, mid 
and late stages in their lifespan.  In addition to this, human dermal fibroblasts 
utilised for reprogramming purposes are often isolated from neonatal foreskin 
tissue (Yu et al, 2007; Lowry et al, 2008; Yu et al, 2009), representing a 
much ‘younger’ population of cells, potentially better for reprogramming 
purposes.   
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MP cells from patient XLIX were successfully reprogrammed, using a non-
integrating system of two plasmids containing all six factors, to hESC-like 
cells ; colonies were identified and isolated that demonstrated tight colony 
boundaries and cells with very high nuclear to cytoplasmic ratio, typical 
morphological characteristics of hESCs (Thomson et al, 1998).  Although 
fibroblasts from the oral mucosa have already been successfully 
reprogrammed, it was carried out using retroviral transfer of the genes 
including the use of C-myc (Miyoshi et al, 2010), which has been linked to 
formation of carcinomas and poses a clinical risk (Okita et al, 2007; 
Yamanaka et al, 2007; Nakagawa et al, 2008).  The work in this chapter 
suggests that reprogramming of oral progenitor cells with non-integrating 
plasmids for transient expression of the pluripotency factors is possible.  The 
resulting iPSCs represent a potential source of cells that are clinically safer 
for translational research, however, this would need to be tested using 
numerous patient samples as definitive proof but these initial results are 
promising.  In addition to this, to confirm that the plasmids have not 
integrated in to the genome, further investigations would need to be carried 
out comparing the episomal expression of the exogenous genes with the 
genomic expression of the endogenous genes in these isolated iPSC lines.  
These two plasmids have been utilised previously to successfully reprogram 
human dermal fibroblasts and demonstrated formation of iPSCs without 
integration of the plasmid (Yu et al, 2009).  Furthermore, progenitor cells 
have been suggested as an underlying reason for reprogramming efficiencies 
of cells isolated from different tissues (Okita et al, 2007; Aasen et al, 2008), 
therefore, an isolated progenitor cell population may represent a preferential 
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source of cells for use in reprogramming.  Moreover, studies have suggested 
that MSC-like cells isolated from DPPC and SHEDs are reprogrammed at a 
potentially higher efficiency (Yan et al, 2010). 
Colonies were identified both on iMEFs and iFCFs, confirming that both cell 
types were able to support the growth of iPSCs from MPs.  More colonies 
were identified and isolated from iMEF feeders than on iFCFs and this could 
potentially be as a result of the culture conditions which probably need 
optimising for use with iFCFs to improve iPSC production efficiency.  In 
addition to this, iFCFs were prepared from foreskin fibroblasts previously 
isolated by members of the Wound Biology Group which had been in 
cryopreservation for a number of years.  The resulting foreskin fibroblasts 
were irradiated for use as feeder layers at p15-18, corresponding to 
approximately 40-45 population doublings.  This is relatively late when 
compared to MEFs, which are only used as feeders below p4 (approximately 
10-15 population doublings) as they become less effective as feeder cells 
after this time (Jozefczuk et al, 2012).  It has been demonstrated that foreskin 
fibroblast feeders can support growth of hESC when they are between 9-25 
population doublings (Hovatta et al, 2003) so using cells as feeders beyond 
this time point may reduce their ability to support growth of hESCs cells.  
However, the fact that the foreskin fibroblasts utilised in this thesis were able 
to support the growth of the single iPSC line identified is encouraging for the 
future of these iPSCs for potential use in therapeutic applications and further 
investigations using foreskin fibroblasts at an earlier stage would be 
interesting to identify if this improves the reprogramming efficiency. 
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4.5.2 Characterisation of MP iPSCs  
Characterisation of iPSCs formed on both types of feeder layers was next 
undertaken.  Immunocytochemistry was employed as a simple and relatively 
quick method to screen these isolated lines and compare them to hESCs to 
confirm successful reprogramming.  In addition to this, MP cells from the 
patient XLIX were used as a comparative control to determine if any of these 
markers were expressed prior to reprogramming.  Oct-4 and Sox-2 are two 
transcription factors associated with pluripotent stem cells and it has already 
been demonstrated (Chapter 3) that MP cells express these transcription 
factors at the RNA level.  MP XLIX were positive for these transcription 
factors, which is expected and confirms that MP XLIX are producing these 
factors at the protein level, validating the findings in Chapter 3 and is 
consistent with previous reports on OMLP-PCs (Marynka-Kalmani et al, 
2010).  All populations of iPSCs on iMEF, iPSC on iFCF and H9 were also 
positive for these transcription factors, which have previously been reported 
for both iPSCs and hESCs at the RNA and protein level (Bhattacharya et al, 
2005; Lowry et al, 2008; Maherali et al, 2008; Mali et al, 2008; Li et al, 2009).  
On the other hand, the cell surface markers SSEA-4, SSEA-5, TRA-1-60 and 
TRA-1-18 (Thomson et al, 1998; Tang et al, 2011) were only positively 
produced by iPSCs and H9 cells but were not detected in MP XLIX cell 
population adding weight to the fact that these MP iPSC had possibly been 
reprogrammed.  The presence of these typical stem cell markers, namely 
SSEA-4, TRA-1-60 and TRA-1-81, in the iPSCs is consistent with the original 
research carried out for hESCs (Thomson et al, 1998) and results 
demonstrated for iPSCs by several research groups (Takahashi et al, 2007; 
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Maherali, 2007; Miyoshi et al, 2010) confirming the presence of pluripotent 
stem cells.  Moreover, the expression of SSEA-5 further confirms that these 
cells are in an undifferentiated state, given that expression of SSEA-5 is the 
first of the investigated markers known to be lost upon differentiation of the 
stem cells (Tang et al, 2011).  The presence of pluripotency markers; Oct-4, 
SSEA-4, TRA-1-60 and TRA-1-81 observed for OMLP-iPSCs is consistent 
with those observed for iPSCs derivation from the OMLP utilising retroviral 
integration (Myioshi et al, 2010).  The major difference demonstrated by the 
retroviral integration in comparison to plasmid transfection was formation of 
iPSC-like colonies after 13 days.  The plasmid system resulted in a longer 
time period before colony formation was observed, suggesting better 
efficiency from retroviral systems (Myioshi et al, 2010). 
In order to establish whether these iPSCs had pluripotent stem cell 
properties, their ability to differentiate down all three germ layers was 
investigated in vitro, a method commonly used as a test for pluripotency prior 
to carrying out a teratoma assay (Maherali et al, 2008).  Before differentiation 
was initiated, the ability for iPSCs to form EBs was tested.  EBs readily 
formed when populations of iPSCs, maintained both on iMEFs and iFCFs, 
were cultured on non-tissue culture coated plastic without growth factor, 
consistent with standard protocols for hESC EB culture (Bhattacharya et al, 
2005) and EB formation observed with other iPSC lines (Zhang et al, 2009; 
Sullivan et al, 2010; Hu et al, 2010).  Additionally, when MP XLIX cells were 
cultured on non-tissue culture coated plastic as a comparative control, they 
too formed EB-like structures.  Although these EBs were observed to 
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increase in size in all tested cell populations, this was most apparent with 
iP14 where the EBs formed were larger, similar to previous findings with 
hESC (Itskovitz-eldor et al, 2000).  When subjected to differentiation 
conditions only the differentiated EBs from iP14 positively produced early 
markers of mesoderm (Brachyury), endoderm (α-1-fetoprotein) and ectoderm 
(βIII tubulin), consistent with previous reports for iPSCs (Aasen et al, 2008; 
Maherali et al, 2008; Mali et al, 2008; Lin et al, 2009).  Expression of both βIII 
tubulin and α-1-fetoprotein were detected in iP17 EBs but they had a very 
limited production of Brachyury, this indicates potentially a more limited 
differentiation capacity than iP14.  The limited production of Brachyury further 
suggests that the foreskin fibroblasts used as feeder layers in this 
investigation potentially did not fully support the growth and maintenance of 
iPSCs.  Staining with additional early stage markers of mesoderm, ectoderm 
and endoderm would provide further evidence of pluripotency and 
subsequent performance of an in vivo teratoma assay would provide 
definitive proof of the pluripotency of these cells.  Presence of all three 
markers was not detected in differentiated EB-like structures of MP XLIX, 
suggesting that MP XLIX do not display these pluripotent properties prior to 
reprogramming.  This provided further evidence that MP iPSCs are 
responding differently and have been reprogrammed. 
It should be noted that iPSC colonies identified and isolated would need to be 
checked by karyotyping to ensure that the cells are karyotypically normal.  
This is routinely performed for hESCs (Narva et al, 2010) and importantly in 
iPSCs due to the genetic manipulation involved in reprogramming (Yu et al, 
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2007).  In addition to this, the iPSCs still require testing for their ability to form 
teratomas in immune-compromised mice, which remains the ultimate test for 
confirmation of pluripotency (Thomson et al,1998; Takahashi et al, 2007). 
4.6 Conclusion 
The work in this Chapter has demonstrated that OP cells isolated from the 
oral mucosa lamina propria can be reprogrammed to cells demonstrating 
typical stem cell markers and pluripotent characteristics of hESCs using a 
non-integrating system with all 6 reprogramming factors; Oct-4, Sox-2, 
Nanog, Lin-28, Klf-4 and C-myc (Yu et al, 2009).  The resulting iPSCs 
demonstrated expression of early stage markers of the mesoderm, endoderm 
and ectoderm, confirming the potential for these cells to differentiate into cell 
types from all three germ layers. Furthermore, the early indication that these 
MP iPSCs can be formed and maintained on foreskin fibroblast feeder layers, 
leading in colony formation with similar properties to those formed and 
maintained on mouse embryonic fibroblast feeder layers, adds more promise 
for the potential use of these cells in clinical applications making MP iPSCs a 
great potential source of cells for cell-based therapies. 
  
5 - Neural differentiation of oral 
mucosa lamina propria 
progenitor cells versus oral 
mucosa derived iPSCs
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5.1 Introduction 
One area that has received much consideration recently is the possibility for 
ASC, hESC and iPSCs to differentiation into functional neurons.  The 
resulting neurons would create an invaluable source of cells for use in neural 
damage. The limited regenerative capacity of neurons is well known and 
although some evidence does exist for neurogenesis in adult humans 
(Eriksson et al, 1998; Curtis et al, 2011), nerve regeneration following injury 
still remains a surgical challenge.  This is largely due to the fact that once 
nerves are damaged, there are molecules present within the myelin sheath 
that inhibit axon re-growth, thereby limiting the regenerative capacity (Ng et 
al, 1996). This leads to devastating results, for example, paralysis following 
spinal cord injury, and therefore cell based therapies are being sought to 
overcome this problem. 
The ability for pluripotent stem cells (ESCs and more lately iPSCs) to 
differentiate into neurons has received much attention in recent years 
including their differentiation towards neural precursors, the functional ability 
of these differentiated cells and promoted functional recovery of in vivo 
models (Dhara et al, 2008; Ladewig et al, 2008; Hu et al, 2010; Young et al, 
2011; Haythornthwaite et al, 2012; Takazawa et al, 2012).  Given the ability 
of ESCs and iPSCs to self-renew and the fact they possess pluripotent 
properties (Thomson et al, 1998; Takahashi et al, 2007), differentiation can 
be difficult to control and thus there are concerns about transplanting a 
population of cells that potentially still contain undifferentiated stem cells with 
self-renewal characteristics (Vats et al, 2005; Cunningham et al, 2012). 
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However, utilising the correct culture conditions, growth factors and signals to 
direct differentiation of pluripotent stem cells towards a pre-differentiated 
functional phenotype could make these an attractive cell source to target. 
Adult stem cells have also demonstrated potential in this field and although 
adult stem cells have a more limited differentiation potential, they are an 
invaluable source of cells for differentiation. They have potential therapeutic 
purpose as an autologous, and potentially allogeneic, source of cells, with 
both MSCs and OMLP-PCs demonstrating immunosuppressive properties 
(Le Blanc et al, 2004, Davies et al, 2012).  Progenitor cells isolated from the 
OMLP have demonstrated some limited potential to differentiate into cells 
with neural marker expression (Davies et al, 2010; Marynka-Kalmani et al, 
2010).  OMLP-PCs have been isolated from single cells forming a colonies of 
progenitor cells for use in differentiation studies.  Clonally-derived cultures 
are advantageous as cells are, in theory identical and will therefore 
differentiate in a similar manner.  Thus, these cells represent a more 
efficacious and controllable population for use in therapeutic applications.  
These protocols have involved the formation of neurpsphere-like structure 
followed by directed differentiation using defined media conditions (Davies et 
al, 2010).  Additions of growth factors know to be involved with neural 
differentiation including; Brain Derived Neurotrophic Factor (BDNF), 
Neurotrophin 3 (NT3) and Nerve Growth Factor (NGR) have also been 
utilised (Davies et al, 2010, Marynka-Kalmani et al, 2010). 
As yet however, the ability of OMLP-PCs to form a functional neural 
phenotype in vitro has not been investigated.  Therefore, the purpose of this 
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chapter is to investigate and compare the abilities of multipotent OMLP-PCs 
verses pluripotent OMLP-iPSCs to differentiate into functional neural 
phenotypes to assess these different cell sources for use as potential 
avenues for therapeutic application.  Not only will such cells have the 
potential for use in many regenerative medicine applications but they may 
also help further our understanding in this wide field. 
5.1.1 Hypothesis 
iPSCs are a better cell source for neural differentiation when compared to 
OMLP-PCs. 
 
5.1.2 Aims 
 To differentiate OMLP-PCs  and OMLP- iPSCs down a neural lineage 
 Carry out functional testing of these differentiated cell types 
 Carry out a comparative analysis of the differentiation potential of 
OMLP-PCs  and oral iPSCs 
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5.2 Materials and Methods 
Methods describing specific cell culture protocols (oral mucosa lamina 
propria cells, human embryonic stem cells and oral iPSCs), imaging of cells 
and gene expression studies have been described elsewhere (Chapter 2). 
5.2.1 End-point PCR Analysis of Stem Cell and Neural Crest 
Marker Expression 
PCR was carried out as described in Chapter 2 using primers specific to 
stem cell markers, haemopoietic markers, neural crest markers and a house 
keeping gene (Table 5.1).  These were used to confirm previous findings 
(Davies et al, 2010). 
5.2.2 Neural Differentiation 
In order to establish the differences in differentiation capacity, different 
colonies isolated from OMLP-PCs were examined for their ability to 
differentiate down a neural lineage.  Colonies were isolated from several 
patients: XLVII, XLVIII, XLIX, L and LII.  iPSCs derived from  patient XLIX 
were also investigated. 
5.2.2.1 Formation of neurospheres 
Human laminin (Sigma-aldrich, UK) was diluted to 20µg/mL in cold 
Dulbecco’s PBS.  One well of a 6 well TC plate was coated with 1mL of the 
human laminin solution and left at room temperature overnight.  The laminin 
solution was then removed and the well washed once with PBS before use.  
Each cell type was cultured and passaged when confluent as previously 
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described (Chapter 2, Section 2.2.1.3 and Chapter 4, Section 4.2.2.8.3).  
Cells (utilised between 20-25 PDL for colonies, MP and TP cells.  iP14 were 
utilised at passage 28 and H9 cells at passage 92) were plated at a density 
of 5 x 105 cells/well of a 6 well plate.  As passaging of H9 cells and iP14 cells 
leads to colony clumps, a parallel culture of cells was passaged using 
collagenase IV to lift the colonies which were then removed and spun at 200 
x g for 2 minutes to pellet.  The supernatant was removed and the pellet re-
suspended in 1 ml of pre-warmed accutase and left for 5 minutes before 
being triturated, using a 200µL pipette, to form a single cell suspension.  This 
was then used to perform a cell count to determine the approximate number 
of cells that would be obtained from one well of a 6 well plate of either iP14 of 
H9 cells.  Cells were then maintained in 2mL X-vivo 10 medium (Lonza, UK) 
supplemented with 0.1mM β-Mercaptoethanol, 0.1mM NEAA and 80ng/mL 
bFGF.  Medium was changed daily and neurosphere-like structures formed 
over 6-8 days.   
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β-actin 
NM_00
1101.3 
F 5’-CCACACTGTGCCCATCTACGAGGGGT-3’ 
R 5’-AGGGCAGTGATCTCCTTCTGCATCCT-3’ 
564 – 589 
1043 - 1018 
60 454 
P75 
NM_00
2507.3 
F 5’-CTGCAAGCAGAACAAGCAAG -3’ 
R 5’-GGCCTCATGGGTAAAGGAGT -3’ 
956–975 
1265-1246 
58 310 
Twist 
NM_00
0474.3 
F 5’-TCGAGAGATGATGCAGGACGT -3’ 
R 5’-TCTGGCTCTTCCTCGCTGTT-3’ 
345-365 
425-406 
58 81 
Slug 
NM_00
3068.4 
F 5’-CATACAGCCCCATCACTGTG -3’ 
R 5’-CTTGGAGGAGGTGTCAGATG-3’ 
330-349 
466-447 
58 135 
CD90 
NM_00
6288.3 
F 5’-ATGAACCTGGCCATCAGCATCG -3' 
R 5'-CACGAGGTGTTCTGAGCCAGCA -3' 
449-470 
873-852 
55 425 
CD45 
NM_00
2838.4 
F 5’-GTGACCCCTTACCTACTCACACCACTG -3’ 
R 5’-TAAGGTAGGCATCTGAGGTGTTCGCTG -3’ 
353–379  
808-782  
65 456 
CD34 
NM_00
102510
9.1 
F 5’-ACAGGAGAAAGGCTGGGCGAAGACCCT -3’ 
R 5’-TCCCCTGGGGGTTCCTGTATTGCGGCA-3’ 
1216–1242  
1771-1745  
65 556 
Table 5.1: Forward and reverse primers of target genes; housekeeping 
gene β-actin, P75, Twist, Slug, CD90, CD45 and CD34. Annealing temperature 
and product length is listed for each gene. 
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5.2.2.2 Differentiation down a neural lineage using defined medium 
conditions 
Matrigel® was thawed overnight at 4ºC as polymerisation at room 
temperature is rapid.  An aliquot of Matrigel® was diluted on ice to 0.1% v/v 
in DMEM: F-12 (3:1) using cooled pipette tips.  One well of a 6 well TC plate 
was coated with 1mL of this Matrigel® solution and 100µL of solution was 
used to coat one well of a chamber slide.  These were placed in the incubator 
to polymerise at 37ºC for 1 hour and then left at room temperature overnight.  
When spheres were ready to be split, medium was removed from the 
adherent spheres and replaced with 1mL of 1mg/mL collagenase IV and the 
plate returned to the incubator and left for 5-10 minutes to digest the spheres.  
This resulted in cell clumping from the digested spheres, so a parallel culture 
of cells was set up to trypsinise for cell counting purposes as described 
above for iPSCs and H9 cells. 
When matrigel-coated plates were required, the pre-incubated matrigel 
solution was removed and cells seeded onto the surface at a density of 5.6 x 
103 cells/cm2 in medium 1: DMEM-F12 supplemented with 10% FCS and 
40ng/mL bFGF.  Two mL of medium 1 was used per well of a 6 well plate 
and 200µL per well of a chamber slide. Medium changes were performed 
every 2-3 days for a period of 7 days.  After this time medium 1 was 
exchanged for medium 2: DMEM-F12 supplemented with 10% FCS, a 
cocktail of neurotrophic factors; nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT3) (all at 10ng/mL).  Cells 
were fed medium 2 every 2-3 days for a further period of 7 days. 
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5.2.3 Neural Marker Expression 
5.2.3.1 End point PCR analysis of neural marker expression 
End-point PCR was carried out as previously described in Chapter 2 (Section 
2.2.2.6) for neural marker expression (see Table 5.2) of samples pre- and 
post-neural differentiation.  Primers were designed using NCBI/Primer Blast 
and specificity was confirmed using Blast database and confirming product 
size following gel electrophoresis. 
5.2.3.2 Immunocytochemistry for neural markers 
Following 14 days of neural differentiation, chamber slides were fixed in ice 
cold 1:1 (v/v) acetone:methanol for 15 minutes 4ºC.  Each chamber was then 
washed 3 times in PBS for 5 minutes.  Non-specific binding of the secondary 
antibody was blocked using a solution of 2% (w/v) BSA (diluted in PBS) and 
left to incubate for 1 hour at room temperature.  This was aspirated off and 
replaced with primary antibody (Rabbit polyclonal antibody against 
Neurofilament Medium (NF-M) diluted 1:500 (concentration not determined 
by manufacturer) and Mouse monoclonal antibodies against microtubule-
associated protein 2 (MAP-2; 2.3mg/mL) diluted 1:500, Neuron-specific βIII 
tubulin, (βIII tubulin; 1mg/mL) diluted 1:1000 and glial fibrillary acidic protein 
(GFAP; 2mg/mL) diluted 1:200 in 2% BSA in PBS and incubated at 4°C 
overnight.  Following this incubation the chamber slides were washed 3 times 
for 5 minutes with PBS.  Secondary antibodies (Swine anti-rabbit (0.81g/L) 
and Rabbit anti-mouse (2.3g/L), both Dako, UK) were diluted 1:50 in 2%
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BSA in PBS and added to the cells and incubated for 1 hour at room 
temperature.  Chamber slides were washed 3 times for 5 minutes with PBS 
before counterstaining the nuclei with DAPI in mounting medium (1.5µg/mL 
Vector shield, UK).  Appropriate IgG controls (Santa Cruz Biotechnology, UK) 
were used for each antibody to verify specificity by absence of staining.  
Fluorescent images were acquired as described in Chapter 2 (Section 
2.3.1.10). 
5.2.4 Calcium imaging within differentiated cells 
The presence of calcium channels was investigated using fura-2 
acetoxymethyl ester (Molecular Probes, Eugene, USA), a calcium indicator 
dye that binds to intracellular free calcium and emits light at different 
wavelengths when bound and unbound to calcium.  Cells were cultured on 
Matrigel®-coated 13mm glass cover slips and subjected to the 14 day neural 
differentiation protocol (see section 5.2.2).  Following differentiation, cell were 
loaded with 6µM fura-2 in neural differentiation medium (DMEM:F12 
supplemented with 10% FBS) and incubated for 30 minutes at 37ºC.  
Following incubation, cover slips were placed in a perfusion chamber sealed 
with petroleum jelly.  Cells were visualised using an Olympus IX71 equipped 
with a monochromator-based fluorescence system (Cairn Instruments, 
Faversham, UK).  Cover slips were continuously perfused with an 
Extracellular Solution (ECS) consisting of: 135mM NaCl, 5mM KCl, 5mM 
HEPES, 10mM Glucose, 1.2mM MgCl2 and 1.25mM CaCl2.  Fura-2 was 
excited at 340 and 380nm and images were captured at 510nm by a slow-
scan CCD camera (Kinetic Imaging Ltd, Nottingham, UK).  Emission ratios 
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for 340/380nm were calculated following subtraction of background using 
Andor IQ 1.3 software (Andor Technology, Belfast, UK).  Gamma-
aminobutyric acid (GABA), L-Glutamic acid, N-methyl-D-aspartate (NMDA) 
(all at 100µM), kainite, 2-amino-3-(3-hydroxy-5-methyk-isoxazol-4-
yl)propanoic acid (AMPA) and Adenosine triphosphate (ATP) (all at 50µM) 
(Sigma-aldrich, UK) were applied to the cells using a multi-barrel motorised 
solution exchanger (Bio Logic Rapid Solution Changer RSC-100; Molecular 
Kinetics, Pullman, WA) for 15 seconds each with 135 seconds perfused with 
ECS to depolarise the cells and determine neural excitability. 
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5.3 Results 
5.3.1 Expression of Stem Cell and Neural Crest Markers in 
OMLP-PCs 
Single cell-derived colonies were isolated from numerous patients and 
expanded as previously described in Chapter 2.  To confirm these cells were 
of neural crest origin and expressed putative stem cell markers, RNA was 
extracted from each cell population prior to neural differentiation and PCR 
was performed for CD90 (a typical MSC marker), CD34, CD45, 
(Haematopoietic markers) and Twist, Slug and P75 (Neural crest markers) 
(Pittenger et al, 1999; Vernon and LaBonne, 2006; Lee et al, 2007; Davies et 
al, 2010).  Total human RNA (Stratagene, UK) was used as a positive control 
for the markers and two negatives were used, a reverse transcription (RT) 
negative and a water negative (DEPC).  All OMLP colonies were found to 
positively express CD90, Twist, Slug and P75 (Figure 5.1).  Expression of 
both CD34 and CD45 were found to be absent in all colonies. 
 
. 
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5.3.2 Neural Differentiation of Cell Populations of the Oral 
Mucosa Lamina Propria Progenitor Cells and iPSCs 
Single cell-derived colonies were isolated from five patients: XLVII, XLVIII, 
XLIX, L and LII and used for neural differentiation (10XLIX, 7XLIX, 17XLVII, 
9XLVIII, 9L and 4LII).  In addition to these colonies, iPSCs derived from 
patient XLIX (iP14), MP XLIX, TP XLIX and H9 were used to make 
comparisons with respect to differentiation potential  
5.3.2.1 Formation of Neurosphere-like Structures Using Defined Culture 
Conditions 
Each population of cells (colonies, iPSCs, MP XLIX, TP XLIX and H9) were 
cultured on laminin-coated plates in X-VIVO 10 with 80ng/mL of bFGF to 
induce neurosphere formation.  During the first 24 hours of culture, three 
colonies; 7XLIX, 10XLIX & 9XLVIII demonstrated morphology typical of 
fibroblasts (Figures 5.2 A, B & D), two had cells that coalesced with a 
spherical morphology (Figures 5.2 C & E) and one colony was demonstrating 
both fibroblast-like morphology and some spherical cells (Figure 5.2 F).  
Following 7 days in culture, four colonies had successfully formed 
neurosphere-like structures (Figures 5.2 A’, B’, C’ & E’) whilst two colonies 
demonstrated a monolayer of confluent fibroblast-like cells (Figure 5.2 D’ & 
F’).  
Twenty four hours following X-VIVO-10 treatment on laminin coated plates, 
TP XLIX and MP XLIX cell populations displayed a typical fibroblast-like 
morphology (5.3 A & B) whilst after the same duration in culture, iP14 and H9 
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cells demonstrated both cells with a spherical morphology that clumped 
together and flattened fibroblastic cells (Figures 5.3 C & D).  Following 7 days 
in culture, TP XLIX failed to generate any neurosphere-like structures and 
had formed confluent monolayer of cells with a. fibroblast-like morphology 
(Figure 5.3 A’). MP XLIX formed neurosphere-like structures, however, there 
were still fibroblast-like cells populating the space around the neurosphere-
like structure (Figure 5.3 B’). Large neurosphere-like structures were 
observed in iP14 cultures, again with some fibroblast-like cells in monolayer 
around the neurosphere-like structure (Figure 5.3 C’). H9 cells also 
demonstrated formation of neurosphere-like structures but again some 
fibroblast-like cells remained in monolayer (Figure 5.3 D’). The cell 
populations that formed neurosphere-like structures were used to determine 
the potential of these cells to differentiate down the neural lineage.  
5.3.2.2 Neural Differentiation Using Defined Culture Conditions  
7XLIX, 10XLIX, 17XLVII, 9L, MP XLIX, iP14 and H9 cell populations were 
used in neural differentiation experiments.  Each cell population was seeded 
onto matrigel-coated plates and treated with two different neural 
differentiation conditions for a total of 14 days.  Following 7 days of treatment 
with medium 1, OMLP colonies demonstrate a flattening out and the 
attainment of a bipolar conformation (Figures 5.4 A, B, C & D).  After a further 
7 days in medium 2, with a cocktail of neural growth factors, cells began to 
develop long neural-like processes.   
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Figure 5.2: Bright field images of Neurosphere formation for colonies 
cultured on laminin in X-VIVO 10 +80ng/mL bFGF.  (A) 7XLIX 24 hours 
following passage, (A’) 7XLIX following 7 days of treatment.  (B) 10XLIX 24 hours 
following passage, (B’) 10XLIX following 7 days of treatment.  (C) 17XLVII 24 
hours following passage, (C’) 17XLVII following 7 days of treatment.  (D) 9XLVIII 
24 hours following passage, (D’) 9XLVIII following 7 days of treatment.  (E) 9L 24 
hours following passage, (E’) 9L following 7 days of treatment.  (F) 4LII 24 hours 
following passage, (F’) 4LII following 7 days of treatment. 
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Figure 5.3: Bright field images of Neurosphere formation for TP 
XLIX, MP XLIX, iP14 and H9 cultured on laminin in X-VIVO 10 
+80ng/mL bFGF.  (A) TP XLIX 24 hours following passage, (A’) TP 
XLIX following 7 days of treatment.  (B) MP XLIX 2 4hours following 
passage, (B’) MP XLIX following 7 days of treatment.  (C) iP14 24 
hours following passage, (C’) iP14 following 7 days of treatment.  (D) 
H9 24 hours following passage, (D’) H9 following 7 days of treatment 
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These were most obvious in 7XLIX but were also evident in 10XLIX with 9L 
cultures demonstrating limited neural-like processes growing over the 
confluent monolayer (Figure 5.4 A’, B’ & D’). However, 17XLVII demonstrated 
a more confluent monolayer of cells and such neural processes were not 
evident (Figure 5.4 C’). 
After seven days of treatment MP XLIX cells, like the OMLP-PC colonies, 
flattened out and adopted a bipolar conformation (Figure 5.5 A).  Unlike the 
colonies however, these cells were considerably more confluent.  iP14 and 
H9 cells also demonstrated flattened cells after the first 7 days in medium 1 
however, the morphology of these cells was different to MP XLIX and to the 
OMLP-PC colonies (Figures 5.5 B & C).  Following a further 7 days in culture 
with medium 2, MP XLIX demonstrated a monolayer of confluent cells with 
no obvious neural-like processes (Figure 5.5 A’), iP14 demonstrated cells 
with a stressed appearance (large cells with many visible stress fibres) and 
some evidence of cell death (Figure 5.5 B’) and H9 demonstrated some cells 
with long processes also with some evidence of cell death (Figure 5.5 C’). 
5.3.2.3 Expression of neural markers  
Confirmation of neural differentiation was carried out utilising both, PCR 
analysis for typical early and late stage neural markers and 
immunocytochemistry to test for the presence of typical neural markers at the 
protein level. 
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Figure 5.4: Bright field images of neural differentiation of 
colonies.  (A) 7XLIX following 7 days on medium 1, (A’) 7 XLIX 
following 7 days treatment on medium 2.  (B) 10 XLIX following 7 days 
on medium 1,   (B’) 10 XLIX following 7 days treatment on medium 2.  
(C) 17 XLVII following 7 days treatment on medium 1, (C’) 17 XLVII 
following 7 days treatment on medium 2.  (D) 9L following 7 days 
treatment on medium 1, (D’) 9L following 7 days treatment on medium 
2. 
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Figure 5.5: Bright field images of neural differentiation of MP 
XLIX, iP14 and H9.  (A) MP XLIX following 7 days on medium 1, (A’) 
MP XLIX following 7 days treatment on medium 2.  (B) iP14 following 7 
days on medium 1, (B’) iP14 following 7 days treatment on medium 2.  
(C) H9 following 7 days treatment on medium 1, (C’) H9 following 7 
days treatment on medium 2. 
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5.3.2.3.1 PCR analysis 
RNA was extracted from the cell populations before and after differentiation 
to carry out PCR analysis.  Nestin is a neural precursor/progenitor cell 
marker expressed in early neural development and MAP-2 is an early stage 
marker of neural differentiation, whilst NF-M is a late stage marker of 
differentiation.  Nestin was expressed in all OMLP-PC colonies pre- and post- 
differentiation (Figure 5.6 A).  It was also positively expressed in MP XLIX 
and H9 pre- and post- differentiation, however, it was only expressed pre-
differentiation in iP14 (Figure 5.6 B).  Similarly MAP-2 was expressed in all 
OMLP-PC colonies, MP XLIX and H9 pre- and post-differentiation with the 
exception of 9L and 10XLIX (where MAP-2 was upregulated following 
differentiation) and iP14 (where expression was not detected after 
differentiation (Figure 5.6 A & B)).  NF-M was found to be upregulated in MP 
XLIX and all OMLP colonies following differentiation (Figure 5.6 A & B).  
Expression of NF-M was detected pre-differentiation for both iP14 and H9, 
but only in H9 post-differentiation. 
5.3.2.3.2 Immunocytochemistry analysis of neural differentiation markers 
In addition to MAP-2, βIII tubulin is an additional early stage marker of neural 
differentiation and its expression at the protein level is commonly used as an 
indicator of neurons.  βIII tubulin, MAP-2 and NF-M production was detected 
following neural differentiation of 7XLIX, 10XLIX, 17XLVII and 9L (Figures 
5.7-5.10 A, B & C). All primary omission controls were negative (Figure 5.7-
5.10 D, E & F) and all secondary and IgG controls were negative (Figures 
5.7-5.10 G, H, I & J). Percentage positivity was found to be above 80% for 
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the neural markers in all colonies with the exception of NF-M which was 
found to be lower in 10XLIX (71.61%) and 9L (33.47%) (Table 5.3).  A 
minimal level of βIII tubulin, MAP-2 and NF-M was detected in MP XLIX cell 
populations following differentiation (Figures 5.11 A, B & C and Table 5.3) but 
these neural markers were not detected in differentiated populations of iP14 
& H9 (Figures 5.11 D, E, F, G, H &I).  All primary omission, secondary 
omission and IgG controls were found to be negative (see appendix VII). 
5.3.2.4 Functional Testing of Differentiated Neurons  
Three OMLP-PC colonies were selected for calcium imaging; 10XLIX, 7XLIX 
and 9L. 17 XVII was not used at this stage as treated cells became too 
confluent after 14 days of differentiation making calcium imaging extremely 
difficult.  MP XLIX, iP14 and H9 were also not selected for calcium imaging 
as they failed to form neurons as identified by immunocytochemistry (section 
5.3.2.3).  Each of the tested differentiated cell populations was treated with 6 
neuron receptor agonists to evoke calcium influx.  Following incubation with 
fura-2, 10XLIX cell populations failed to demonstrate calcium influx in 
response to treatment with KCl, NMDA, AMPA, Kainate or GABA however, 
calcium influx into the cell was evident following treatment with ATP (Figure 
5.12).  When 9L was treated with these neurotransmitters, an influx of 
calcium was evident following treatment with KCl and GABA (Figure 5.13).  
Following treatment 7XLIX cell populations demonstrate calcium influx 
following treatment with KCl, ATP and GABA (Figure 5.14). 
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Figure 5.6: PCR analysis of early stage; nestin & MAP-2 and late stage; 
NF-M. (A) OMLP-PC colonies pre- and post-differentiation (Irrelevant samples 
removed from lanes 7 & 10).  (B) MP XLIX, iP14 and H9 pre and post 
differentiation (irrelevant samples removed from lanes 3 & 4 of gel). 
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Figure 5.7: Immunocytochemistry analysis of early & late stage neural 
markers for 7XLIX: (A) βIII Tubulin with DAPI counterstain.  (B) MAP-2 with DAPI 
counterstain.  (C) NF-M with DAPI counterstain.  (D) Primary omission control for 
βIII tubulin.  (E) Primary omission control for MAP-2.  (F) Primary omission control 
for NF-M.  (G) Secondary omission control for swine anti-rabbit.  (H) Secondary 
omission control for rabbit anti-mouse.  (I) IgG (rabbit) control.  (J) IgG (mouse) 
control. 
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Figure 5.8: Immunocytochemistry analysis of early & late stage neural 
markers for 10XLIX: (A) βIII Tubulin with DAPI counterstain.  (B) MAP-2 with 
DAPI counterstain.  (C) NF-M with DAPI counterstain.  (D) Primary omission 
control for βIII tubulin.  (E) Primary omission control for MAP-2.  (F) Primary 
omission control for NF-M.  (G) Secondary omission control for swine anti-rabbit.  
(H) Secondary omission control for rabbit anti-mouse.  (I) IgG (rabbit) control.  (J) 
IgG (mouse) control. 
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Figure 5.9: Immunocytochemistry analysis of early & late stage neural markers 
for 17XLVII: (A) βIII Tubulin with DAPI counterstain.  (B) MAP-2 with DAPI 
counterstain.  (C) NF-M with DAPI counterstain.  (D) Primary omission control for 
βIII tubulin.  (E) Primary omission control for MAP-2.  (F) Primary omission control 
for NF-M.  (G) Secondary omission control for swine anti-rabbit.  (H) Secondary 
omission control for rabbit anti-mouse.  (I) IgG (rabbit) control.  (J) IgG (mouse) 
control. 
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Figure 5.10: Immunocytochemistry analysis of early & late stage neural 
markers for 9L: (A) βIII Tubulin with DAPI counterstain.  (B) MAP-2 with DAPI 
counterstain.  (C) NF-M with DAPI counterstain.  (D) Primary omission control for 
βIII tubulin.  (E) Primary omission control for MAP-2.  (F) Primary omission control 
for NF-M.  (G) Secondary omission control for swine anti-rabbit.  (H) Secondary 
omission control for rabbit anti-mouse.  (I) IgG (rabbit) control.  (J) IgG (mouse) 
control. 
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Figure 5.11: Immunocytochemistry analysis of early & late stage neural 
markers for MP XLIX, iP14 and H9: (A) βIII Tubulin with DAPI counterstain for MP 
XLIX.  (B) Map-2 with DAPI counterstain for MPXLIX.  (C) NF-M with DAPI 
counterstain for MP XLIX.  (D) βIII Tubulin with DAPI counterstain for iP14.  (E) 
MAP-2 with DAPI counterstain for iP14.  (F) NF-M with DAPI counterstain for iP14.  
(G) βIII Tubulin with DAPI counterstain for H9.  (H) Map-2 with DAPI counterstain 
for H9.  (I) NF-M with DAPI counterstain for H9 (see appendix VII for controls) 
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Neural Markers 
Cell Sample βIII Tubulin MAP-2 NF-M 
10XLIX 82% 91% 72% 
7XLIX 89% 95% 82% 
17XLVII 90% 99% 82% 
9L 93% 88% 33% 
OPXLIX <1.0% <1.0% <1.0% 
iP14 0.0% 0.0% 0.0% 
H9 0.0% 0.0% 0.0% 
Table 5.3: Percentage positivity of OMLP colonies, MPXLIX, iP14 and H9 
stained with βIII tubulin, Map-2 and NF-M 
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5.4 Summary 
 OMLP-PC colonies form cells with morphology similar to neurons, 
positively express neural markers and demonstrate potential 
differentiation towards a functional neural phenotype 
 Merged progenitors form partial neurospheres and appear to 
preferentially proliferate more than differentiate 
 iPSC and H9 cells fail to differentiate into cells that demonstrate the 
presence of the neural markers at a protein level utilising the protocol 
investigated  
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5.5 Discussion 
The main aim of this chapter was to carry out a comparative analysis of the 
potential for OMLP-PC colonies and iPSCs to differentiate down neural 
pathways.  As the iPSC were derived from MP XLIX, this merged progenitor 
cell population was also used as a comparison in addition to TP XLIX. Given 
the similarities between iPSC and hESCs, the ability of human ES cells (H9) 
to differentiate down a neural lineage was also investigated. In this instance, 
one method for differentiation was used to compare differentiation potential 
between all populations. 
Six colonies were selected from five patients to carry out neural 
differentiation due to their ability to grow in culture following isolation and 
expansion.  Prior to differentiation, these cells were found to express CD90, 
Twist, Slug and p75 but were negative for CD34 and CD45, confirming that 
these cells are derived from the neural crest and consistent with previous 
findings of oral mucosal progenitor cells (Davies et al, 2010; Marynka-
Kalmani et al, 2010).  They express a typical MSC marker but were not of 
haematopoietic origin comparable to reports for progenitor cells isolated from 
other dental tissues including; SHEDs (Nourbakhsh et al, 2011) and gingival 
progenitor cells (Zhang et al, 2009) as well as MSCs isolated from BMSCs 
and other adult tissues including; fat, spleen and thymus (Pittenger et al, 
1999; Krampera et al, 2007). 
Varying degrees of differentiation potential between OMLP colonies was 
discovered.  Here, four single cell derived colonies out of six demonstrated 
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the ability to form neurosphere-like structures similar to those described in 
previous reports for OMLP (Davies et al, 2010) and progenitor cells from 
other dental tissues including; dental follicle stem cells (Vollner et al, 2009) 
and PDL (Widera et al, 2007).  Those colonies that failed to generate these 
structures continued to proliferate over the seven day protocol to confluence.  
Only the populations that formed neurosphere-like structures were taken 
through to the terminal neural differentiation protocol.  Cells from these 
colonies extended long neural-like processes and were used for further 
analysis.  The morphology observed was consistent with previous findings 
following neural differentiation of cells isolated from dental tissues such as 
OMLP, PDL, SHEDs and DPPCs (Arthur et al, 2008; Davies et al, 2010; 
Marynka-Kalmani et al, 2010; Nourbakhsh et al, 2011) as well as those 
observed from neural differentiated MSCs isolated from bone marrow, fat, 
spleen and thymus (Krampera et al, 2007).  A varying degree of 
differentiation potential was also evident in the merged colonies, where, 
some cells coalesce to form neurosphere-like structures.  However, there 
were other cells that continued to proliferate around the periphery of the 
sphere and when taken through the differentiation protocol.  It was evident 
that these cells continue to proliferate to confluence and were potentially 
limiting the neural differentiation ability of the neurosphere-like structures.  In 
contrast, TP XLIX failed to form any neurosphere-like structures and was 
therefore not taken through neural differentiation.  It has been demonstrated 
that progenitor cells isolated from the OMLP can be differentiated to cells that 
express neural markers without the need for formation of a neurosphere-like 
structure however, this was achieved using much lower cell densities at the 
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onset of differentiation (Marynka-Kalmani et al, 2010).  It is therefore possible 
that, if cells were seeded at a lower density, they may still possess the ability 
to differentiate down a neural lineage.  In this case all cell seeding densities 
were kept the same in order to carry out a comparison. 
Both iPSC and H9 cells formed neurosphere-like structures however, both 
cultures had numerous cells in monolayer culture that surrounded the 
sphere-like structures.  When they were taken through neural differentiation, 
there was evidence of substantial cell death (as evidenced by a low cell 
density) in both cultures and the differentiated iPSCs that did survive the 14 
days of culture, adopted a stressed appearance, typical of senescent cells.  A 
limited number of surviving differentiated H9 cells did adopt cell morphology 
that was similar to that of neural cells.  The ability for hESCs to differentiate 
down neural lineages has previously been reported (Lee et al, 2007; Dhara et 
al, 2008;) and similar studies have been carried out for iPSCs (Hu et al, 2010 
Boulting et al, 2011).  Moreover, a differentiated functional phenotype has 
been demonstrated by both hESCs and iPSCs (Lee et al, 2007; Young et al, 
2011; Karumbayaram et al, 2009; Zeng et al, 2010; Haythornthwaite et al, 
2012).  However, differences between the neural differentiation potential of 
hESC and iPSCs have been reported, indicating that iPSCs do differentiate 
down a neural lineage with a much lower efficiency and more variability than 
hESCs (Hu et al, 2010).   
The difference observed between the differentiation of OP cells compared to 
iPSCs and hESC is most likely due to the two different cell populations 
targeted for differentiation; adult stem cells (colonies and MP XLIX) and 
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pluripotent stem cells (hESC (H9) and iPSCs (iP14)).  Adult stem cells are a 
population of cells that are already partially committed to become cells from 
their germ layer of origin, whereas hESC and iPSCs are at a much earlier 
developmental stage.  Neural differentiation of iPSCs and hESCs commonly 
mimic neural stem cell culture and requires the formation of spherical 
aggregates known as embryoid bodies (EBs), formed by culturing the cells in 
suspension (Carpenter et al, 2001; Itsykson et al, 2005; Zhou et al, 2008).  
The downside of the formation of EBs from these pluripotent stem cells is 
that the process is variable and can largely depend upon the length of time in 
suspension culture and the culture conditions.  Differentiation following 
plating can be spontaneous rather than lineage specific however, culturing 
EBs with Noggin has been found to increase the potency of neural 
differentiation due to the inhibition of BMP signalling pathways, suppressing 
non-neural differentiation (Itsykson et al, 2005).  Similarly, the addition of 
Noggin following plating appears to increase neural differentiation efficiency 
(Zhou et al, 2008).  
Only one protocol was utilised to compare the neural differentiation potential 
of the different cell types in this chapter and this protocol was initially 
developed for the differentiation of an adult stem cell population.  Although 
the protocol includes the formation of a spherical body, these conditions were 
optimised for use with OP cells and it did not include the addition of inhibitors 
of BMP signalling pathways, which could potentially cause differentiation at a 
much lower efficiency with hESC and with great variability in iPSCs (Itsykson 
et al, 2005).  This suggests that different culture conditions would be required 
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to optimise neural differentiation for each cell type.  This would essentially 
require a greater understanding of the neural differentiation process of cells 
and the signals involved which is still not yet fully understood.  
RNA was extracted pre- and post-differentiation to establish 
presence/absence of typical neural markers; nestin, MAP-2 and NF-M.  
Nestin is an early stage marker during neural development, often used as a 
neural precursor/progenitor cell marker and is down-regulated as cells 
become terminally differentiated, whilst NF-M (Steinert and Liem, 1990) and 
MAP-2 expression (Ferreira et al, 1990) increase as cells mature. 
Expression of the neural markers by end-point PCR analysis was indicative 
of a neuronal-like phenotype and was evidenced by the OMLP-PC colonies 
and the merged colony population (MP XLIX).  These cell populations 
demonstrated positive expression of the neural precursor marker, nestin both 
before and after differentiation which has previously been reported for oral 
progenitor cells (Marynka-Kalmani et al, 2010) in addition to progenitor cells 
isolated from other dental tissues including; SHEDs (Miura et al, 2003; 
Nourbakhsh et al, 2011) and DPPCs (Arthur et al, 2008).  MAP-2 was also 
detected pre-differentiation in all OMLP colonies and MP XLIX with the 
exception of 9L and minimal detection in 10XLIX, where both colonies 
demonstrate up-regulation post-differentiation potentially confirming a more 
terminally differentiated phenotype.  This is consistent with previous findings 
for oral mucosal progenitor cells (Marynka-Kalmani et al, 2010), whilst MAP-2 
expression in other colonies and merged colony populations appeared 
unchanged following differentiation which is consistent with previous reports 
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for SHEDs (Nourbakhsh et al, 2011).  NF-M was up-regulated following 
differentiation in colonies and MPXLIX which again is potentially indicative of 
a more terminally differentiated neural-like phenotype, similar to previous 
differentiation studies carried out on MSCs (Park et al 2011).  Whilst iP14 
and H9 both demonstrated expression of nestin, MAP-2 and NF-M pre-
differentiation, these markers were not detected post differentiation in iP14 
and, with the exception of MAP-2 which was up-regulated, appeared 
unchanged in differentiated H9 cells.  These three markers have previously 
been reported following differentiation of hESC down neural lineages 
(Francis and Wei, 2010).  Quantitative PCR analysis would be required to 
identify any changes in the levels of expression of these genes. 
Immunocytochemistry for typical neural differentiation markers (βIII tubulin, 
MAP-2 and NF-M) was carried out to determine the presence/absence of 
these markers at the protein level and provide further evidence of a 
differentiated neural phenotype.  Protein for all three markers was detected in 
all colonies of the oral progenitor cells which has previously been reported for 
progenitor cells derived from oral mucosa and gingival tissues (Zhang et al, 
2009; Davies et al, 2010; Marynka-Kalmani et al, 2010), additionally the 
presence of βIII tubulin has been reported in neural differentiated SCAP cells 
(Sonoyama et al, 2008) and the presence of NF-M following neural 
differentiation of DPPCs has been reported (Arthur et al, 2008).  Minimal 
detection was demonstrated in the merged colony populations, which is 
surprising as the merged population consists of many different colonies and 
several of these, like the colonies described in this chapter, will have the 
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potential ability to differentiate towards a neural-like phenotype.  However, as 
already discussed, this may be as a result of the culture conditions including 
the incomplete formation of neurosphere-like structures as well as continued 
proliferation of the cell surrounding the partially formed spheres.  There was 
no staining detected in iP14 or H9 differentiated cells, which is unsurprising 
given the amount of cell death observed in these cultures under these 
specified culture conditions. 
Morphology and expression of neural markers simply provide further support 
of potential neural identity.  However, in order to confirm potential ability to 
function as an excitable cell, these differentiated cells must be tested for 
critical characteristics that would allow the cell to function as a neuron. Based 
on morphology, end-point PCR analysis and presence of protein, three 
colonies (10XLIX, 7 XLIX and 9L) were selected to carry out functional 
testing by performing calcium imaging to detect the presence or absence of 
functional calcium channels.  Calcium influx occurred in 10XLIX as a result of 
exposure to ATP. Whilst 9L did not react to ATP, an influx of calcium 
occurred following treatment with both KCl and GABA and interestingly 
7XLIX had a calcium influx as a result of treatment with all three; ATP, KCl 
and GABA. 
Calcium influx as a result of ATP suggests the presence of P2X 
purinoceptors which potentially indicates the presence of glial cells; 
astrocytes and oligodendrocytes, (James & Butt, 2001; James and Butt, 
2002; Di Garbo et al, 2007), key cells in the functioning of the CNS. The 
response of the cells to both GABA and KCl caused membrane 
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depolarization by Ca2+ influx which occurs at presynaptic membranes. This 
provides evidence of neural-like activity, potentially via GABAa receptors, 
consistent with previous data (Stell et al, 2007; Stell, 2011).  Development of 
GABAa receptors have recently been found to form before ionotropic 
glutamate receptors; NMDA & AMPA, during neural differentiation of mouse 
neural stem cells (Muth-Kohne et al, 2010).  This would suggest that these 
cells here are potentially at an early stage of neural differentiation and are 
perhaps neural precursor-like cells, as they do not respond to NMDA and 
AMPA confirming that there were no active ionotropic glutamate receptors 
present.  Further investigation would be required to confirm whether these 
cells will eventually form functional receptors by identifying the expression of 
the subunits for the NMDA and AMPA receptors.  Additionally, expression of 
a limited number of neural markers was investigated utilising simple end 
point-PCR and therefore it may be beneficial to identify the expression level 
of these and additional neural markers using qPCR methods during the 
differentiation protocol.  Investigations into the expression levels of genes 
known to be involved in neurogenesis by qPCR would provide further data on 
the potential neural development of these cells and provide potential reasons 
behind the lack of response to NMDA and AMPA. 
The neural precursor-like cells that result from this protocol developed for 
differentiation of OMLP-PCs lack the ability for full neural functionality despite 
cells demonstrating morphology, marker expression and some calcium influx 
of neural cells.  This could be as a result of a number of different reasons 
relating to the protocol.  The protocol utilises a cocktail of growth factors; 
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BDNF, NGF & NT3 added to the final neural differentiation medium. These 
factors are known to induce process extensions and are potentially 
responsible for the neural-like morphology observed in the differentiated 
colonies.  These process extensions would potentially result in upregulation 
of neural cell adhesion molecule (Ncam) via binding to P75 (Mirnics et al, 
2005; Thornton et al, 2008).  However, further investigation would be 
required to confirm expression levels of neural markers, such as Ncam, by 
qPCR analysis during the differentiation protocol to map any changes 
observed.  It would also be interesting to determine the expression levels of 
factors actively known to inhibit neural differentiation and maturation to 
determine whether this protocol is limiting the differentiation potential by 
promoting expression of these factors.  Factors such as Sox-2 are actively 
known to inhibit neural stem cell differentiation whilst maintaining cells in a 
pluripotent state (Graham et al, 2003). This would significantly impair the 
ability of these cells to form fully functional differentiated neurons as 
downregulation of Sox-2 is also known to be linked to additional markers 
upregulated during the onset of a functional neural phenotype; neurogenin-2 
(Ngn-2) and Mash-1 (Bylund et al, 2003).  These markers could be utilised to 
provide further evidence of level of neural differentiation/maturation.   
5.6 Conclusion 
The protocol utilised in these experiments allowed colonies from the OMLP to 
differentiate towards to neural-like phenotype.  The differentiated phenotype 
was supported by morphology, expression of neural markers at the 
messenger RNA and protein level and their response to appropriate agonists 
 Chapter 5 Neural differentiation of OMLP-PCs versus OMLP-iPSCs 
208 
 
causing calcium influx.  Together these data suggest that cells from OMLP-
PCs can be differentiated towards neural precursor-like cells with the 
potential to form a functional neural phenotype following further 
differentiation.  The merged colony populations and pluripotent cell 
populations did not respond to this protocol in the same way as OMLP-PCs 
colonies.  This is not however, confirmation that these cells are less efficient 
at neural differentiation but more indicative that different optimised cell 
culture conditions are required to preferentially direct these cells down a 
functional neural lineage. 
  
6 - General Discussion
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Isolation of progenitor cells from the OMLP and their subsequent 
reprogramming provided two different stem cell populations from one tissue; 
OMLP-PC (multipotent ASCs) and OMLP-iPSC (pluripotent stem cells).  The 
main purpose of this thesis was to take these two cell populations and 
determine the neural differentiation potential of each cell type.  The objective 
was to establish whether the neural differentiation of reprogrammed OMLP-
PCs was potentially superior when compared to direct neural differentiation 
of OMLP-PCs.  The reality is however, that each route has its own distinct 
advantages and limitations and neural differentiation potential of the OMLP-
iPSCs is yet to be determined. 
Like many dental tissues, the buccal mucosa harbours a population of neural 
crest derived progenitor cells that exist within the lamina propria (Huang et al, 
2009 Davies et al, 2010; Marynka-Kalmani et al, 2010).  Typically, like other 
mesenchymally derived stem cells, they express MSC markers, demonstrate 
the ability to differentiate into chondrocytes, adipocytes, osteocytes (Davies 
et al, 2010; Marynka-Kalmani et al, 2010) and have potent 
immunomodulation properties (Davies et al, 2012).  This means that they 
could be used in either autologous or allogeneic treatments without the need 
for immunosuppression.  ASCs all tend to demonstrate many similar 
properties to one another but the question remains is one population of ASCs 
“better” than the other? 
The OMLP represents an attractive source of cells for use in tissue 
engineering applications attributed to many features.  Their proliferative 
potential is greater than bone marrow derived MSCs (Bruder et al, 1997; 
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Davies et al, 2010), making these cells potentially more useful when thinking 
about the scalability of clinically relevant cell numbers for patient treatments 
which may be more achievable with OMLP-PCs.  More importantly, taking a 
biopsy from a patient is minimally invasive and can be obtained during 
routine dental procedures and would therefore, be available to majority of 
people.  Furthermore, the wound site in the oral mucosa heals very rapidly 
with minimal scarring when compared to the skin leaving no lasting visible 
defect. 
Despite these attractive properties, cells from the OMLP are developmentally 
more differentiated than hESC and would therefore be deemed to have a 
potentially more limited differentiation potential. For the first time, derivation 
of iPSCs has been demonstrated to be possible from the OMLP utilising non-
integrating plasmid technology.  Reprogramming these cells utilising iPSC 
technologies is thought to potentially counteract these limitations with 
reduced ethical complications compared to hESC use.  At present the 
complete differentiation potential of each of these cell types; iPSC and ASCs, 
is not completely known or understood and therefore it is not known which 
cell type would offer the most beneficial starting point with respect to 
translational medicine. 
Investigating the effects of oxidative stress on cells from the OMLP by 
treating with ascorbic acid was due to the reported benefit of an increased 
reprogramming efficiency of dermal fibroblasts to iPSCs following ascorbic 
acid treatment (Esteban et al, 2010).  Having observed no benefit whilst 
culturing the OMLP-PCs with ascorbic acid, largely as a result of the ascorbic 
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acid potentially acting as a pro-oxidant in culture media at normal oxygen 
levels (Duarte et al, 2007), it was decided to discontinue with this approach 
and instead, untreated OMLP-PCs were utilised in reprogramming 
investigations.  Although efficiency of the reprogramming technique is 
important when thinking about future clinical applications, reprogramming is a 
difficult technique that requires the process to work in a particular cell type 
before the efficiency can be improved. 
It would nevertheless be interesting to investigate the effects of oxidative 
stress on stem cell properties of OMLP-PCs cultured in hypoxic and 
normoxic culture conditions.  Minimising oxidative stress by reducing 
environmental oxygen levels would potentially more closely mimic the natural 
environment the cells exist within. In addition to this determining the potential 
effects of hypoxia on reprogramming efficiency of OMLP-PCs would also be 
interesting and studies have demonstrated increased efficiencies (Yoshida et 
al, 2009). 
Reprogramming efficiencies of cells isolated from different tissues does vary 
and the presence of endogenous progenitor cells has been suggested to 
underlie these differences i.e better efficiencies are observed in host tissues 
where progenitor cells represent a larger proportion of the original population 
(Okita et al, 2007; Aasen et al, 2008).  Cells isolated from dental tissues have 
demonstrated an increased reprogramming efficiency compared to dermal 
fibroblasts (Yan et al, 2010).  Although differences were observed between 
the reprogramming of dermal fibroblasts and the OMLP-PCs in this thesis, 
this is potentially attributed to the differences in cell PDLs at the point of 
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nucleofection.  Nevertheless, it would be interesting to test this hypothesis 
with the OMLP-PCs by utilising dermal fibroblasts at the same PDL. 
The iPSCs derived from OMLP-PCs demonstrated some classical 
morphological and phenotypical characteristics typical of hESCs. This 
includes the production of stem cell surface markers; SSEA-4, SSEA-5, TRA-
1-60, TRA-1-80 and transcription factors; Oct-4 and Sox-2 (Andrews et al, 
1984; Wenk et al, 1994; Thomson et al, 1995; Thomson et al, 1998).  
Moreover, confirmation that the iPSCs had the potential ability to differentiate 
towards lineages of all three germ layers demonstrated by expression of 
early markers of the mesoderm, endoderm and ectoderm suggests that 
iPSCs from the oral mucosa may have pluripotent properties and therefore 
great potential for use in clinical applications. 
In recent years, the epigenetic memory of reprogrammed cells has been 
investigated and as such this would form some interesting investigations to 
determine the level of memory these reprogrammed OMLP-iPSCs maintain 
and whether or not this would affect any resulting differentiation potential.  
Studies have demonstrated that the starting cell can affect reprogramming 
efficiency and also the differentiation potential of the resulting iPSCs. (Kim et 
al, 2010; Kim et al, 2010; Bar-Nur et al, 2011) 
Future potential for reduction in the levels of genetic manipulation are 
promising for cells isolated from the OMLP given the expression levels 
detected for Klf-4 and C-Myc. It would be interesting to test the potential for 
iPSC derivation from OMLP-PCs utilising a reduced number of factors, 
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minimising genetic manipulation and hence improving the safety of these 
cells for potential therapeutic applications.  Reprogramming of neural stem 
cells to iPSC has been demonstrated with retroviral induction of a single 
factor; Oct-4 (Kim et al, 2009) indicating that production of iPSCs with 
reduced genetic manipulation is possible.  However, the use of retroviruses 
to introduce the factors, as previously discussed, limits the clinical usefulness 
of these cells.  Therefore, developing a non-integrating method with fewer 
factors would be beneficial for future advances in this area. 
The differentiation of colonies isolated from the OMLP demonstrated promise 
in their ability to differentiate down a neural lineage.  The presence of typical 
neural marker expression at the RNA and protein level is encouraging.  
Moreover, their response to neural agonists adds weight to the fact that these 
cells have differentiated towards a more functional neural phenotype.  
However, their inability to respond to key agonists required for fully functional 
neurons (AMPA and NMDA) indicates that these cells are only partially 
committed to a differentiated functional neural phenotype. 
The major difference in neural differentiation observed between OMLP-PCs 
and OMLP-iPSCs was due to the culture conditions utilised.  The protocol 
utilised in this thesis had been optimised for OMLP-PCs (Davies et al, 2010), 
an ASC population that will be at a much later developmental stage than 
iPSCs.  To truly determine the differentiation potential of the OMLP-iPSCs, a 
differentiation protocol optimised for hESCs would be required and will most 
likely involve the inhibition of BMP signalling in the early stages of 
differentiation which have shown some promising results (Itsykson et al, 
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2005; Zhou et al, 2008; Chambers et al, 2009).  Once differentiated, these 
cells could then be tested for typical characteristics of neurons including; 
morphology, presence of neural markers and the potential to function like a 
neuron.  One of the limitations of neural differentiation of iPSCs is the 
reported variability in differentiation potential (Hu et al, 2010).  This may 
necessitate an additional cell selection step following differentiation due to 
potential safety concerns with regards to using undifferentiated iPSCs as cell 
transplants. 
In addition to calcium imaging to determine the presence of calcium 
channels, differentiated cells for both OMLP-PCs and OMLP-iPSCs would 
ideally need to be tested for their ability to fire action potentials as definitive 
proof of the presence of functional neurons.  This would be performed 
utilising whole cell patch clamp technique to record membrane potentials.  
Evidence of this action potential in neural differentiated iPSCs has previously 
been reported (Karumbayaram et al, 2009; Zeng et al, 2010; Haythornthwaite 
et al, 2012) however, this is yet to be reported for neural differentiated cells 
derived from OMLP and other progenitors isolated from dental tissues. 
Only once OMLP-iPSCs demonstrate early neural differentiation, can a true 
comparison of the differentiation capabilities of OMLP-PCs and OMLP-iPSCs 
be made.  This could potentially involve the use of ex vivo and potentially in 
vivo spinal cord injury models to test functional recovery following cell 
transplants. 
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Although evidence of the potential for hESCs, iPSCs or ASCs to terminally 
differentiate towards a neural phenotype is desirable, primarily to establish 
that the cells possess the ability to terminally differentiate in vitro, it may not 
be essential for clinical applications.  It may be more realistic to produce a 
neural precursor cell for transplantation, rather than terminally differentiate 
the cells, and allow the cells to continue to differentiate in vivo.  Stem cell 
transplants into spinal cord injury models have proved promising with some 
degree of functional recovery observed utilising ESCs and BMSCs (Kierstead 
et al, 2005; Kim et al, 2006, Cizkova et al, 2006; Sasaki et al, 2009), this 
provides hope for the use of the OMLP-PCs in such injuries.  Furthermore, 
the ability of iPSCs to form functional neurons in vitro (Karumbayaram et al, 
2009) adds promise for the future use of both OMLP-PCs and OMLP-iPSCs 
in spinal cord injury repair. 
6.1 Conclusion 
There were three main aims to this study; to isolate, expand and characterise 
cell populations from the OMLP, to reprogram OMLP-PCs to iPSCs and 
determine the potential of OMLP-PC and OMLP-iPSCs to differentiate down 
neuronal lineages. 
Cells have been isolated and cultured as both single cell-derived colonies 
and merged progenitor populations.  Isolated colonies have demonstrated 
differentiation towards a neural-like phenotype.  Merged progenitor 
populations have been reprogrammed to iPSCs with promising pluripotent 
properties and the neural differentiation potential of these cells is yet to be 
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determined.  However, the OMLP-iPSCs not only have the potential to 
differentiate towards a neural lineage, they may also demonstrate the ability 
to form cell types of all three germ layers bestowing wide-ranging therapeutic 
applications upon these cells. 
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Appendix I: Table of patient information for samples utilised in this thesis 
 
  
Patient Number Gender Age (At time of sample) 
XLVII Male 36 
XLVIII Male 30 
XLIX Female 38 
L Male 22 
LII Female 19 
LIV Male 22 
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Appendix II: DNA sequence data for pluripotency markers: C-myc, Klf-4, Sox-
2, Lin-28 and Oct-4  
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Appendix III: Quantitative PCR product size confirmation for pluripotency 
markers and the house keeping gene: Oct-4, Sox-2, Nanog, Klf-4, C-myc and 
GAPDH 
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Appendix IV: iP17 controls for pluripotency markers.  (A) Primary 
omission control for oct-4.  (A’) DAPI counterstain for oct-4 primary 
omission.  (B) Primary omission control for sox-2.  (B’) DAPI counterstain 
for oct-4 primary omission.  (C) Primary omission control for SSEA-4.  (C’) 
DAPI counterstain for SSEA-4 primary omission.  (D) Primary omission 
control for SSEA-5.  (D’) DAPI counte stain for SSEA-5 primary omission.  
(E) Primary omission control for TRA-1-60.  (E’) DAPI counterstain for TRA-
1-60 primary omission.  (F) Primary omission control for TRA-1-81.  (F’) 
DAPI counterstain for TRA-1-81 primary omission.  (G) IgG (Rabbit) 
control. (G’) DAPI counterstain for IgG (Rabbit).  (H) IgG (Mouse) control.  
(H’) DAPI counterstain for IgG (Mouse).  (I) IgM control.  (I’) DAPI 
Counterstain for IgM.  (J) Secondary omission control for swine anti rabbit.  
(J’) DAPI counterstain for secondary omission control.  (K) Secondary 
omission control for rabbit anti mouse.  (K’) DAPI counterstain for 
secondary omission control. (Scale bar=100µm) 
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Appendix V: H9 controls for pluripotency markers.  (A) Primary 
omission control for oct-4.  (A’) DAPI Counterstain for oct-4 primary 
omission.  (B) Primary omission control for sox-2.  (B’) DAPI Counterstain 
for oct-4 primary omission.  (C) Primary omission control for SSEA-4.  (C’) 
DAPI Counterstain for SSEA-4 primary omission.  (D) Primary omission 
control for SSEA-5.  (D’) DAPI Counterstain for SSEA-5 primary omission.  
(E) Primary omission control for TRA-1-60.  (E’) DAPI Counterstain for 
TRA-1-60 primary omission.  (F) Primary omission control for TRA-1-81.  
(F’) DAPI Counterstain for TRA-1-81 primary omission.  (G) IgG (Rabbit) 
control. (G’) DAPI Counterstain for IgG (Rabbit).  (H) IgG (Mouse) control.  
(H’) DAPI Counterstain for IgG (Mouse).  (I) IgM control.  (I’) DAPI 
Counterstain for IgM.  (J) Secondary omission control for swine anti rabbit.  
(J’) DAPI Counterstain for secondary omission control.  (K) Secondary 
omission control for rabbit anti mouse.  (K’) DAPI Counterstain for 
secondary omission control.  (Scale bar=100µm) 
 
  
 
 
260 
 
 
Appendix VI: MP XLIX controls for pluripotency markers.  (A) 
Primary omission control for oct-4.  (A’) DAPI Counterstain for oct-4 
primary omission.  (B) Primary omission control for sox-2.  (B’) DAPI 
Counterstain for oct-4 primary omission.  (C) Primary omission control for 
SSEA-4.  (C’) DAPI Counterstain for SSEA-4 primary omission.  (D) 
Primary omission control for SSEA-5.  (D’) DAPI Counterstain for SSEA-5 
primary omission.  (E) Primary omission control for TRA-1-60.  (E’) DAPI 
Counterstain for TRA-1-60 primary omission.  (F) Primary omission control 
for TRA-1-81.  (F’) DAPI Counterstain for TRA-1-81 primary omission.  (G) 
IgG (Rabbit) control. (G’) DAPI Counterstain for IgG (Rabbit).  (H) IgG 
(Mouse) control.  (H’) DAPI Counterstain for IgG (Mouse).  (I) IgM control.  
(I’) DAPI Counterstain for IgM.  (J) Secondary omission control for swine 
anti rabbit.  (J’) DAPI Counterstain for secondary omission control.  (K) 
Secondary omission control for rabbit anti mouse.  (K’) DAPI Counterstain 
for secondary omission control.  (Scale bar=100µm) 
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Appendix VII: Controls for neural markers.  (A) Primary omission 
control of MP XLIX for βIII tubulin.  (B) Primary omission control of MP 
XLIX for MAP-2.  (C) Primary omission control of MP XLIX for NF-M.  (D) 
Primary omission control of iP14 for βIII tubulin.  (E) Primary omission 
control of iP14 for MAP-2.  (F) Primary omission control of iP14 for NF-M.  
(G) Primary omission control of H9 for βIII tubulin.  (H) Primary omission 
control of H9 for MAP-2.  (I) Primary omission control of H9 forNF-M.  (J) 
IgG (Rabbit) control for MP XLIX.  (K) IgG (Mouse) control for MP XLIX.  
(L) Secondary omission control of MP XLIX for swine anti rabbit.  (M) 
Secondary omission control of MP XLIX for rabbit anti mouse (N) IgG 
(Rabbit) control for iP14.  (O) IgG (Mouse) control for iP14.  (P) Secondary 
omission control of iP14 for swine anti rabbit.  (Q) Secondary omission 
control of iP14 for rabbit anti mouse.  (R) IgG (Rabbit) control for H9.  (S) 
IgG (Mouse) control for H9.  (T) Secondary omission control of H9 for swine 
anti rabbit.  (U) Secondary omission control of H9 for rabbit anti.  (Scale 
bar=100µm) 
